BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461-2471. [PMID: 28993052 DOI: 10.1016/s0140-6736(17)31827-5] [Cited by in Crossref: 1136] [Cited by in F6Publishing: 1251] [Article Influence: 189.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu T, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Yang N, Lu J, Shitara K, Lei M, Li M, Bao N, Chen T, Shen L. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis. Int J Cancer 2023;152:749-60. [PMID: 36121651 DOI: 10.1002/ijc.34296] [Reference Citation Analysis]
2 Morinaga T, Iwatsuki M, Yamashita K, Yasuda-Yoshihara N, Yamane T, Matsumoto C, Harada K, Eto K, Kurashige J, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Baba H. Dynamic Alteration in HLA-E Expression and Soluble HLA-E via Interaction with Natural Killer Cells in Gastric Cancer. Ann Surg Oncol 2023;30:1240-52. [PMID: 36149610 DOI: 10.1245/s10434-022-12505-0] [Reference Citation Analysis]
3 Zhang Q, Cao W, Yang C, Hong L, Geng S, Han H, Zhong C. Isothiocyanates attenuate immune checkpoint blockage therapy in gastric cancer via induction of PD-L1 expression. J Nutr Biochem 2023;112:109226. [PMID: 36435292 DOI: 10.1016/j.jnutbio.2022.109226] [Reference Citation Analysis]
4 Wu YX, Zhou XY, Wang JQ, Chen GM, Chen JX, Wang RC, Huang JQ, Chen JS. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer. Immunotherapy 2023;15:101-15. [PMID: 36597704 DOI: 10.2217/imt-2022-0080] [Reference Citation Analysis]
5 Takata N, Kikuchi S, Kuroda S, Tanabe S, Maeda N, Noma K, Takahashi A, Umeda Y, Shikata K, Ozaki K, Fujiwara T. Effect of Patient-Participation Continuous Nutritional Counseling in Gastric Cancer Patients who Underwent Gastrectomy. Ann Surg Oncol 2023;30:1110-8. [PMID: 36161371 DOI: 10.1245/s10434-022-12572-3] [Reference Citation Analysis]
6 Wang B, Zhang Z, Liu W, Tan B. Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis. Biomed Pharmacother 2023;158:114180. [PMID: 36586241 DOI: 10.1016/j.biopha.2022.114180] [Reference Citation Analysis]
7 Zeng Z, Liu Z, Li J, Sun J, Ma M, Ye X, Yu J, Kang W. Baseline splenic volume as a biomarker for clinical outcome and circulating lymphocyte count in gastric cancer. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1065716] [Reference Citation Analysis]
8 Inagaki C, Kawakami H, Maeda D, Sakai D, Urakawa S, Nishida K, Kudo T, Doki Y, Eguchi H, Wada H, Satoh T. The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy.. [DOI: 10.21203/rs.3.rs-2512025/v1] [Reference Citation Analysis]
9 Entezam M, Sanaei MJ, Mirzaei Y, Mer AH, Abdollahpour-Alitappeh M, Azadegan-Dehkordi F, Bagheri N. Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. Life Sci 2023;:121459. [PMID: 36720453 DOI: 10.1016/j.lfs.2023.121459] [Reference Citation Analysis]
10 Haag GM. Systemische Therapieoptionen beim fortgeschrittenen Adenokarzinom des Ösophagus. Onkologie 2023. [DOI: 10.1007/s00761-022-01298-2] [Reference Citation Analysis]
11 Palanivelu L, Liu C, Lin L. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front Immunol 2023;13. [DOI: 10.3389/fimmu.2022.1038226] [Reference Citation Analysis]
12 Luo Y, Yao Y, Wu P, Zi X, Sun N, He J. Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2023;:103922. [PMID: 36696933 DOI: 10.1016/j.critrevonc.2023.103922] [Reference Citation Analysis]
13 Si L, Pan X, He K, Sun L, Wang Y, Xu X, Lu J. PD‐L1 expression by different scoring methods and different cutoff values and correlation with clinicopathological characteristics in gastric cancer: A retrospective study. Precision Medical Sciences 2023. [DOI: 10.1002/prm2.12094] [Reference Citation Analysis]
14 Huang W, Zhang Y, Chen S, Yin H, Liu G, Zhang H, Xu J, Yu J, Xia Y, He Y, Zhang C. Personalized immune subtypes based on machine learning predict response to checkpoint blockade in gastric cancer. Brief Bioinform 2023;24:bbac554. [PMID: 36572651 DOI: 10.1093/bib/bbac554] [Reference Citation Analysis]
15 Thawani R, Agrawal N, Taflin NF, Kardosh A, Chen EY. Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer. Oncologist 2023;28:40-7. [PMID: 36130326 DOI: 10.1093/oncolo/oyac187] [Reference Citation Analysis]
16 Lu S, Chen YG, Liu XW, Yang ZY, Shi M, Yuan H, Liu WT, Ni ZT, Yao XX, Hua ZC, Feng RH, He CY, Zheng YN, Wang ZQ, Sah BK, Chen MM, Zhu ZL, Li C, Zhang J, Yan M, Xia JZ, Zhu ZG, Yan C. A phase II study of perioperative treatment in gastric cancer with No.16a2/b1 lymph node metastasis: DRAGON-06 trial. Future Oncol 2023. [PMID: 36651765 DOI: 10.2217/fon-2022-0718] [Reference Citation Analysis]
17 Aizawa M, Yabusaki H, Matsuki A, Bamba T, Nakagawa S. Predictive significance of surgery-induced lymphopenia on the survival after curative resection for locally advanced gastric cancer: a retrospective cohort analysis. World J Surg Oncol 2023;21:7. [PMID: 36647123 DOI: 10.1186/s12957-023-02887-0] [Reference Citation Analysis]
18 Gong Z, Jia Q, Guo J, Li C, Xu S, Jin Z, Chu H, Wan YY, Zhu B, Zhou Y. Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism. Exp Hematol Oncol 2023;12:7. [PMID: 36635765 DOI: 10.1186/s40164-022-00371-1] [Reference Citation Analysis]
19 Lynch E, Duffy AG, Kelly RJ. Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma. Pharmaceuticals (Basel) 2023;16. [PMID: 36678598 DOI: 10.3390/ph16010102] [Reference Citation Analysis]
20 Li S, Li K, Tian F, Li H, Xia Q, Li T, Dong B, Li D, Yu J, Zhang J, Wang L, Zhang C, Xu S, Zhao Y, Liu Y. A high interferon gamma signature of CD8(+) T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer. Front Immunol 2022;13:1056144. [PMID: 36685525 DOI: 10.3389/fimmu.2022.1056144] [Reference Citation Analysis]
21 Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, Kuwata T, Shitara K. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 2023;8:100762. [PMID: 36610262 DOI: 10.1016/j.esmoop.2022.100762] [Reference Citation Analysis]
22 Xiang X, Guo F, Li G, Ma L, Zhu X, Abdulla Z, Li J, Zhang J, Huang M. Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study. Front Oncol 2022;12:1015962. [PMID: 36686751 DOI: 10.3389/fonc.2022.1015962] [Reference Citation Analysis]
23 Li T, Liu T, Zhao L, Liu L, Zheng X, Wang J, Zhang F, Hu Y. Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study. Front Oncol 2022;12:976078. [PMID: 36686795 DOI: 10.3389/fonc.2022.976078] [Reference Citation Analysis]
24 Yang H, Gou X, Feng C, Zhang Y, Chai F, Hong N, Ye Y, Wang Y, Gao B, Cheng J. Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer. J Transl Med 2023;21:4. [PMID: 36604653 DOI: 10.1186/s12967-022-03845-2] [Reference Citation Analysis]
25 Li J, Chen Z, Chen Y, Zhao J, He M, Li X, Zhang L, Dong B, Zhang X, Tang L, Shen L. CT-based delta radiomics in predicting the prognosis of stage IV gastric cancer to immune checkpoint inhibitors. Front Oncol 2022;12:1059874. [PMID: 36686828 DOI: 10.3389/fonc.2022.1059874] [Reference Citation Analysis]
26 Hu Y, Chen N, Huang RZ, Chen DL. Comprehensive Analysis of Clinicopathological and Molecular Features to Predict Anti-PD-1-Based Therapy Efficacy in Patients with Advanced Gastric Signet Ring Cell Carcinoma. J Pers Med 2023;13:115. [PMID: 36675776 DOI: 10.3390/jpm13010115] [Reference Citation Analysis]
27 Xing Y, Zhang Z, Ding Z, Song W, Li T. Tumor recurrence after pathologic complete response in locally advanced gastric cancer after neoadjuvant therapy: case report and literature review.. [DOI: 10.21203/rs.3.rs-2387247/v1] [Reference Citation Analysis]
28 Xie R, Liu L, Lu X, He C, Li G. Identification of the diagnostic genes and immune cell infiltration characteristics of gastric cancer using bioinformatics analysis and machine learning. Front Genet 2022;13:1067524. [PMID: 36685898 DOI: 10.3389/fgene.2022.1067524] [Reference Citation Analysis]
29 Zhou S, Wang Y, Zhang R, Zeng W, Liu S, Liu S, Liu M, Yang H, Xi M. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy. JAMA Netw Open 2023;6:e2250965. [PMID: 36648946 DOI: 10.1001/jamanetworkopen.2022.50965] [Reference Citation Analysis]
30 Li S, Yu W, Xie F, Luo H, Liu Z, Lv W, Shi D, Yu D, Gao P, Chen C, Wei M, Zhou W, Wang J, Zhao Z, Dai X, Xu Q, Zhang X, Huang M, Huang K, Wang J, Li J, Sheng L, Liu L. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun 2023;14:8. [PMID: 36596787 DOI: 10.1038/s41467-022-35431-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Matsubara Y, Toriyama K, Kadowaki S, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Masuishi T, Bando H, Ando M, Tajika M, Oze I, Hosoda W, Muro K. The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. Esophagus 2023. [PMID: 36595124 DOI: 10.1007/s10388-022-00978-7] [Reference Citation Analysis]
32 Matsunaga T, Saito H, Fukumoto Y, Kuroda H, Taniguchi K, Takahashi S, Osaki T, Iwamoto A, Fukuda K, Shimizu S, Shishido Y, Miyatani K, Fujiwara Y. The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment. Surg Today 2023. [PMID: 36595075 DOI: 10.1007/s00595-022-02638-w] [Reference Citation Analysis]
33 Sugiyama K, Shiraishi K, Motohashi T, Onoda S, Sato M, Kato K, Uda H, Hattori M, Suenaga M, Hirashima N, Shimada M, Kataoka M, Kitagawa C. The Impact of Nutritional Support on Survival Outcomes in Patients with Advanced Gastric Adenocarcinoma Treated with Chemotherapy. Nutr Cancer 2023;:1-9. [PMID: 36591915 DOI: 10.1080/01635581.2022.2162090] [Reference Citation Analysis]
34 Nie C, Lv H, Chen B, Xu W, Wang J, Wang S, Liu Y, He Y, Zhao J, Chen X. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study. Technol Cancer Res Treat 2023;22:15330338221150561. [PMID: 36632666 DOI: 10.1177/15330338221150561] [Reference Citation Analysis]
35 Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
36 Lee D, Choi J, Oh HJ, Ham IH, Lee SH, Nomura S, Han SU, Hur H. Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to Immune Checkpoint Inhibitors in Gastric Cancer. Cancer Res Treat 2023;55:167-78. [PMID: 35609622 DOI: 10.4143/crt.2022.094] [Reference Citation Analysis]
37 Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y, Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, Esaki T, Miura Y, Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan. Gastric Cancer 2023;26:132-44. [PMID: 36316527 DOI: 10.1007/s10120-022-01349-y] [Reference Citation Analysis]
38 Nose Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Yamamoto K, Makino T, Takahashi T, Kawashima A, Haruna M, Hirata M, Ueyama A, Iwahori K, Satoh T, Kurokawa Y, Eguchi H, Doki Y, Wada H. The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer. Cancer Immunol Immunother 2023;72:169-81. [PMID: 35776160 DOI: 10.1007/s00262-022-03240-2] [Reference Citation Analysis]
39 Siddiqi A, Johnston FM. The Perioperative and Operative Management of Esophageal and Gastric Cancer. Surg Oncol Clin N Am 2023;32:65-81. [PMID: 36410922 DOI: 10.1016/j.soc.2022.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kamiimabeppu D, Wakatsuki T, Takahari D, Fukuda N, Shimozaki K, Osumi H, Nakayama I, Ogura M, Ooki A, Shinozaki E, Chin K, Yamaguchi K. Treatment efficacy of ramucirumab-containing chemotherapy in patients with alpha-fetoprotein producing gastric cancer. Int J Clin Oncol 2023;28:121-9. [PMID: 36409433 DOI: 10.1007/s10147-022-02263-0] [Reference Citation Analysis]
41 Businello G, Angerilli V, Lonardi S, Bergamo F, Valmasoni M, Farinati F, Savarino E, Spolverato G, Fassan M. Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. Updates Surg 2023;75:291-303. [PMID: 35834132 DOI: 10.1007/s13304-022-01330-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Araújo D, Ribeiro E, Amorim I, Vale N. Repurposed Drugs in Gastric Cancer. Molecules 2022;28. [PMID: 36615513 DOI: 10.3390/molecules28010319] [Reference Citation Analysis]
43 Fiona Day, Swetha Sridharan, James Lynam, Craig Gedye, Catherine Johnson, Allison Fraser, Stephen R. Thompson, Michael Michael, Trevor Leong, Amitesh Roy, Mahesh Kumar, Andre van der Westhuizen, Gaik T. Quah, Hiren Mandaliya, Girish Mallesara, Joshua Sappiatzer, Christopher Oldmeadow, Jarad Martin. Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group). BMC Cancer 2022;22:1324. [PMID: 36528772 DOI: 10.1186/s12885-022-10407-8] [Reference Citation Analysis]
44 Ou Yamaguchi, Kazuyuki Atarashi, Kenichi Yoshimura, Ayako Shiono, Atsuhito Mouri, Fuyumi Nishihara, Yu Miura, Kosuke Hashimoto, Yoshiaki Miyamoto, Hitoshi Uga, Nobuo Seki, Tomoko Matsushima, Norihiro Kikukawa, Kunihiko Kobayashi, Kyoichi Kaira, Hiroshi Kagamu. Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. BMC Cancer 2022;22:1325. [PMID: 36528575 DOI: 10.1186/s12885-022-10445-2] [Reference Citation Analysis]
45 Cascinu S, Di Bartolomeo M, Lonardi S, Beretta G, Fornaro L, De Vita F. The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion. Front Med (Lausanne) 2022;9:1002435. [PMID: 36590964 DOI: 10.3389/fmed.2022.1002435] [Reference Citation Analysis]
46 Noori M, Yousefi AM, Zali MR, Bashash D. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis. Front Oncol 2022;12:1021859. [PMID: 36591463 DOI: 10.3389/fonc.2022.1021859] [Reference Citation Analysis]
47 Yu X, Wu R, Ji Y, Huang M, Feng Z. Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. Diagnostics (Basel) 2022;12. [PMID: 36553164 DOI: 10.3390/diagnostics12123157] [Reference Citation Analysis]
48 Wang Y, Lei X, Shan F, Li S, Jia Y, Miao R, Xue K, Li Z, Ji J, Li Z. Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study. BMC Cancer 2022;22:1306. [DOI: 10.1186/s12885-022-10272-5] [Reference Citation Analysis]
49 Zhang J, Fu L, Yasuda-yoshihara N, Yonemura A, Wei F, Bu L, Hu X, Akiyama T, Kitamura F, Yasuda T, Semba T, Uchihara T, Itoyama R, Yamashita K, Eto K, Iwagami S, Yashiro M, Komohara Y, Baba H, Ishimoto T. IL-1β derived from mixed-polarized macrophages activates fibroblasts and synergistically forms a cancer-promoting microenvironment. Gastric Cancer 2022. [DOI: 10.1007/s10120-022-01352-3] [Reference Citation Analysis]
50 Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. BMC Cancer 2022;22:1292. [PMID: 36494792 DOI: 10.1186/s12885-022-10398-6] [Reference Citation Analysis]
51 Zheng J, Huang B, Xiao L, Wu M, Li J. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. Front Oncol 2022;12:821626. [PMID: 36568203 DOI: 10.3389/fonc.2022.821626] [Reference Citation Analysis]
52 Shitara K, Kawazoe A, Hirakawa A, Nakanishi Y, Furuki S, Fukuda M, Ueno Y, Raizer J, Arozullah A. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma. Cancer Sci 2022. [PMID: 36478334 DOI: 10.1111/cas.15684] [Reference Citation Analysis]
53 Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X, Liang K, Luo Y, Che K, Wang X, Pan Y, Liu F, Yang J, Liu Q, Yu L, Liu B, Wei J. DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. Cancer Immunol Res 2022;10:1506-24. [PMID: 36206576 DOI: 10.1158/2326-6066.CIR-22-0218] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Li T, Qian C, Gu Y, Zhang J, Li S, Xia N. Current progress in the development of prophylactic and therapeutic vaccines. Sci China Life Sci 2022;:1-32. [PMID: 36469218 DOI: 10.1007/s11427-022-2230-4] [Reference Citation Analysis]
55 Bao Z, Tang Q, Chen H, Zhang B, Shi W, Gu D. An abscopal effect in a gastric cancer patient treated with combined chemoimmunotherapy and palliative radiotherapy. Immunotherapy 2022;14:1429-35. [PMID: 36537254 DOI: 10.2217/imt-2022-0041] [Reference Citation Analysis]
56 Yuan H, Duan DD, Zhang YJ. Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: A meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2022;46:102031. [PMID: 36261109 DOI: 10.1016/j.clinre.2022.102031] [Reference Citation Analysis]
57 Wu F, Xu X, Li W, Hong Y, Lai H, Zhang J, Wu X, Zhou K, Hu N. Nanoparticle-Delivered Transforming Growth Factor-β1 siRNA Induces PD-1 against Gastric Cancer by Transforming the Phenotype of the Tumor Immune Microenvironment. Pharmaceuticals (Basel) 2022;15. [PMID: 36558938 DOI: 10.3390/ph15121487] [Reference Citation Analysis]
58 Shen J, Wang Z. Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review. Front Oncol 2022;12:934249. [PMID: 36505771 DOI: 10.3389/fonc.2022.934249] [Reference Citation Analysis]
59 Ma Y, Xin Y, Su D, Zhou Y, Li H, Zou H, Yu X, Yang Q, Cui J, Wang C, Zhang Y. Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.958783] [Reference Citation Analysis]
60 Tian Z, Liang S, Zhou X, Luo H, Tian M, Zhang X, Guo C, Zhang J. Near-infrared-dye labeled tumor vascular-targeted dimer GEBP11 peptide for image-guided surgery in gastric cancer. Front Oncol 2022;12:885036. [PMID: 36505820 DOI: 10.3389/fonc.2022.885036] [Reference Citation Analysis]
61 Tincknell G, Naveed A, Nankervis J, Mukhtiar A, Piper AK, Becker TM, Chantrill L, Aghmesheh M, Vine KL, Ranson M, Brungs D. HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis. Cancers (Basel) 2022;14. [PMID: 36497236 DOI: 10.3390/cancers14235754] [Reference Citation Analysis]
62 Hamano H, Miyata K, Hara T, Sakaguchi S, Oura M, Niimura T, Aizawa F, Yagi K, Okada N, Miki H, Goda M, Ishizawa-izawa Y, Zamami Y, Yanagawa H, Ishizawa K. Multiple Adverse Events of anti-PD1/PDL1 Therapy: A Case- control Study using a Japanese Prescription-diagnostics Database.. [DOI: 10.21203/rs.3.rs-2268880/v1] [Reference Citation Analysis]
63 Nie C, Xu W, Lv H, Gao X, Li G, Chen B, Wang J, Liu Y, Zhao J, He Y, Wang S, Chen X. Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1043217] [Reference Citation Analysis]
64 Yang Y, Wang F. Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.983892] [Reference Citation Analysis]
65 Chang C, Pei Y, Xu J, Zhang W, Zhang J, Shi S. The full management from first-line to third-line treatments in patients with Her-2–negative advanced gastric cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.949941] [Reference Citation Analysis]
66 Xu X, Zhang L, Qian Y, Fang Q, Xiao Y, Chen G, Cai G, Abula A, Wang Z, Zhai E, Chen J, Cai S, Wu H. A SERPINE1-Based Immune Gene Signature Predicts Prognosis and Immunotherapy Response in Gastric Cancer. Pharmaceuticals 2022;15:1401. [DOI: 10.3390/ph15111401] [Reference Citation Analysis]
67 Tang JL, Zhang B, Xu JP, Qi L, Xin D, Wang L, Wang BZ, Tian YT, Li Y, Huang J. Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer. Cancer Med 2022. [PMID: 36341590 DOI: 10.1002/cam4.5414] [Reference Citation Analysis]
68 Alsina M, Arrazubi V, Diez M, Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol 2022. [PMID: 36344677 DOI: 10.1038/s41575-022-00703-w] [Reference Citation Analysis]
69 Zhang X, Xu S, Wang J, Lv Y, Wang N, Lai R, Sha Z, Zhao Q, Guo Z. Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer? BMC Cancer 2022;22:1136. [DOI: 10.1186/s12885-022-10199-x] [Reference Citation Analysis]
70 Hanada K, Tsunoda S, Nomura M, Fujimura S, Yutaka Y, Nishigori T, Hisamori S, Maekewa H, Hoshino N, Itami A, Tanaka E, Obama K. A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus. surg case rep 2022;8:206. [DOI: 10.1186/s40792-022-01561-z] [Reference Citation Analysis]
71 Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N. First-in-human study of ONO-4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors. Cancer Sci 2023;114:211-20. [PMID: 36082616 DOI: 10.1111/cas.15574] [Reference Citation Analysis]
72 Jeong Y, Cho CE, Kim JE, Lee J, Kim N, Jung WY, Sung J, Kim JH, Lee YJ, Jung J, Pyo J, Song J, Park J, Moon KM, Ahn S. Deep learning model to predict Epstein-Barr virus associated gastric cancer in histology. Sci Rep 2022;12:18466. [PMID: 36323712 DOI: 10.1038/s41598-022-22731-x] [Reference Citation Analysis]
73 Yang J, Janjigian YY. Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer. Thoracic Surgery Clinics 2022;32:467-478. [DOI: 10.1016/j.thorsurg.2022.07.002] [Reference Citation Analysis]
74 Moehler M, Högner A, Wagner AD, Obermannova R, Alsina M, Thuss-Patience P, van Laarhoven H, Smyth E. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. Eur J Cancer 2022;176:13-29. [PMID: 36183651 DOI: 10.1016/j.ejca.2022.08.023] [Reference Citation Analysis]
75 Sewastjanow-Silva M, Yamashita K, Rosa Vicentini E, Hirschmann M, Pool Pizzi M, Trail AM, Waters RE, Rogers JE, Ajani JA. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives. Expert Rev Anticancer Ther 2022;22:1177-81. [PMID: 36266061 DOI: 10.1080/14737140.2022.2139241] [Reference Citation Analysis]
76 Cheng Y, Bu D, Zhang Q, Sun R, Lyle S, Zhao G, Dong L, Li H, Zhao Y, Yu J, Hao X. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. Journal of Advanced Research 2022. [DOI: 10.1016/j.jare.2022.10.019] [Reference Citation Analysis]
77 Zeng Y, Jin RU. Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer. Semin Cancer Biol 2022;86:566-82. [PMID: 34933124 DOI: 10.1016/j.semcancer.2021.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
78 Miao K, Zhang L. Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. Cancer Pathogenesis and Therapy 2022. [DOI: 10.1016/j.cpt.2022.11.003] [Reference Citation Analysis]
79 El Helali A, Tao J, Wong CHL, Chan WW, Mok K, Wu WF, Shitara K, Mohler M, Boku N, Pang H, Lam KO. A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.908026] [Reference Citation Analysis]
80 Wang T, Lin M, Mao J, Tian L, Gan H, Hu X, Yan L, Long H, Cai J, Zheng X, Xiao Y, Li D, Shuai X, Pang P. Inflammation-Regulated Nanodrug Sensitizes Hepatocellular Carcinoma to Checkpoint Blockade Therapy by Reprogramming the Tumor Microenvironment. ACS Appl Mater Interfaces 2022. [DOI: 10.1021/acsami.2c14448] [Reference Citation Analysis]
81 Cui Q, Mao Y, Wu D, Hu Y, Ma D, Zhang L, Liu H. Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.952494] [Reference Citation Analysis]
82 Chakravorty S, Afzali B, Kazemian M. EBV-associated diseases: Current therapeutics and emerging technologies. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1059133] [Reference Citation Analysis]
83 Liu D, Zhou J, Wang Y, Li M, Jiang H, Liu Y, Yin X, Ge M, Xiang X, Ying J, Huang J, Zhang YQ, Cheng Y, Huang Z, Yuan X, Han W, Yan D, Wang X, Liu P, Wang L, Zhang X, Luo S, Liu T, Shen L. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. BMC Med 2022;20:408. [PMID: 36280870 DOI: 10.1186/s12916-022-02605-9] [Reference Citation Analysis]
84 Pan Y, Lu L, Liu H, Chen D, Han N, Yao R, Wang X, Gao X, Yu J, Chen L, Zhou F, Hao G, Lu Y, Li M, He G, Kang F, Li Z, Tang Y, Zhang J, Wei L, Nie Y. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1003859] [Reference Citation Analysis]
85 Goetze TO, Al-batran S. Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer. Cancers 2022;14:5200. [DOI: 10.3390/cancers14215200] [Reference Citation Analysis]
86 Kubota Y, Aoki Y, Kawazoe A, Shitara K. Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience. Cancer Manag Res 2022;14:3083-94. [PMID: 36275782 DOI: 10.2147/CMAR.S351791] [Reference Citation Analysis]
87 Zhang L, Wang W, Ge S, Li H, Bai M, Duan J, Yang Y, Ning T, Liu R, Wang X, Ji Z, Wang F, Zhang H, Ba Y, Deng T. Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single- Arm, Phase II Trial.. [DOI: 10.21203/rs.3.rs-2052138/v1] [Reference Citation Analysis]
88 Ikoma T, Matsumoto T, Kurioka Y, Takatani M, Nagai H, Matsumoto Y, Satake H, Yasui H. Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy. JCM 2022;11:6100. [DOI: 10.3390/jcm11206100] [Reference Citation Analysis]
89 Wakasugi A, Sasaki A, Okamoto R, Motomura Y. Eldest gastric cancer patient with high microsatellite instability responding to pembrolizumab. Int Cancer Conf J 2023;12:59-62. [PMID: 36605839 DOI: 10.1007/s13691-022-00581-8] [Reference Citation Analysis]
90 Gordon A, Johnston E, Lau DK, Starling N. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments. Onco Targets Ther 2022;15:1183-96. [PMID: 36238135 DOI: 10.2147/OTT.S282718] [Reference Citation Analysis]
91 Li X, Dong H, Chen L, Wang Y, Hao Z, Zhang Y, Jiao Y, Zhao Z, Peng X, Zhan X. Identification of N7-methylguanosine related subtypes and construction of prognostic model in gastric cancer. Front Immunol 2022;13:984149. [DOI: 10.3389/fimmu.2022.984149] [Reference Citation Analysis]
92 Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, Zeng Q, Zeng L, Pan Y, Chen ZS, He Y. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther 2022;7:358. [PMID: 36209270 DOI: 10.1038/s41392-022-01190-w] [Reference Citation Analysis]
93 Zheng Y, Mislang ARA, Coward J, Cosman R, Cooper A, Underhill C, Zhu J, Xiong J, Jiang O, Wang H, Xie Y, Zhou Y, Jin X, Li B, Wang ZM, Kwek KY, Xia D, Xia Y, Xu N. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Cancer Immunol Immunother 2022;71:2371-2379. [DOI: 10.1007/s00262-022-03160-1] [Reference Citation Analysis]
94 Azuma T, Kano M, Iwata S, Honda S, Miyoshi Y, Nishiguchi J. Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. PLoS ONE 2022;17:e0274451. [DOI: 10.1371/journal.pone.0274451] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Wang Q, Cao T, Zhang X, Hui J, Wang C, Zhang W, Wang P, Zhou Y, Han S, Wang F. ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity. Journal of Immunology Research 2022;2022:1-16. [DOI: 10.1155/2022/6863240] [Reference Citation Analysis]
96 Zhang C, Sun D, Li C, Liu Y, Zhou Y, Zhang J. Development of cancer-associated fibroblasts subtype and prognostic model in gastric cancer and the landscape of tumor microenvironment. Int J Biochem Cell Biol 2022;:106309. [PMID: 36174922 DOI: 10.1016/j.biocel.2022.106309] [Reference Citation Analysis]
97 Gou M, Qian N, Zhang Y, Wei L, Fan Q, Wang Z, Dai G. Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy. Front Immunol 2022;13:950868. [DOI: 10.3389/fimmu.2022.950868] [Reference Citation Analysis]
98 . Stomach (Gastric) Cancer. Fundamentals of Cancer Detection, Treatment, and Prevention 2022. [DOI: 10.1002/9783527838561.ch17] [Reference Citation Analysis]
99 Grassadonia A, De Luca A, Carletti E, Vici P, Di Lisa FS, Filomeno L, Cicero G, De Lellis L, Veschi S, Florio R, Brocco D, Alberti S, Cama A, Tinari N. Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer. Cancers 2022;14:4670. [DOI: 10.3390/cancers14194670] [Reference Citation Analysis]
100 Zhao Y, Bai Y, Shen M, Li Y. Therapeutic strategies for gastric cancer targeting immune cells: Future directions. Front Immunol 2022;13:992762. [DOI: 10.3389/fimmu.2022.992762] [Reference Citation Analysis]
101 Kudo-saito C, Boku N, Hirano H, Shoji H. Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer. Front Immunol 2022;13:1009701. [DOI: 10.3389/fimmu.2022.1009701] [Reference Citation Analysis]
102 Salati M, Caputo F, Bocconi A, Cerri S, Baldessari C, Piacentini F, Dominici M, Gelsomino F. Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma. Front Oncol 2022;12:993573. [DOI: 10.3389/fonc.2022.993573] [Reference Citation Analysis]
103 Kim CM, Lee JB, Shin SJ, Ahn JB, Lee M, Kim HS. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. ESMO Open 2022;7:100577. [PMID: 36156450 DOI: 10.1016/j.esmoop.2022.100577] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
104 Luo H, Ye M, Hu Y, Wu M, Cheng M, Zhu X, Huang K. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma. Aging (Albany NY) 2022;14. [PMID: 36152044 DOI: 10.18632/aging.204291] [Reference Citation Analysis]
105 Liang H, Li Z, Huang Z, Wu C, Qiu Y, Liang Y, Chen X, Li F, Xu Z, Li G, Liu H, Zhao L. Prognostic characteristics and clinical response to immunotherapy targeting programmed cell death 1 for patients with advanced gastric cancer with liver metastases. Front Immunol 2022;13:1015549. [DOI: 10.3389/fimmu.2022.1015549] [Reference Citation Analysis]
106 Zhang C, Liu T, Wang J, Zhang J. Development and verification of an immune-related gene prognostic index for gastric cancer. Sci Rep 2022;12:15693. [PMID: 36127384 DOI: 10.1038/s41598-022-20007-y] [Reference Citation Analysis]
107 Tian Y, Huang A, Tian M, Wang K, Dang Q, Zhang C, Liu H, Zhao J, Yang X, Zhang C, Guo L, Chen F. Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e30151. [PMID: 36086680 DOI: 10.1097/MD.0000000000030151] [Reference Citation Analysis]
108 Mare M, Memeo L, Colarossi C, Giuffrida D. Third- and Late Line Treatments of Metastatic Gastric Cancer: Still More to Be Done. Current Oncology 2022;29:6433-6444. [DOI: 10.3390/curroncol29090506] [Reference Citation Analysis]
109 Agnarelli A, Vella V, Samuels M, Papanastasopoulos P, Giamas G. Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications. Cancers 2022;14:4378. [DOI: 10.3390/cancers14184378] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Kepenekian V, Bhatt A, Péron J, Alyami M, Benzerdjeb N, Bakrin N, Falandry C, Passot G, Rousset P, Glehen O. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol 2022. [PMID: 36071285 DOI: 10.1038/s41571-022-00675-5] [Reference Citation Analysis]
111 Wang J, Tu S, Chavda VP, Chen ZS, Chen X. Successes and failures of immunotherapy for gastric cancer. Drug Discov Today 2022;27:103343. [PMID: 36075377 DOI: 10.1016/j.drudis.2022.103343] [Reference Citation Analysis]
112 Pavlakis N, Tincknell G, Lim LE, Muro K, Obermannova R, Lorenzen S, Chua YJ, Jackson C, Karapetis CS, Price T, Chantrill L, Segelov E, Lordick F. European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. Ther Adv Med Oncol 2022;14:17588359221118874. [PMID: 36051471 DOI: 10.1177/17588359221118874] [Reference Citation Analysis]
113 Jia M, Jia J, Xu J, Xue H. . CMAR 2022;Volume 14:2625-38. [DOI: 10.2147/cmar.s372125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Norwood DA, Montalvan EE, Dominguez RL, Morgan DR. Gastric Cancer: Emerging Trends in Prevention, Diagnosis, and Treatment. Gastroenterol Clin North Am 2022;51:501-18. [PMID: 36153107 DOI: 10.1016/j.gtc.2022.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Kadono T, Yamamoto S, Kato K. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer. Jpn J Clin Oncol 2022:hyac138. [PMID: 36047845 DOI: 10.1093/jjco/hyac138] [Reference Citation Analysis]
116 Zhu J, Luo M, Liang D, Gao S, Zheng Y, He Z, Zhao W, Yu X, Qiu K, Wu J. Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data. International Immunopharmacology 2022;110:109053. [DOI: 10.1016/j.intimp.2022.109053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Yin Y, Lin Y, Yang M, Lv J, Liu J, Wu K, Liu K, Li A, Shuai X, Cai K, Wang Z, Wang G, Shen J, Zhang P, Tao K. Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial. Front Oncol 2022;12:959295. [DOI: 10.3389/fonc.2022.959295] [Reference Citation Analysis]
118 Valcarcel S, Gallego J, Jimenez-Fonseca P, Diez M, de Castro EM, Hernandez R, Arrazubi V, Custodio A, Cano JM, Montes AF, Macias I, Visa L, Calvo A, Tocino RV, Lago NM, Limón ML, Granja M, Gil M, Pimentel P, Macia-Rivas L, Pérez CH, Mangas M, Carnicero AM, Cerdà P, Gonzalez LG, Navalon FG, Rambla MDM, Richard MM, Carmona-Bayonas A. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. J Cancer Res Clin Oncol 2022. [PMID: 36042046 DOI: 10.1007/s00432-022-04294-6] [Reference Citation Analysis]
119 Cai H, Li M, Deng R, Wang M, Shi Y. Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy. Biomark Res 2022;10:67. [PMID: 36042469 DOI: 10.1186/s40364-022-00413-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Decarli K, Strosberg J, Almhanna K. Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. Cancers 2022;14:4201. [DOI: 10.3390/cancers14174201] [Reference Citation Analysis]
121 Xu X, Zhou N, Lan H, Yang F, Dong B, Zhang X. The Ferroptosis Molecular Subtype Reveals Characteristics of the Tumor Microenvironment, Immunotherapeutic Response, and Prognosis in Gastric Cancer. IJMS 2022;23:9767. [DOI: 10.3390/ijms23179767] [Reference Citation Analysis]
122 Jiang F, Zhang Z, Chong X, Shen L, Fan M, Liu X, An J, Peng Z, Zhang C. Extracellular Vesicle-Derived Protein File from Peripheral Blood Predicts Immune-Related Adverse Events in Gastric Cancer Patients Receiving Immunotherapy. Cancers 2022;14:4167. [DOI: 10.3390/cancers14174167] [Reference Citation Analysis]
123 Chang L, Cheng Q, Ma Y, Wu C, Zhang X, Ma Q, He L, Li Q, Tao J. Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor. J Immunother 2022. [PMID: 36006239 DOI: 10.1097/CJI.0000000000000438] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Gong Z, Jia Q, Xu S, Jin Z, Chu H, Wan YY, Zhu B, Zhou Y. Caspase-8 Contributes to Immuno-Hot Microenvironment by Promoting Phagocytosis via an Ecto-Calreticulin-dependent Mechanism.. [DOI: 10.21203/rs.3.rs-1984457/v1] [Reference Citation Analysis]
125 Fong C, Johnston E, Starling N. Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer. Curr Treat Options Oncol 2022. [PMID: 35980522 DOI: 10.1007/s11864-022-01004-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Akita M, Maeda E, Ishida R, Morikawa T, Nishimura T, Abe K, Kozuki A, Tanaka T, Kaneda K. A good surgical field for para-aortic nodal dissection in gastric cancer by the Cattell-Braasch maneuver. Langenbecks Arch Surg 2022. [PMID: 35978050 DOI: 10.1007/s00423-022-02657-8] [Reference Citation Analysis]
127 Mussafi O, Mei J, Mao W, Wan Y. Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. Front Oncol 2022;12:948405. [DOI: 10.3389/fonc.2022.948405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
128 Sukri A, Hanafiah A, Kosai NR. The Roles of Immune Cells in Gastric Cancer: Anti-Cancer or Pro-Cancer? Cancers (Basel) 2022;14:3922. [PMID: 36010915 DOI: 10.3390/cancers14163922] [Reference Citation Analysis]
129 Hamada K, Tsunoda T, Yoshimura K. Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. Life (Basel) 2022;12:1229. [PMID: 36013407 DOI: 10.3390/life12081229] [Reference Citation Analysis]
130 Fong C, Chau I. HER2 Inhibition in Gastric Cancer-Novel Therapeutic Approaches for an Established Target. Cancers (Basel) 2022;14:3824. [PMID: 35954487 DOI: 10.3390/cancers14153824] [Reference Citation Analysis]
131 Bao Z, Zhang Y, Yu P, Wang Y, Hu C, Xia Y, Yuan L, Xu Z, Cheng X. High CHAF1A Expression Levels Are Positively-Correlated with PD-L1 Expression and Indicate Poor Prognosis in Gastric Cancer. Evid Based Complement Alternat Med 2022;2022:1323321. [PMID: 35911136 DOI: 10.1155/2022/1323321] [Reference Citation Analysis]
132 Zaanan A. Immunothérapie dans le traitement du cancer gastrique métastatique. Bulletin du Cancer 2022. [DOI: 10.1016/j.bulcan.2022.07.002] [Reference Citation Analysis]
133 Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, Wright J, Forde PM, Ferris RL. Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer 2022;10:e005036. [PMID: 35973745 DOI: 10.1136/jitc-2022-005036] [Reference Citation Analysis]
134 Chen Y, Bai B, Ying K, Pan H, Xie B. Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022. [DOI: 10.1016/j.bbcan.2022.188775] [Reference Citation Analysis]
135 Deng R, Zheng H, Cai H, Li M, Shi Y, Ding S. Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. Front Immunol 2022;13:923477. [DOI: 10.3389/fimmu.2022.923477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
136 Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications 2022;2:739-753. [DOI: 10.1158/2767-9764.crc-22-0050] [Reference Citation Analysis]
137 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
138 Udagawa H, Takahashi S, Hirao M, Tahara M, Iwasa S, Sato Y, Hamakawa T, Shitara K, Horinouchi H, Chin K, Masuda N, Suzuki T, Okumura S, Takase T, Nagai R, Yonemori K. Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer. Cancer Med 2023;12:1269-78. [PMID: 35864593 DOI: 10.1002/cam4.4996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Dai P, Rao X, Zhang X, Qiu E, Wu G, Lin Y, Li S, Li Z, Cai Z, Han S. Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery. Front Immunol 2022;13:908558. [PMID: 35844567 DOI: 10.3389/fimmu.2022.908558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Jiang M, Zhang C, Hu Y, Li T, Yang G, Wang G, Zhu J, Shao C, Hou H, Zhou N, Liu K, Zhang X. Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma. Oncologist 2022;27:e856-69. [PMID: 35857405 DOI: 10.1093/oncolo/oyac136] [Reference Citation Analysis]
141 Nakazawa N, Sohda M, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sano A, Sakai M, Ogawa H, Shirabe K, Saeki H. Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study. Ann Surg Oncol 2022. [PMID: 35857197 DOI: 10.1245/s10434-022-12226-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Tian Y, Zhang C, Dang Q, Wang K, Liu Q, Liu H, Shang H, Zhao J, Xu Y, Wu T, Liu W, Yang X, Safi M, Wu YS. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/4976032] [Reference Citation Analysis]
143 Darling HS. Advances in immunotherapy for metastatic esophageal cancer. IJMIO 2022;0:1-8. [DOI: 10.25259/ijmio_14_2022] [Reference Citation Analysis]
144 Patel MA, Kratz JD, Lubner SJ, Loconte NK, Uboha NV. Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice. J Clin Oncol 2022;:JCO2102500. [PMID: 35839430 DOI: 10.1200/JCO.21.02500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Li X, Xu J, Xie J, Yang W. Research progress in targeted therapy and immunotherapy for gastric cancer. Chin Med J (Engl) 2022. [PMID: 35830242 DOI: 10.1097/CM9.0000000000002185] [Reference Citation Analysis]
146 Kim CG, Hong M, Jeung HC, Lee G, Chung HC, Rha SY, Kim HS, Lee CK, Lee JH, Han Y, Kim JH, Lee SY, Kim H, Shin SJ, Baek SE, Jung M. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer 2022;172:387-99. [PMID: 35839733 DOI: 10.1016/j.ejca.2022.05.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Liu S, Gao W, Ning Y, Zou X, Zhang W, Zeng L, Liu J. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:908173. [DOI: 10.3389/fimmu.2022.908173] [Reference Citation Analysis]
148 Xu H, Hong Z, Xu M, Kong Y, Ma Y, Shan C, Xing P, Zhang L. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report. Front Immunol 2022;13:926740. [DOI: 10.3389/fimmu.2022.926740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Wylie LA, Baker HC, Smyth EC. Mind the target: programmed death ligand 1 in oesophagogastric cancers. Curr Opin Oncol 2022. [PMID: 35787595 DOI: 10.1097/CCO.0000000000000859] [Reference Citation Analysis]
150 Stroes CI, Schokker S, Khurshed M, van der Woude SO, Mathôt RA, Slingerland M, de Vos-Geelen J, Zucchetti M, Matteo C, van Dijk E, Ylstra B, Thijssen V, Derks S, Godefa T, Dijksterhuis W, Breimer GE, van Delden OM, Verhoeven RH, Meijer SL, Bijlsma MF, van Laarhoven HW. A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). Ther Adv Med Oncol 2022;14:17588359221109196. [PMID: 35782751 DOI: 10.1177/17588359221109196] [Reference Citation Analysis]
151 Yu P, He W, Zhang Y, Hu C, Wu Y, Wang Y, Bao Z, Xia Y, Zhang R, Cao M, Yuan L, Cheng X, Xu Z, Cui Q. SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/8829649] [Reference Citation Analysis]
152 Nie C, He Y, Lv H, Gao M, Gao X, Chen B, Xu W, Wang J, Liu Y, Zhao J, Chen X. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study. Front Oncol 2022;12:885350. [DOI: 10.3389/fonc.2022.885350] [Reference Citation Analysis]
153 Lu Z, Yang S, Luo X, Shi Y, Lee JS, Deva S, Liu T, Chao Y, Zhang Y, Huang R, Xu Y, Shen Z, Shen L. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. Gastric Cancer 2022. [PMID: 35778636 DOI: 10.1007/s10120-022-01308-7] [Reference Citation Analysis]
154 Kwon M, Kim G, Kim R, Kim KT, Kim ST, Smith S, Mortimer PGS, Hong JY, Loembé AB, Irurzun-Arana I, Koulai L, Kim KM, Kang WK, Dean E, Park WY, Lee J. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J Immunother Cancer 2022;10:e005041. [PMID: 35790315 DOI: 10.1136/jitc-2022-005041] [Reference Citation Analysis]
155 Morimoto K, Yamada T, Morimoto Y, Ishikawa T, Asai J, Fujihara A, Arai A, Katoh N, Ukimura O, Hirano S, Itoh Y, Takayama K. A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors. International Immunopharmacology 2022;108:108775. [DOI: 10.1016/j.intimp.2022.108775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Rowsell A, Sodergren SC, Vassiliou V, Darlington AS, Guren MG, Alkhaffaf B, Moorbey C, Dennis K, Terada M. Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences. Gastric Cancer 2022;25:665-77. [PMID: 35689705 DOI: 10.1007/s10120-022-01309-6] [Reference Citation Analysis]
157 Jin X, Liu Z, Yang D, Yin K, Chang X. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Front Immunol 2022;13:948647. [DOI: 10.3389/fimmu.2022.948647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Sclafani F, Hendlisz A. Editorial: 'All you need is immunotherapy': a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers? Curr Opin Oncol 2022;34:379-81. [PMID: 35837708 DOI: 10.1097/CCO.0000000000000856] [Reference Citation Analysis]
159 Wen W, Zhang Y, Zhang H, Chen Y. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2022. [PMID: 35771261 DOI: 10.1007/s00432-022-04057-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Kusaba H, Moriyama S, Hieda M, Ito M, Ohmura H, Isobe T, Tsuchihashi K, Fukata M, Ariyama H, Baba E. IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism. Jpn J Clin Oncol 2022:hyac103. [PMID: 35766165 DOI: 10.1093/jjco/hyac103] [Reference Citation Analysis]
161 Dong M, Yu T, Zhang Z, Zhang J, Wang R, Tse G, Liu T, Zhong L. ICIs-Related Cardiotoxicity in Different Types of Cancer. JCDD 2022;9:203. [DOI: 10.3390/jcdd9070203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
162 Shao X, Zhan S, Quan Q, Shen Y, Chen S, Zhang X, Li R, Liu M, Cao L. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer. Int Immunopharmacol 2022;110:108988. [PMID: 35777267 DOI: 10.1016/j.intimp.2022.108988] [Reference Citation Analysis]
163 Liu R, Wang X, Ji Z, Deng T, Li HL, Zhang YH, Yang YC, Ge SH, Zhang L, Bai M, Ning T, Ba Y. Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report. World J Clin Cases 2022; 10(18): 6184-6191 [DOI: 10.12998/wjcc.v10.i18.6184] [Reference Citation Analysis]
164 Wei J, Lu X, Liu Q, Fu Y, Liu S, Li L, Liu F, Fan X, Yang J, Yang Y, Zhao Y, Guan W, Liu B. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. Cancer Manag Res 2022;14:2007-15. [PMID: 35747712 DOI: 10.2147/CMAR.S355687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Onoyama T, Ishikawa S, Isomoto H. Gastric cancer and genomics: review of literature. J Gastroenterol 2022. [PMID: 35751736 DOI: 10.1007/s00535-022-01879-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Liao J, Ye Y, Xu X. Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer. Clin Transl Oncol 2022. [PMID: 35732871 DOI: 10.1007/s12094-022-02857-0] [Reference Citation Analysis]
167 Wang J, He Y, Zhang B, Lv H, Nie C, Chen B, Xu W, Zhao J, Cheng X, Li Q, Tu S, Chen X. The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. Front Oncol 2022;12:924149. [PMID: 35719979 DOI: 10.3389/fonc.2022.924149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Chen L, Zhao R, Sun H, Huang R, Pan H, Zuo Y, Zhang L, Xue Y, Li X, Song H. The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors. Front Pharmacol 2022;13:833584. [DOI: 10.3389/fphar.2022.833584] [Reference Citation Analysis]
169 Aoki Y, Kawazoe A, Kubota Y, Chida K, Mishima S, Kotani D, Nakamura Y, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, Kuwata T, Shitara K. Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. Int J Clin Oncol 2022. [PMID: 35713753 DOI: 10.1007/s10147-022-02200-1] [Reference Citation Analysis]
170 Zhou C, Shangguan C, Shi M, Xi W, Wu J, Yang H, Guo L, Cai Q, Shi Y, Liu J, Zhang J. Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial). Future Oncol 2022. [PMID: 35703115 DOI: 10.2217/fon-2021-1579] [Reference Citation Analysis]
171 Kang D, Kim I. Molecular Mechanisms and Potential Rationale of Immunotherapy in Peritoneal Metastasis of Advanced Gastric Cancer. Biomedicines 2022;10:1376. [DOI: 10.3390/biomedicines10061376] [Reference Citation Analysis]
172 Wu Q, Luo S, Xie X. Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75? J Immunother 2022. [PMID: 35674663 DOI: 10.1097/CJI.0000000000000426] [Reference Citation Analysis]
173 Iikura Y, Aoyama T, Hiraide M, Wakatsuki T, Nakayama I, Ogura M, Ooki A, Takahari D, Chin K, Yamaguchi K, Hama T. Safety evaluation of fixed-dose nivolumab in patients with gastric cancer. Health Sci Rep 2022;5:e673. [PMID: 35662976 DOI: 10.1002/hsr2.673] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Xu JL, Yuan L, Hu C, Weng CY, Xu HD, Shi YF, Huang L, Ying JE, Xu ZY, Qin JJ, Cheng XD. Trametes robiniophila Murr Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Modulating Tumor Microenvironment. Front Pharmacol 2022;13:911663. [PMID: 35656301 DOI: 10.3389/fphar.2022.911663] [Reference Citation Analysis]
175 Yamaguchi K, Yoshihiro T, Ariyama H, Ito M, Nakano M, Semba Y, Nogami J, Tsuchihashi K, Yamauchi T, Ueno S, Isobe T, Shindo K, Moriyama T, Ohuchida K, Nakamura M, Nagao Y, Ikeda T, Hashizume M, Konomi H, Torisu T, Kitazono T, Kanayama T, Tomita H, Oda Y, Kusaba H, Maeda T, Akashi K, Baba E. Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model. Gastric Cancer 2022. [PMID: 35661943 DOI: 10.1007/s10120-022-01307-8] [Reference Citation Analysis]
176 Xu B, Chen F, Zhang X, Wang Z, Che K, Wu N, Yu L, Fan X, Liu B, Wei J. Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers 2022;14:2758. [DOI: 10.3390/cancers14112758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Chia DKA, Gwee YX, Sundar R. Resistance to systemic immune checkpoint inhibition in the peritoneal niche. J Immunother Cancer 2022;10:e004749. [PMID: 35728873 DOI: 10.1136/jitc-2022-004749] [Reference Citation Analysis]
178 Matsumoto Y, Sasaki T, Kondou Y, Oshida S, Suzuki T, Nakamura Y, Kudara N, Akamatsu Y, Sato Y. Surgical treatment of metastatic brain tumor from gastric cancer during therapy with nivolumab: A case report. Interdisciplinary Neurosurgery 2022;28:101503. [DOI: 10.1016/j.inat.2022.101503] [Reference Citation Analysis]
179 Bouriez D, Gronnier C, Najah H, Collet D. Making It Stick: Management of Gastroesophageal Junction Adenocarcinoma with Poorly-Cohesive Cells (PCC). Dig Dis Sci 2022;67:2005-9. [PMID: 35430699 DOI: 10.1007/s10620-022-07437-4] [Reference Citation Analysis]
180 Sohn BS. Recent Progress in Immunotherapy for Advanced Gastric Cancer. JDCR 2022;10:22-30. [DOI: 10.52927/jdcr.2022.10.1.22] [Reference Citation Analysis]
181 Gwee YX, Chia DKA, So J, Ceelen W, Yong WP, Tan P, Ong CJ, Sundar R. Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. J Clin Oncol 2022;:JCO2102745. [PMID: 35649219 DOI: 10.1200/JCO.21.02745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
182 Boisteau E, François E, Aparicio T, Le Malicot K, Boulahssass R, Lecomte T, Laurent-Puig P, Guiu B, Paillaud E, Galais MP, Lopez-Trabada Ataz D, Tougeron D, Dourthe LM, Guimbaud R, Samalin E, Moreau M, Louvet C, Lepage C, Lièvre A. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer. Dig Liver Dis 2022;54:747-54. [PMID: 35351371 DOI: 10.1016/j.dld.2022.03.001] [Reference Citation Analysis]
183 Qin L, Wang L, Zhang J, Zhou H, Yang Z, Wang Y, Cai W, Wen F, Jiang X, Zhang T, Ye H, Long B, Qin J, Shi W, Guan X, Yu Z, Yang J, Wang Q, Jiao Z. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Sci Adv 2022;8:eabn3774. [PMID: 35613265 DOI: 10.1126/sciadv.abn3774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore) 2022;101:e29304. [PMID: 35623069 DOI: 10.1097/MD.0000000000029304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Gao J, Huo S, Zhang Y, Zhao Z, Pan H, Liu X. Construction of ovarian metastasis-related immune signature predicting prognosis of gastric cancer patients. Cancer Med 2023;12:913-29. [PMID: 35621244 DOI: 10.1002/cam4.4857] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Blatt S, Krüger M, Rump C, Zimmer S, Sagheb K, Künzel J. Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma. PLoS ONE 2022;17:e0269136. [DOI: 10.1371/journal.pone.0269136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Wei T, Ye B, Wu P, Li C, Chao Y, Lee P, Huang Y, Lee K, Hou M. Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. PLoS ONE 2022;17:e0268920. [DOI: 10.1371/journal.pone.0268920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Amemiya K, Hirotsu Y, Nagakubo Y, Watanabe S, Amemiya S, Mochizuki H, Oyama T, Kondo T, Omata M. Simple IHC reveals complex MMR alternations than PCR assays: Validation by LCM and next-generation sequencing. Cancer Med 2022;11:4479-90. [PMID: 35596629 DOI: 10.1002/cam4.4832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
189 Saito N, Sato Y, Abe H, Wada I, Kobayashi Y, Nagaoka K, Kushihara Y, Ushiku T, Seto Y, Kakimi K. Selection of RNA-based evaluation methods for tumor microenvironment by comparing with histochemical and flow cytometric analyses in gastric cancer. Sci Rep 2022;12:8576. [PMID: 35595859 DOI: 10.1038/s41598-022-12610-w] [Reference Citation Analysis]
190 Liu S, Li Z, Li H, Wen X, Wang Y, Chen Q, Xu X. TGFβ-Associated Signature Predicts Prognosis and Tumor Microenvironment Infiltration Characterization in Gastric Carcinoma. Front Genet 2022;13:818378. [DOI: 10.3389/fgene.2022.818378] [Reference Citation Analysis]
191 Uchida Y, Kinose D, Nagatani Y, Tanaka-Mizuno S, Nakagawa H, Fukunaga K, Yamaguchi M, Nakano Y. Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors. BMC Cancer 2022;22:551. [PMID: 35578210 DOI: 10.1186/s12885-022-09642-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Zhao X, Xia X, Wang X, Bai M, Zhan D, Shu K. Deep Learning-Based Protein Features Predict Overall Survival and Chemotherapy Benefit in Gastric Cancer. Front Oncol 2022;12:847706. [DOI: 10.3389/fonc.2022.847706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Namikawa T, Marui A, Yokota K, Kawanishi Y, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer. Langenbecks Arch Surg 2022. [PMID: 35551466 DOI: 10.1007/s00423-022-02543-3] [Reference Citation Analysis]
194 Whooley J, Alazzawi M, Donlon NE, Bolger JC, Robb WB. PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm. Dis Esophagus 2022;35:doab063. [PMID: 34553222 DOI: 10.1093/dote/doab063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
195 Xavier CB, Lopes CDH, Harada G, Peres EDB, Katz A, Jardim DL. Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. Translational Oncology 2022;19:101383. [DOI: 10.1016/j.tranon.2022.101383] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Mulder K, Lim H, Ravi D, Ahmed S, Brunet B, Davies J, Doll C, Dueck D, Gordon V, Hebbard P, Kim CA, Le D, Lee-ying R, Mcghie JP, Park J, Renouf DJ, Schellenberg D, Wong RPW, Zaidi A, Ahmed S. Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers—A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference. Current Oncology 2022;29:3160-70. [DOI: 10.3390/curroncol29050257] [Reference Citation Analysis]
197 Li L, Chen W, Wu G, Zhang Y. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study. Disease Markers 2022;2022:1-10. [DOI: 10.1155/2022/4322404] [Reference Citation Analysis]
198 Ivey A, Pratt H, Boone BA. Molecular pathogenesis and emerging targets of gastric adenocarcinoma. J Surg Oncol 2022;125:1079-95. [PMID: 35481910 DOI: 10.1002/jso.26874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
199 Chen Y, Sun Z, Wan L, Chen H, Xi T, Jiang Y. Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response. Front Immunol 2022;13:890922. [DOI: 10.3389/fimmu.2022.890922] [Reference Citation Analysis]
200 Zhan M, Xu T, Zheng H, He Z. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study. Front Public Health 2022;10:790225. [PMID: 35309225 DOI: 10.3389/fpubh.2022.790225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
201 Fujiwara Y, Horita N, Harrington M, Namkoong H, Miyashita H, Galsky MD. Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03203-7] [Reference Citation Analysis]
202 Zhao X, Wu P, Liu D, Li C, Xue L, Liu Z, Zhu M, Yang J, Chen Z, Li Y, She Y, Srinivasan K. An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma. Journal of Healthcare Engineering 2022;2022:1-13. [DOI: 10.1155/2022/3035073] [Reference Citation Analysis]
203 Wang Z, Wang X, Xu Y, Li J, Zhang X, Peng Z, Hu Y, Zhao X, Dong K, Zhang B, Gao C, Zhao X, Chen H, Cai J, Bai Y, Sun Y, Shen L. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC Med 2022;20:133. [PMID: 35443723 DOI: 10.1186/s12916-022-02327-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Yu M, Zhang Y, Mao R, Zhu C, Zhao R, Jin L. A Risk Model of Eight Immune-Related Genes Predicting Prognostic Response to Immune Therapies for Gastric Cancer. Genes 2022;13:720. [DOI: 10.3390/genes13050720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Ishido K, Tanabe S, Katada C, Ishibashi Y, Kitahara G, Onoue M, Kubota Y, Furue Y, Wada T, Watanabe A, Kusano C. Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab. J Gastrointest Canc. [DOI: 10.1007/s12029-022-00823-1] [Reference Citation Analysis]
206 Matsunaga T, Saito H, Kuroda H, Osaki T, Takahashi S, Iwamoto A, Fukumoto Y, Taniguchi K, Fukuda K, Miyauchi W, Shishido Y, Miyatani K, Fujiwara Y. CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09482-8] [Reference Citation Analysis]
207 Chen X, Zhang H, Wang M, Liu H, Hu Y, Lin T, Chen H, Zhao M, Chen T, Li G, Yu J, Zhao L. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients. Front Immunol 2022;13:783695. [PMID: 35401534 DOI: 10.3389/fimmu.2022.783695] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Haddad R, Zlotnik O, Goshen-lago T, Levi M, Brook E, Brenner B, Kundel Y, Ben-aharon I, Kashtan H. Tumor Lymphocyte Infiltration Is Correlated with a Favorable Tumor Regression Grade after Neoadjuvant Treatment for Esophageal Adenocarcinoma. JPM 2022;12:627. [DOI: 10.3390/jpm12040627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
209 Morinaga T, Iwatsuki M, Yamashita K, Matsumoto C, Harada K, Kurashige J, Iwagami S, Baba Y, Yoshida N, Komohara Y, Baba H. Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer. Ann Surg Oncol 2022. [PMID: 35412205 DOI: 10.1245/s10434-022-11665-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
210 Chen C, Chen Y, Jin X, Ding Y, Jiang J, Wang H, Yang Y, Lin W, Chen X, Huang Y, Teng L. Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD. Front Mol Biosci 2022;9:793403. [DOI: 10.3389/fmolb.2022.793403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H, Zhang Z, Lu L, Zhang X. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. Front Immunol 2022;13:862084. [DOI: 10.3389/fimmu.2022.862084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
212 Kim JH, Ryu M, Park YS, Ma J, Lee SY, Kim D, Kang Y. Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09488-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Kang YK, Reck M, Nghiem P, Feng Y, Plautz G, Kim HR, Owonikoko TK, Boku N, Chen LT, Lei M, Chang H, Lin WH, Roy A, Bello A, Sheng J. Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. J Immunother Cancer 2022;10:e004273. [PMID: 35383114 DOI: 10.1136/jitc-2021-004273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Booth ME, Smyth EC. Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy. BioDrugs 2022. [PMID: 35384619 DOI: 10.1007/s40259-022-00527-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Lei L, Li N, Yuan P, Liu D. A new risk model based on a 11-m6A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer. BMC Cancer 2022;22:365. [PMID: 35382776 DOI: 10.1186/s12885-021-09062-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
216 Wang H, Rong J, Zhao Q, Song C, Zhao R, Chen S, Xie Y, Su T. Identification and Validation of Immune Cells and Hub Genes in Gastric Cancer Microenvironment. Disease Markers 2022;2022:1-18. [DOI: 10.1155/2022/8639323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
217 Shi Y, Zheng H, Wang M, Ding S. Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention. Helicobacter 2022;27:e12878. [PMID: 35112435 DOI: 10.1111/hel.12878] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
218 Maderer A, Lorenzen S, Thuss-patience P, Götze T, Moehler M. Regorafenib und Nivolumab (RegoNivo) versus Drittlinie bei Therapie-resistenten Ösophagus-Magen-Karzinomen (GEJC). Forum 2022;37:163-165. [DOI: 10.1007/s12312-022-01050-2] [Reference Citation Analysis]
219 Zhang J, Wang H, Yuan C, Wu J, Xu J, Chen S, Zhang C, He Y. ITGAL as a Prognostic Biomarker Correlated With Immune Infiltrates in Gastric Cancer. Front Cell Dev Biol 2022;10:808212. [DOI: 10.3389/fcell.2022.808212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
220 Loizides S, Papamichael D. Considerations and Challenges in the Management of the Older Patients with Gastric Cancer. Cancers (Basel) 2022;14:1587. [PMID: 35326739 DOI: 10.3390/cancers14061587] [Reference Citation Analysis]
221 Takashima Y, Komatsu S, Ohashi T, Kiuchi J, Kamiya H, Shimizu H, Arita T, Konishi H, Shiozaki A, Kubota T, Okamoto K, Fujiwara H, Tsuda H, Otsuji E. Overexpression of Tetraspanin31 contributes to malignant potential and poor outcomes in gastric cancer. Cancer Sci 2022. [PMID: 35307915 DOI: 10.1111/cas.15342] [Reference Citation Analysis]
222 Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Nakamura M, Okuda H, Iwanaga I, Kato T, Nakano S, Sato A, Harada K, Oba K, Sakata Y, Sakamoto N, Komatsu Y. Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201). Oncologist 2022:oyab062. [PMID: 35303078 DOI: 10.1093/oncolo/oyab062] [Reference Citation Analysis]
223 Jing C, Wang J, Zhu M, Bai Z, Zhao B, Zhang J, Yin J, Yang X, Liu Z, Zhang Z, Deng W. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. Cancer Immunol Immunother 2022. [PMID: 35304622 DOI: 10.1007/s00262-022-03174-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
224 Hu N, Li W, Hong Y, Zeng Z, Zhang J, Wu X, Zhou K, Wu F. A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer. Mol Ther Oncolytics 2022;24:148-59. [PMID: 35024441 DOI: 10.1016/j.omto.2021.12.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
225 Ding P, Guo H, Sun C, Yang P, Kim NH, Tian Y, Liu Y, Liu P, Li Y, Zhao Q. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study. BMC Gastroenterol 2022;22:121. [PMID: 35287591 DOI: 10.1186/s12876-022-02199-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
226 Mizukami T, Minashi K, Hara H, Nishina T, Amanuma Y, Takahashi N, Nakasya A, Takahashi M, Nakajima TE. An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer. Invest New Drugs. [DOI: 10.1007/s10637-022-01223-9] [Reference Citation Analysis]
227 Alsina M, Tabernero J, Diez M. Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond. Cancers 2022;14:1408. [DOI: 10.3390/cancers14061408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Lin F, Chen H, Jiang T, Zheng J, Liu Q, Yang B, Wang X, Lin X. The effect of low-dose chemotherapy on the tumor microenvironment and its antitumor activity combined with anti-PD-1 antibody. Immunotherapy 2022. [PMID: 35259922 DOI: 10.2217/imt-2021-0018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Ooki A, Yamaguchi K. The dawn of precision medicine in diffuse-type gastric cancer. Ther Adv Med Oncol 2022;14:175883592210830. [DOI: 10.1177/17588359221083049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
230 Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, Horinouchi H, Kinoshita T, Yoshikawa T, Muro K, Nishikawa H, Suna H, Kodera Y. A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer 2022. [PMID: 35254550 DOI: 10.1007/s10120-022-01286-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Bai Y, Xie T, Wang Z, Tong S, Zhao X, Zhao F, Cai J, Wei X, Peng Z, Shen L. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. J Immunother Cancer 2022;10:e004080. [PMID: 35241494 DOI: 10.1136/jitc-2021-004080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Xu X, Li J, Gao Y, Lv W, Wei Q, Tang X, Hu J, Yuan X, Wu W, Zhang L, Luo C, Chen L, Ying J, Zhu X, Xu Q, Yang D. Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/2162229] [Reference Citation Analysis]
233 Onayemi O, Oyekola I, Adebisi T. Knowledge and Compliance with Infectious Disease Preventive Measures among Market-Involved Individuals: A Case of COVID-19. Entrepreneurship and Post-Pandemic Future 2022. [DOI: 10.1108/978-1-80117-902-720221011] [Reference Citation Analysis]
234 Högner A, Moehler M. Immunotherapy in Gastric Cancer. Current Oncology 2022;29:1559-74. [DOI: 10.3390/curroncol29030131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
235 Rodrigues S, Figueiredo C. Recent insights into the use of immune checkpoint inhibitors in gastric cancer. Porto Biomedical Journal 2022;7:e162. [DOI: 10.1097/j.pbj.0000000000000162] [Reference Citation Analysis]
236 Lou S, Wang Y, Zhang J, Yin X, Zhang Y, Wang Y, Xue Y. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer. Front Immunol 2021;12:806324. [PMID: 35082793 DOI: 10.3389/fimmu.2021.806324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
237 Högner A, Thuss-patience P. Neue Entwicklungen in der Immuntherapie des Ösophagus- und Magenkarzinoms. TumorDiagnostik & Therapie 2022;43:104-111. [DOI: 10.1055/a-1688-7767] [Reference Citation Analysis]
238 Su J, Chen D, Ruan Y, Tian Y, Lv K, Zhou X, Ying D, Lu Y. LncRNA MBNL1-AS1 represses gastric cancer progression via the TGF-β pathway by modulating miR-424-5p/Smad7 axis. Bioengineered 2022;13:6978-95. [PMID: 35311623 DOI: 10.1080/21655979.2022.2037921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Umeda S, Kanda M, Shimizu D, Nakamura S, Sawaki K, Inokawa Y, Hattori N, Hayashi M, Tanaka C, Nakayama G, Kodera Y. Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. Gastric Cancer. [DOI: 10.1007/s10120-022-01284-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
240 Choi S, Park S, Kim H, Kang SY, Ahn S, Kim K. Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. Biomedicines 2022;10:543. [DOI: 10.3390/biomedicines10030543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
241 Kataoka S, Moriguchi M, Okishio S, Takahashi A, Okuda K, Seko Y, Umemura A, Yamaguchi K, Miyagawa-Hayashino A, Itoh Y. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. Clin J Gastroenterol 2022. [PMID: 35201598 DOI: 10.1007/s12328-022-01590-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Fang F, Zhang T, Li Q, Chen X, Jiang F, Shen X. The tumor immune-microenvironment in gastric cancer. Tumori 2022;:3008916211070051. [PMID: 35196917 DOI: 10.1177/03008916211070051] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
243 Qu Z, Wang Q, Wang H, Jiao Y, Li M, Wei W, Lei Y, Zhao Z, Zhang T, Zhang Y, Gu K. The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy. Front Oncol 2022;12:783197. [PMID: 35178344 DOI: 10.3389/fonc.2022.783197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
244 Cowzer D, Janjigian YY. Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer 2022. [PMID: 35179774 DOI: 10.1002/cncr.34140] [Reference Citation Analysis]
245 Takei S, Kawazoe A, Shitara K. The New Era of Immunotherapy in Gastric Cancer. Cancers (Basel) 2022;14:1054. [PMID: 35205802 DOI: 10.3390/cancers14041054] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
246 Chevallay M, Wassmer CH, Iranmanesh P, Jung MK, Mönig SP. Multimodal treatment in oligometastatic gastric cancer. World J Gastrointest Oncol 2022; 14(2): 434-449 [DOI: 10.4251/wjgo.v14.i2.434] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Chen R, Li Q, Xu S, Ye C, Tian T, Jiang Q, Shan J, Ruan J. Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment. Cancer Cell Int 2022;22:73. [PMID: 35148789 DOI: 10.1186/s12935-021-02435-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
248 Konwar M, Bose D, Maurya M, Ravi R. A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis. J Oncol Pharm Pract 2022;:10781552221074315. [PMID: 35147454 DOI: 10.1177/10781552221074315] [Reference Citation Analysis]
249 Costa G, Younes H, Kourie HR, Kattan J. The rapidly evolving landscape of advanced gastric cancer therapy. Future Oncol 2022. [PMID: 35129395 DOI: 10.2217/fon-2021-1499] [Reference Citation Analysis]
250 Tanaka Y, Chiwaki F, Kojima S, Kawazu M, Komatsu M, Ueno T, Inoue S, Sekine S, Matsusaki K, Matsushita H, Boku N, Kanai Y, Yatabe Y, Sasaki H, Mano H. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer 2021;2:962-77. [PMID: 35121863 DOI: 10.1038/s43018-021-00240-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
251 Lv W, Cheng K, Li X, Feng L, Li H, Li J, Chang C, Cao D. Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer. Front Oncol 2021;11:759652. [PMID: 35096571 DOI: 10.3389/fonc.2021.759652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Puhr HC, Ilhan-mutlu A. Innovative strategies in metastatic gastric cancer: a short review. memo 2022;15:29-34. [DOI: 10.1007/s12254-021-00762-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
253 Ma Z, Ding Y, Jing J, Du L, Zhang X, Liu H, He P. ATRA promotes PD-L1 expression to control gastric cancer immune surveillance. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174822] [Reference Citation Analysis]
254 Roviello G, Catalano M, Iannone LF, Marano L, Brugia M, Rossi G, Aprile G, Antonuzzo L. Current status and future perspectives in HER2 positive advanced gastric cancer. Clin Transl Oncol 2022;24:981-96. [PMID: 35091998 DOI: 10.1007/s12094-021-02760-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
255 Jiang Y, Li Y, Wang LXW. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Int J Clin Pharm 2022. [PMID: 35088231 DOI: 10.1007/s11096-021-01372-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
256 Chen Q, Du X, Hu S, Huang Q. NF-κB-Related Metabolic Gene Signature Predicts the Prognosis and Immunotherapy Response in Gastric Cancer. Biomed Res Int 2022;2022:5092505. [PMID: 35036435 DOI: 10.1155/2022/5092505] [Reference Citation Analysis]
257 Ando T, Sakumura M, Mihara H, Fujinami H, Yasuda I. A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. Healthcare 2022;10:218. [DOI: 10.3390/healthcare10020218] [Reference Citation Analysis]
258 Hori H, Fujita K, Nishio A, Nishijima M, Inaba M, Anami T, Matsui S, Kitamura Y, Matsuoka R, Watanabe A. Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature. Clin J Gastroenterol 2022. [PMID: 35072901 DOI: 10.1007/s12328-022-01593-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Chu Z, Lin H, Zhan Q, Liu T, Wang Y. A retrospective analysis of first-line PD-1 monoclonal antibodies treatment in patients with leptomeningeal metastasis from solid tumors. J Oncol Pharm Pract. [DOI: 10.1177/10781552221074622] [Reference Citation Analysis]
260 Lai D, Tan L, Zuo X, Liu D, Jiao D, Wan G, Lu C, Shen D, Gu X. Prognostic Ferroptosis-Related lncRNA Signatures Associated With Immunotherapy and Chemotherapy Responses in Patients With Stomach Cancer. Front Genet 2021;12:798612. [PMID: 35047016 DOI: 10.3389/fgene.2021.798612] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
261 Lin J, Lin J, Lin JP, Zheng C, Li P, Xie J, Wang J, Lu J, Chen Q, Huang C. Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion. Front Immunol 2022;12:783243. [DOI: 10.3389/fimmu.2021.783243] [Reference Citation Analysis]
262 Liang X, Zha L, Yu G, Guo X, Qin C, Cheng A, Wang Z, Laudadio I. Construction and Comprehensive Prognostic Analysis of a Novel Immune-Related lncRNA Signature and Immune Landscape in Gastric Cancer. International Journal of Genomics 2022;2022:1-23. [DOI: 10.1155/2022/4105280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
263 Ma ES, Wang ZX, Zhu MQ, Zhao J. Immune evasion mechanisms and therapeutic strategies in gastric cancer. World J Gastrointest Oncol 2022; 14(1): 216-229 [DOI: 10.4251/wjgo.v14.i1.216] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Crit Rev Oncol Hematol 2022;:103597. [PMID: 35033663 DOI: 10.1016/j.critrevonc.2022.103597] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
265 Principe DR, Kamath SD, Korc M, Munshi HG. The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. Pharmacol Ther 2022;236:108111. [PMID: 35016920 DOI: 10.1016/j.pharmthera.2022.108111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
266 Gou M, Qu T, Wang Z, Yan H, Si Y, Zhang Y, Dai G. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer. J Immunol Res 2021;2021:2549295. [PMID: 34993252 DOI: 10.1155/2021/2549295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
267 Yoshikawa AK, Yamaguchi K, Muro K, Takashima A, Ichimura T, Sakai D, Kadowaki S, Chin K, Kudo T, Mitani S, Kitano S, Thai D, Zavodovskaya M, Liu J, Boku N, Satoh T. Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. J Immunother Cancer 2022;10:e003518. [PMID: 34992093 DOI: 10.1136/jitc-2021-003518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
268 Mori T, Tanaka H, Deguchi S, Yamakoshi Y, Miki Y, Yoshii M, Tamura T, Toyokawa T, Lee S, Muguruma K, Ohira M. Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer. PLoS ONE 2022;17:e0262455. [DOI: 10.1371/journal.pone.0262455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Weadick CS, Duffy AG, Kelly RJ. Recent advances in immune-based approaches for the treatment of esophagogastric cancer. Expert Opin Emerg Drugs 2022;:1-13. [PMID: 34937483 DOI: 10.1080/14728214.2021.2020757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
270 Sano A, Sohda M, Nakazawa N, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sakai M, Ogawa H, Shirabe K, Saeki H. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer 2022;22:22. [PMID: 34980017 DOI: 10.1186/s12885-021-09118-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
271 Yu HY, Li CP, Huang YH, Hsu SJ, Wang YP, Hsieh YC, Fang WL, Huang KH, Li AF, Lee RC, Lee KL, Wu YH, Lai IC, Yang WC, Hung YP, Wang YC, Chen SH, Chen MH, Chao Y. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers (Basel) 2022;14:218. [PMID: 35008382 DOI: 10.3390/cancers14010218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
272 Surana R, Pant S. Immunotherapy in Gastrointestinal Malignancies. Adv Exp Med Biol 2021;1342:259-72. [PMID: 34972968 DOI: 10.1007/978-3-030-79308-1_8] [Reference Citation Analysis]
273 Meng Y, Li Y, Fang D, Huang Y. Identification of solute carrier family genes related to the prognosis and tumor-infiltrating immune cells of pancreatic ductal adenocarcinoma. Ann Transl Med 2022;10:57. [PMID: 35282128 DOI: 10.21037/atm-21-6341] [Reference Citation Analysis]
274 李 艳. Research Progress and Future Treatment of Advanced Gastric Cancer. ACM 2022;12:4523-4529. [DOI: 10.12677/acm.2022.125654] [Reference Citation Analysis]
275 Pehlivanoglu B, Unlu SM. Biomarkers in Gastrointestinal System Carcinomas. Biomarkers in Carcinoma of Unknown Primary 2022. [DOI: 10.1007/978-3-030-84432-5_7] [Reference Citation Analysis]
276 Matsumoto T, Yamamura S, Ikoma T, Kurioka Y, Doi K, Yasuda T, Boku S, Kawai T, Shibata N, Nagai H, Tsuduki T, Shimada T, Matsumoto Y, Tsumura T, Takatani M, Yasui H, Satake H. Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study. Clin Med Insights Oncol 2022;16:117955492211371. [DOI: 10.1177/11795549221137135] [Reference Citation Analysis]
277 Li S, Chau I. Approach to Immunotherapy in Oesophageal Cancer. Cancer Immunotherapy 2022. [DOI: 10.1007/13905_2021_11] [Reference Citation Analysis]
278 Kobayashi S, Komaya K, Takagi T, Maeda T, Kato M, Sekimura A, Yokoyama T, Hori A. A Case of Advanced Gastric Cancer That Was Difficult to Treat During Chemotherapy for Advanced Lung Cancer. J J R M 2022;70:504-509. [DOI: 10.2185/jjrm.70.504] [Reference Citation Analysis]
279 Jin J, Tu J, Ren J, Cai Y, Chen W, Zhang L, Zhang Q, Zhu G. Comprehensive Analysis to Identify MAGEA3 Expression Correlated With Immune Infiltrates and Lymph Node Metastasis in Gastric Cancer. Front Oncol 2021;11:784925. [PMID: 34970496 DOI: 10.3389/fonc.2021.784925] [Reference Citation Analysis]
280 Li T, He Y, Zhong Q, Yu J, Chen X. Advances in Treatment Models of Advanced Gastric Cancer. Technol Cancer Res Treat 2022;21:153303382210903. [DOI: 10.1177/15330338221090353] [Reference Citation Analysis]
281 Naganuma K, Horita Y, Matsuo K, Miyama Y, Mihara Y, Yasuda M, Nakano S, Hamaguchi T. An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer. Intern Med . [DOI: 10.2169/internalmedicine.9161-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
282 Kim M, Seo AN. Molecular Pathology of Gastric Cancer. J Gastric Cancer 2022;22:264. [DOI: 10.5230/jgc.2022.22.e35] [Reference Citation Analysis]
283 Kang Y, Chen L, Ryu M, Oh D, Oh SC, Chung HC, Lee K, Omori T, Shitara K, Sakuramoto S, Chung I, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen J, Bai L, Oh S, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(21)00692-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 60] [Article Influence: 36.0] [Reference Citation Analysis]
284 Merz V, Casalino S, Melisi D. Target Therapy and Immunotherapy in Gastric Cancer. Gastric Cancer: the 25-year R-Evolution 2022. [DOI: 10.1007/978-3-030-73158-8_28] [Reference Citation Analysis]
285 Sakellis CG, Jacene HA, Van den Abbeele AD. Diagnostic Applications of Nuclear Medicine: Gastric Cancers. Nuclear Oncology 2022. [DOI: 10.1007/978-3-031-05494-5_14] [Reference Citation Analysis]
286 Sakellis CG, Jacene HA, Van den Abbeele AD. Diagnostic Applications of Nuclear Medicine: Gastric Cancers. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_14-2] [Reference Citation Analysis]
287 李 晓. The Efficacy and Safety of PD-1/PD-L1 Immunosuppressive Agents in Advanced Esophageal Cancer: A Meta-Analysis. ACM 2022;12:828-837. [DOI: 10.12677/acm.2022.122120] [Reference Citation Analysis]
288 Nagaoka K, Tanaka Y, Hino O. The Tumor Microenvironment in Hepatocellular Carcinoma. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_66] [Reference Citation Analysis]
289 Enomoto N, Yamada K, Terayama M, Kato D, Yagi S, Wake H, Takemura N, Kiyomatsu T, Kokudo N. Current status of immune checkpoint inhibitor therapy for advanced esophageal squamous cell carcinoma. Glob Health Med 2021;3:378-85. [PMID: 35036619 DOI: 10.35772/ghm.2020.01112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
290 Yue Y, Lin X, Qiu X, Yang L, Wang R. The Molecular Roles and Clinical Implications of Non-Coding RNAs in Gastric Cancer. Front Cell Dev Biol 2021;9:802745. [PMID: 34966746 DOI: 10.3389/fcell.2021.802745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
291 Koo DH, Ryu MH, Lee MY, Moon MS, Kang YK. New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy. World J Gastroenterol 2021; 27(48): 8357-8369 [DOI: 10.3748/wjg.v27.i48.8357] [Reference Citation Analysis]
292 Nagaoka K, Sun C, Kobayashi Y, Kanaseki T, Tokita S, Komatsu T, Maejima K, Futami J, Nomura S, Udaka K, Nakagawa H, Torigoe T, Kakimi K. Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy. Cancers 2021;14:106. [DOI: 10.3390/cancers14010106] [Reference Citation Analysis]
293 Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel) 2021;14:109. [PMID: 35008273 DOI: 10.3390/cancers14010109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
294 Kamposioras K, Ntellas P, Nikolaou M, Germetaki T, Gazouli I, Dadouli K, Zarkavelis G, Amylidi AL, Tolia M, Mauri D. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature. JNCI Cancer Spectr 2021;5:pkab088. [PMID: 34926989 DOI: 10.1093/jncics/pkab088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
295 Takami T, Yasuda K, Uozumi N, Musiake Y, Shintani H, Kataoka N, Yamaguchi T, Makimoto S. Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report. J Med Case Rep 2021;15:604. [PMID: 34930435 DOI: 10.1186/s13256-021-03200-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
296 Ruan DY, Chen YX, Wei XL, Wang YN, Wang ZX, Wu HX, Xu RH, Yuan SQ, Wang FH. Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. Gastroenterol Rep (Oxf) 2021;9:560-70. [PMID: 34925853 DOI: 10.1093/gastro/goab032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
297 Yajima S, Sugawara K, Iwai M, Tanaka M, Seto Y, Todo T. Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma. Mol Ther Oncolytics 2021;23:402-11. [PMID: 34853811 DOI: 10.1016/j.omto.2021.10.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
298 Soond SM, Zamyatnin AA Jr. Helicobacter pylori and gastric cancer: a lysosomal protease perspective. Gastric Cancer 2021. [PMID: 34918208 DOI: 10.1007/s10120-021-01272-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
299 Ohkuma R, Ieguchi K, Watanabe M, Takayanagi D, Goshima T, Onoue R, Hamada K, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies. Biomedicines 2021;9:1929. [PMID: 34944745 DOI: 10.3390/biomedicines9121929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
300 Besova NS, Kalinin AE, Nered SN, Triakin AA, Gamaiunov SV, Kozlov NA, Stilidi IS, Karachun AM, Kononets PV, Malikhova OA, Riabov AB, Khomiakov VM, Fedenko AA, Bolotina LV, Falaleeva NA, Nevol'skikh AA, Ivanov SA, Khailova ZV, Gevorkian TG, Butenko AV, Gil'mutdinova IR, Eremushkin MA, Ivanova GE, Kondrat'eva KO, Konchugova TV, Krutov AA, Obukhova OA, Semiglazova TI, Filonenko EV, Khulamkhanova MM, Romanov AI. Gastric cancer: Russian clinical guidelines. J Mod Onco 2021;23:541-571. [DOI: 10.26442/18151434.2021.4.201239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
301 Li S, Luk HY, Xia C, Chen Z, Chan PKS, Boon SS. Oesophageal carcinoma: The prevalence of DNA tumour viruses and therapy. Tumour Virus Res 2021;13:200231. [PMID: 34920177 DOI: 10.1016/j.tvr.2021.200231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
302 Chen DL, Sheng H, Zhang DS, Jin Y, Zhao BT, Chen N, Song K, Xu RH. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Mol Cancer 2021;20:166. [PMID: 34911533 DOI: 10.1186/s12943-021-01475-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
303 Calvo V, Fernández MA, Collazo-Lorduy A, Franco F, Núñez B, Provencio M. Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. Lung Cancer Manag 2021;10:LMT51. [PMID: 34899991 DOI: 10.2217/lmt-2021-0003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
304 Yu S, Wang Y, Peng K, Lyu M, Liu F, Liu T. Establishment of a Prognostic Signature of Stromal/Immune-Related Genes for Gastric Adenocarcinoma Based on ESTIMATE Algorithm. Front Cell Dev Biol 2021;9:752023. [PMID: 34900998 DOI: 10.3389/fcell.2021.752023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
305 Gao L, Xue J, Liu X, Cao L, Wang R, Lei L. A risk model based on autophagy-related lncRNAs for predicting prognosis and efficacy of immunotherapy and chemotherapy in gastric cancer patients. Aging (Albany NY) 2021;13:25453-65. [PMID: 34897033 DOI: 10.18632/aging.203765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
306 Shah MA, Cunningham D, Metges JP, Van Cutsem E, Wainberg Z, Elboudwarej E, Lin KW, Turner S, Zavodovskaya M, Inzunza D, Liu J, Patterson SD, Zhou J, He J, Thai D, Bhargava P, Brachmann CB, Cantenacci DVT. Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival. J Immunother Cancer 2021;9:e003580. [PMID: 34893523 DOI: 10.1136/jitc-2021-003580] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
307 Li C, Chen X, Ren X, Chen JL, Chen H, Yu JJ, Ran QC, Kang S, Chen XM, Zhao ZJ. Identification of Hypoxia-Related Molecular Classification and Associated Gene Signature in Oral Squamous Cell Carcinoma. Front Oncol 2021;11:709865. [PMID: 34888229 DOI: 10.3389/fonc.2021.709865] [Reference Citation Analysis]
308 Mei Y, Shi M, Zhu Z, Yuan H, Yan C, Li C, Feng T, Yan M, Zhang J, Zhu Z. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. Future Oncol 2022;18:139-48. [PMID: 34877867 DOI: 10.2217/fon-2021-1020] [Reference Citation Analysis]
309 Chakrabarti J, Koh V, Steele N, Hawkins J, Ito Y, Merchant JL, Wang J, Helmrath MA, Ahmad SA, So JBY, Yong WP, Zavros Y. Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids. Cancers 2021;13:6158. [DOI: 10.3390/cancers13246158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
310 Wang Z, Liu C, Bai Y, Zhao X, Cui L, Peng Z, Zhang X, Wang X, Zhao Z, Li J, Shen L. Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. Front Oncol 2021;11:761110. [PMID: 34858840 DOI: 10.3389/fonc.2021.761110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
311 Miyazaki H, Nishikawa K, Hamakawa T, Toshiyama R, Miyo M, Takahashi Y, Miyake M, Miyamoto A, Kato T, Mori K, Hirao M. A Case of Recurrence of HER2-Positive Esophagogastric Junction Cancer in Which Fourth-Line Treatment with Nivolumab Was Effective after Pseudo Progression-Like Growth. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2021;54:853-860. [DOI: 10.5833/jjgs.2020.0113] [Reference Citation Analysis]
312 Song S, Chen Q, Li Y, Lei G, Scott A, Huo L, Li CY, Estrella JS, Correa A, Pizzi MP, Ma L, Jin J, Liu B, Wang Y, Xiao L, Hofstetter WL, Lee JH, Weston B, Bhutani M, Shanbhag N, Johnson RL, Gan B, Wei S, Ajani JA. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut 2021;70:2238-48. [PMID: 33487592 DOI: 10.1136/gutjnl-2020-321175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
313 Hu HM, Tsai HJ, Ku HY, Lo SS, Shan YS, Chang HC, Chao Y, Chen JS, Chen SC, Chiang CJ, Li AF, Wang HP, Wang TE, Bai LY, Wu MS, Chen LT, Liu TW, Yang YH. Survival outcomes of management in metastatic gastric adenocarcinoma patients. Sci Rep 2021;11:23142. [PMID: 34848751 DOI: 10.1038/s41598-021-02391-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
314 Tanaka K, Tanabe H, Sato H, Ishikawa C, Goto M, Yanagida N, Akabane H, Yokohama S, Hasegawa K, Kitano Y, Sugiyama Y, Uehara K, Kobayashi Y, Murakami Y, Kunogi T, Sasaki T, Takahashi K, Ando K, Ueno N, Kashima S, Moriichi K, Sato K, Yuzawa S, Tanino M, Taruiishi M, Sumi Y, Mizukami Y, Fujiya M, Okumura T. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC). Cancer Med 2022;11:406-16. [PMID: 34845844 DOI: 10.1002/cam4.4461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
315 Alsina M, Diez M, Tabernero J. Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma. Expert Opin Emerg Drugs 2021;26:385-400. [PMID: 34814781 DOI: 10.1080/14728214.2021.2010705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
316 Paydary K, Reizine N, Catenacci DVT. Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence. Cancers (Basel) 2021;13:5929. [PMID: 34885039 DOI: 10.3390/cancers13235929] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
317 Saito N, Kobayashi Y, Nagaoka K, Kushihara Y, Sato Y, Wada I, Kakimi K, Seto Y. Two distinct phenotypes of immunologically hot gastric cancer subtypes. Biochem Biophys Rep 2021;28:101167. [PMID: 34786494 DOI: 10.1016/j.bbrep.2021.101167] [Reference Citation Analysis]
318 Kole C, Charalampakis N, Tsakatikas S, Kouris NI, Papaxoinis G, Karamouzis MV, Koumarianou A, Schizas D. Immunotherapy for gastric cancer: a 2021 update. Immunotherapy 2021. [PMID: 34784774 DOI: 10.2217/imt-2021-0103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
319 Bausys A, Gricius Z, Aniukstyte L, Luksta M, Bickaite K, Bausys R, Strupas K. Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer. World J Clin Cases 2021; 9(32): 9711-9721 [PMID: 34877310 DOI: 10.12998/wjcc.v9.i32.9711] [Reference Citation Analysis]
320 Diniz TP, da Costa WL Jr, Gomes CC, de Jesus VHF, Felismino TC, Torres SM, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, Dias-Neto E, Curado MP, Coimbra FJF. Symptomatic Recurrence and Survival Outcomes After Curative Treatment of Gastric Cancer: Does Intensive Follow-up Evaluation Improve Survival? Ann Surg Oncol 2021. [PMID: 34782973 DOI: 10.1245/s10434-021-10724-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
321 Chen ZD, Zhang PF, Xi HQ, Wei B, Chen L, Tang Y. Recent Advances in the Diagnosis, Staging, Treatment, and Prognosis of Advanced Gastric Cancer: A Literature Review. Front Med (Lausanne) 2021;8:744839. [PMID: 34765619 DOI: 10.3389/fmed.2021.744839] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
322 Basile D, Simionato F, Cappetta A, Garattini SK, Roviello G, Aprile G. State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. Biologics 2021;15:451-62. [PMID: 34764633 DOI: 10.2147/BTT.S290323] [Reference Citation Analysis]
323 Ma E, Hou S, Wang Y, Xu X, Wang Z, Zhao J. Identification and Validation of an Immune-Related lncRNA Signature to Facilitate Survival Prediction in Gastric Cancer. Front Oncol 2021;11:666064. [PMID: 34760687 DOI: 10.3389/fonc.2021.666064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
324 Niclauss N, Gütgemann I, Dohmen J, Kalff JC, Lingohr P. Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. Cancers (Basel) 2021;13:5660. [PMID: 34830815 DOI: 10.3390/cancers13225660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
325 Zheng H, Li Z, Li J, Zheng S, Zhao E. Construction, Validation, and Visualization of Two Web-Based Nomograms to Predict Overall and Cancer-Specific Survival in Patients with Gastric Cancer and Lung Metastases. J Oncol 2021;2021:5495267. [PMID: 34759968 DOI: 10.1155/2021/5495267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
326 Wang A, Chu H, Jin Z, Jia Q, Zhu B. Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. Dis Markers 2021;2021:9453692. [PMID: 34754345 DOI: 10.1155/2021/9453692] [Reference Citation Analysis]
327 Sato S, Oshima Y, Matsumoto Y, Seto Y, Yamashita H, Hayano K, Kano M, Ono HA, Mitsumori N, Fujisaki M, Kunisaki C, Akiyama H, Endo I, Ichikawa Y, Urakami H, Kubo H, Nagaoka S, Shimada H. The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi-institutional cohort study. Ann Gastroenterol Surg 2021;5:794-803. [PMID: 34755011 DOI: 10.1002/ags3.12489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
328 Huang M, Li J, Yu X, Xu Q, Zhang X, Dai X, Li S, Sheng L, Huang K, Liu L. Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis. Front Oncol 2021;11:734323. [PMID: 34745955 DOI: 10.3389/fonc.2021.734323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
329 Jian D, Qian C, Wang D, Ma Q, Wang L, Li C, Xu M, Dai N, Chen Q, He J, Zhang H, Yuan M, Chen R, Chao R, Feng Y. Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage III gastric cancer: a case report. Ann Transl Med 2021;9:1489. [PMID: 34734041 DOI: 10.21037/atm-21-4295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
330 Ding Z, Li R, Han J, Sun D, Shen L, Wu G. Identification of an Immune-Related LncRNA Signature in Gastric Cancer to Predict Survival and Response to Immune Checkpoint Inhibitors. Front Cell Dev Biol 2021;9:739583. [PMID: 34722522 DOI: 10.3389/fcell.2021.739583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
331 Rao X, Jiang J, Liang Z, Zhang J, Zhuang Z, Qiu H, Luo H, Weng N, Wu X. Down-Regulated CLDN10 Predicts Favorable Prognosis and Correlates With Immune Infiltration in Gastric Cancer. Front Genet 2021;12:747581. [PMID: 34721537 DOI: 10.3389/fgene.2021.747581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
332 Zhang X, Yang L, Kong M, Ma J, Wei Y. Development of a prognostic signature of patients with esophagus adenocarcinoma by using immune-related genes. BMC Bioinformatics 2021;22:536. [PMID: 34724890 DOI: 10.1186/s12859-021-04456-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
333 Chen K, Gu Y, Cao Y, Fang H, Lv K, Liu X, He X, Wang J, Lin C, Liu H, Zhang H, He H, Xu J, Li H, Li R. TIM3+ cells in gastric cancer: clinical correlates and association with immune context. Br J Cancer 2021. [PMID: 34725458 DOI: 10.1038/s41416-021-01607-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
334 Wang Y, Shang K, Zhang N, Zhao J, Cao B. Tumor-Associated Macrophage-Derived Exosomes Promote the Progression of Gastric Cancer by Regulating the P38MAPK Signaling Pathway and the Immune Checkpoint PD-L1. Cancer Biother Radiopharm 2021. [PMID: 34698510 DOI: 10.1089/cbr.2021.0218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
335 Wang Z, Wang Z, Hu X, Han Q, Chen K, Pang G. Extracellular Matrix-Associated Pathways Promote the Progression of Gastric Cancer by Impacting the Dendritic Cell Axis. Int J Gen Med 2021;14:6725-39. [PMID: 34675633 DOI: 10.2147/IJGM.S334245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
336 Cao B, Liu M, Huang J, Zhou J, Li J, Lian H, Huang W, Guo Y, Yang S, Lin L, Cai M, Zhi C, Wu J, Liang L, Hu Y, Hu H, He J, Liang B, Zhao Q, Zhu K. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int J Biol Sci 2021;17:3850-61. [PMID: 34671203 DOI: 10.7150/ijbs.64630] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
337 Jin X, Wu S, Bai Y. Risk factors and characteristics of bacterial infection during first-line chemotherapy for metastatic gastric or gastroesophageal junction adenocarcinoma. Support Care Cancer 2021. [PMID: 34677650 DOI: 10.1007/s00520-021-06557-3] [Reference Citation Analysis]
338 Bolger JC, Donohoe CL, Lowery M, Reynolds JV. Advances in the curative management of oesophageal cancer. Br J Cancer 2021. [PMID: 34675397 DOI: 10.1038/s41416-021-01485-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
339 Körfer J, Lordick F, Hacker UT. Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. Cancers (Basel) 2021;13:5216. [PMID: 34680363 DOI: 10.3390/cancers13205216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
340 Kim JH, Zang DY, Jang HJ, Kim HS. A Bayesian network meta-analysis on systemic therapy for previously treated gastric cancer. Crit Rev Oncol Hematol 2021;167:103505. [PMID: 34656747 DOI: 10.1016/j.critrevonc.2021.103505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
341 Bando H, Tsukada Y, Ito M, Yoshino T. Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. Clin Colorectal Cancer 2021:S1533-0028(21)00099-2. [PMID: 34776358 DOI: 10.1016/j.clcc.2021.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
342 Wang Z, Peng Z, Liu Q, Guo Z, Menatola M, Su J, Li T, Ge Q, Wang P, Shen L, Jin R. Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma. Cancers (Basel) 2021;13:5175. [PMID: 34680324 DOI: 10.3390/cancers13205175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
343 Yang Z, Xue F, Li M, Zhu X, Lu X, Wang C, Xu E, Wang X, Zhang L, Yu H, Ren C, Wang H, Wang Y, Chen J, Guan W, Xia X. Extracellular Matrix Characterization in Gastric Cancer Helps to Predict Prognosis and Chemotherapy Response. Front Oncol 2021;11:753330. [PMID: 34646782 DOI: 10.3389/fonc.2021.753330] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
344 Ushimaru Y, Nishikawa K, Yasuhara Y, Kawabata R, Makari Y, Fujita J, Kitagawa A, Ohara N, Miyake Y, Maeda S, Nakahira S, Nakata K, Miyamoto A. Successful laparoscopic conversion surgery for gastric cancer with para-aortic lymph node metastasis after third-line chemotherapy: a case report. Int Cancer Conf J 2021;:1-7. [PMID: 34660169 DOI: 10.1007/s13691-021-00516-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Front Oncol 2021;11:756365. [PMID: 34631593 DOI: 10.3389/fonc.2021.756365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
346 Nie C, Lv H, Liu Y, Chen B, Xu W, Wang J, Chen X. Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study. Front Oncol 2021;11:741865. [PMID: 34631579 DOI: 10.3389/fonc.2021.741865] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
347 Ruiz Hispán E, Pedregal M, Cristobal I, García-Foncillas J, Caramés C. Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials. J Clin Med 2021;10:4649. [PMID: 34682772 DOI: 10.3390/jcm10204649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
348 Song S, Liu S, Wei Z, Jin X, Mao D, He Y, Li B, Zhang C. Identification of an Immune-Related Long Noncoding RNA Pairs Model to Predict Survival and Immune Features in Gastric Cancer. Front Cell Dev Biol 2021;9:726716. [PMID: 34621744 DOI: 10.3389/fcell.2021.726716] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
349 Watanabe H, Fujikawa H, Komori K, Kano K, Takahashi K, Yamada T, Inokuchi Y, Machida N, Yokose T, Rino Y, Masuda M, Ogata T, Oshima T. Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy. Case Rep Gastroenterol 2021;15:562-7. [PMID: 34616257 DOI: 10.1159/000514396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
350 Nagaoka K, Shirai M, Taniguchi K, Hosoi A, Sun C, Kobayashi Y, Maejima K, Fujita M, Nakagawa H, Nomura S, Kakimi K. Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. J Immunother Cancer 2020;8:e001358. [PMID: 33093158 DOI: 10.1136/jitc-2020-001358] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
351 Bolandi N, Derakhshani A, Hemmat N, Baghbanzadeh A, Asadzadeh Z, Afrashteh Nour M, Brunetti O, Bernardini R, Silvestris N, Baradaran B. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. Int J Mol Sci 2021;22:10719. [PMID: 34639059 DOI: 10.3390/ijms221910719] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
352 Miyashita K, Karayama M, Inoue Y, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kono M, Matsui T, Niwa M, Koda K, Toyoshima M, Matsushima S, Matsuura S, Asada K, Fujii M, Kusagaya H, Matsuda H, Inui N, Suda T. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. BMC Pulm Med 2021;21:309. [PMID: 34600514 DOI: 10.1186/s12890-021-01681-6] [Reference Citation Analysis]
353 de Klerk LK, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJ. Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. J Immunother Cancer 2021;9:e002472. [PMID: 34593617 DOI: 10.1136/jitc-2021-002472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
354 Rajappa SJ, Nusrath S. Nivolumab a New Standard of Care in Adjuvant Settings in Esophageal and Gastroesophageal Junctional Cancer Patients. Indian J Med Paediatr Oncol 2021;42:468-469. [DOI: 10.1055/s-0041-1739189] [Reference Citation Analysis]
355 Toda M, Nomura T, Tachibana T, Sato T, Fukushima N. The Controlling Nutritional Status (CONUT) Score Can Be Used to Predict the Therapeutic Effect and Prognosis of Nivolumab for Unresectable Advanced Gastric Cancer. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2021;54:657-664. [DOI: 10.5833/jjgs.2020.0172] [Reference Citation Analysis]
356 Abdolahi S, Ghazvinian Z, Muhammadnejad S, Ahmadvand M, Aghdaei HA, Ebrahimi-Barough S, Ai J, Zali MR, Verdi J, Baghaei K. Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model. Front Pharmacol 2021;12:733075. [PMID: 34588986 DOI: 10.3389/fphar.2021.733075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
357 Jiang Q, Chen L, Chen H, Tang Z, Liu F, Sun Y. Integrated Analysis of Stemness-Related LncRNAs Helps Predict the Immunotherapy Responsiveness of Gastric Cancer Patients. Front Cell Dev Biol 2021;9:739509. [PMID: 34589496 DOI: 10.3389/fcell.2021.739509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
358 Klein S, Duda DG. Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. Cancers (Basel) 2021;13:4919. [PMID: 34638408 DOI: 10.3390/cancers13194919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
359 Wang KX, Cui TY, Yang XD, Wang GQ, Jiang QS, Sun H, Jiang NY, Yong XM, Shi CB, Ding YB, Chen XF, Fang YY. Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial. Onco Targets Ther 2021;14:4859-65. [PMID: 34584426 DOI: 10.2147/OTT.S316288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
360 Jiang Q, Chen H, Tang Z, Sun J, Ruan Y, Liu F, Sun Y. Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer. BMC Cancer 2021;21:1067. [PMID: 34587919 DOI: 10.1186/s12885-021-08798-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
361 de la Fouchardiere C, Decoster L, Samalin E, Terret C, Kenis C, Droz JP, Coutzac C, Smyth E. Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature. Cancer Treat Rev 2021;100:102289. [PMID: 34583303 DOI: 10.1016/j.ctrv.2021.102289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
362 Zhang SX, Liu W, Ai B, Sun LL, Chen ZS, Lin LZ. Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review. Recent Pat Anticancer Drug Discov 2021. [PMID: 34587888 DOI: 10.2174/1574892816666210929165729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
363 Ma W, Li W, Xu L, Liu L, Xia Y, Yang L, Da M. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden. Pathol Oncol Res 2021;27:1609852. [PMID: 34566519 DOI: 10.3389/pore.2021.1609852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
364 Yamaguchi K, Boku N, Muro K, Yoshida K, Baba H, Tanaka S, Akamatsu A, Sano T. Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study. Gastric Cancer 2021. [PMID: 34581902 DOI: 10.1007/s10120-021-01244-y] [Reference Citation Analysis]
365 Maoxi Z, Jinmin X, Xiaozhu Z, Yubing Y, Yuxi Z. PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials. J Oncol 2021;2021:3048974. [PMID: 34567113 DOI: 10.1155/2021/3048974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
366 Ishii T, Shitara K. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer. Expert Rev Anticancer Ther 2021;21:1193-201. [PMID: 34543577 DOI: 10.1080/14737140.2021.1982698] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
367 Xie T, Zhang Z, Zhang X, Qi C, Shen L, Peng Z. Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:646355. [PMID: 34540656 DOI: 10.3389/fonc.2021.646355] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
368 Hu J, Yang S, Wang J, Zhang Q, Zhao L, Zhang D, Yu D, Jin M, Ma H, Liu H, Xue J, Zhang T. Blood alkaline phosphatase predicts prognosis of patients with advanced HER2-negative gastric cancer receiving immunotherapy. Ann Transl Med 2021;9:1316. [PMID: 34532453 DOI: 10.21037/atm-21-3376] [Reference Citation Analysis]
369 Baxter MA, Marinho J, Soto-Perez-de-Celis E, Rodriquenz MG, Arora SP, Lok WCW, Shih YY, Liposits G, O'Hanlon S, Petty RD. Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the young international society of geriatric oncology. J Geriatr Oncol 2021:S1879-4068(21)00207-1. [PMID: 34548259 DOI: 10.1016/j.jgo.2021.09.006] [Reference Citation Analysis]
370 Cordova-Delgado M, Bravo ML, Cumsille E, Hill CN, Muñoz-Medel M, Pinto MP, Retamal IN, Lavanderos MA, Miquel JF, Rodriguez-Fernandez M, Liao Y, Li Z, Corvalán AH, Armisén R, Garrido M, Quiñones LA, Owen GI. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer. BMC Cancer 2021;21:1030. [PMID: 34525956 DOI: 10.1186/s12885-021-08745-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
371 Ziogas DC, Gkoufa A, Cholongitas E, Diamantopoulos P, Anastasopoulou A, Ascierto PA, Gogas H. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. J Immunother Cancer 2020;8:e001322. [PMID: 33144335 DOI: 10.1136/jitc-2020-001322] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
372 Huynh J, Patel K, Gong J, Cho M, Malla M, Parikh A, Klempner S. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. Curr Treat Options Oncol 2021;22:100. [PMID: 34524553 DOI: 10.1007/s11864-021-00893-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
373 Businello G, Angerilli V, Parente P, Realdon S, Savarino E, Farinati F, Grillo F, Vanoli A, Galuppini F, Paccagnella S, Pennelli G, Mastracci L, Saragoni L, Fassan M. Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions. Int J Mol Sci 2021;22:9950. [PMID: 34576114 DOI: 10.3390/ijms22189950] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
374 Koh SA. An update on immunotherapy with PD-1 and PD-L1 blockade. Yeungnam Univ J Med 2021. [PMID: 34496466 DOI: 10.12701/yujm.2021.01312] [Reference Citation Analysis]
375 Gervaso L, Pellicori S, Cella CA, Bagnardi V, Lordick F, Fazio N. Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal. Ther Adv Med Oncol 2021;13:17588359211029559. [PMID: 34484429 DOI: 10.1177/17588359211029559] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
376 Ueno S, Uenomachi M, Kusaba H, Ito M, Suzuki K, Ohmura H, Tsuchihashi K, Ariyama H, Akashi K, Baba E. Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report. Mol Clin Oncol 2021;15:221. [PMID: 34476105 DOI: 10.3892/mco.2021.2379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
377 Ramaswamy A, Bajaj K, Talwar V, Prabhash K, Batra U, Dhabhar B, Sharma M, Ghadyalpatil N, Ct S, Goyal G, Muzamil J, Bhatt A, Jain P, Ranade A, Kamath M, Gawande JP, Thippeswamy R, Mirani J, Reddy N, Ganguly S, Mishra SK, Madabhavi I, Hp S, Panda SS, Patil S, Bhargava P, Ostwal V. Ramucirumab in Indian Patients with Advanced Gastric Cancer—Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit? South Asian J Cancer. [DOI: 10.1055/s-0041-1728980] [Reference Citation Analysis]
378 Kim HD, Ryu MH, Park YS, Lee SY, Moon M, Kang YK. Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab. Gastric Cancer 2021. [PMID: 34468871 DOI: 10.1007/s10120-021-01233-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
379 Olnes MJ, Martinson HA. Recent advances in immune therapies for gastric cancer. Cancer Gene Ther 2021;28:924-34. [PMID: 33664460 DOI: 10.1038/s41417-021-00310-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
380 Shimozaki K, Nakayama I, Takahari D, Kamiimabeppu D, Osumi H, Wakatsuki T, Ooki A, Ogura M, Shinozaki E, Chin K, Yamaguchi K. A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care. ESMO Open 2021;6:100234. [PMID: 34461485 DOI: 10.1016/j.esmoop.2021.100234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
381 Ge Y, Zhang H, Weygant N, Yao J. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Front Pharmacol 2021;12:640099. [PMID: 34447305 DOI: 10.3389/fphar.2021.640099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
382 Hußtegge M, Hoang NA, Rebstock J, Monecke A, Gockel I, Weimann A, Schumacher G, Bechmann I, Lordick F, Kallendrusch S, Körfer J. PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. Oncoimmunology 2021;10:1960729. [PMID: 34434611 DOI: 10.1080/2162402X.2021.1960729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
383 Komatsu M, Hirai M, Kobayashi K, Hashidate H, Fukumoto J, Sato A, Usuda H, Tanaka K, Takahashi K, Kuwabara S. A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer. BMC Gastroenterol 2021;21:333. [PMID: 34445963 DOI: 10.1186/s12876-021-01904-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
384 Yue T, Zuo S, Zhu J, Guo S, Huang Z, Li J, Wang X, Liu Y, Chen S, Wang P. Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients. Front Cell Dev Biol 2021;9:704242. [PMID: 34414187 DOI: 10.3389/fcell.2021.704242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
385 Lou S, Meng F, Yin X, Zhang Y, Han B, Xue Y. Comprehensive Characterization of RNA Processing Factors in Gastric Cancer Identifies a Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses. Front Immunol 2021;12:719628. [PMID: 34413861 DOI: 10.3389/fimmu.2021.719628] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
386 Namikawa T, Marui A, Yokota K, Fujieda Y, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment. In Vivo 2021;35:2929-35. [PMID: 34410989 DOI: 10.21873/invivo.12584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
387 Puccini A, Battaglin F, Iaia ML, Lenz HJ, Salem ME. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. J Immunother Cancer 2020;8:e000404. [PMID: 32393474 DOI: 10.1136/jitc-2019-000404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
388 Kim H, Kim H, Lee M, Kwon M, Hong JY, Lee J, Lim HY, Kang WK, Kim ST. When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. J Cancer 2021;12:5681-6. [PMID: 34405028 DOI: 10.7150/jca.62853] [Reference Citation Analysis]
389 Kang BW, Chau I. Molecular target: pan-AKT in gastric cancer. ESMO Open. 2020;5:e000728. [PMID: 32948630 DOI: 10.1136/esmoopen-2020-000728] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
390 Kouzu K, Tsujimoto H, Kishi Y, Ueno H, Shinomiya N. Role of Microbial Infection-Induced Inflammation in the Development of Gastrointestinal Cancers. Medicines (Basel) 2021;8:45. [PMID: 34436224 DOI: 10.3390/medicines8080045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
391 Ooki A, Yamaguchi K. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration. Gastric Cancer 2021. [PMID: 34398359 DOI: 10.1007/s10120-021-01235-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
392 Oh S, Kim E, Lee H. Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:3612. [PMID: 34441907 DOI: 10.3390/jcm10163612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
393 Lyadova MA, Lyadov VK. Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. J Mod Onco 2021;23:319-326. [DOI: 10.26442/18151434.2021.2.200502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
394 Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Hanai N, Muro K, Hida T. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer 2021;21:924. [PMID: 34399710 DOI: 10.1186/s12885-021-08661-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
395 Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798 [PMID: 34457186 DOI: 10.4251/wjgo.v13.i8.772] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
396 Zeng D, Wu J, Luo H, Li Y, Xiao J, Peng J, Ye Z, Zhou R, Yu Y, Wang G, Huang N, Wu J, Rong X, Sun L, Sun H, Qiu W, Xue Y, Bin J, Liao Y, Li N, Shi M, Kim KM, Liao W. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J Immunother Cancer 2021;9:e002467. [PMID: 34376552 DOI: 10.1136/jitc-2021-002467] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
397 Besova NS. Nivolumab as a representative of immune checkpoint inhibitors in late-line treatment for disseminated gastric cancer. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-9-96-107] [Reference Citation Analysis]
398 Kankeu Fonkoua LA, Yoon HH. Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. Onco Targets Ther 2021;14:4361-81. [PMID: 34385820 DOI: 10.2147/OTT.S216047] [Reference Citation Analysis]
399 Qiao Y, Liu C, Zhang X, Zhou Q, Li Y, Xu Y, Gao Z, Xu Y, Kong L, Yang A, Mei M, Ren Y, Wang X, Zhou X. PD-L2 based immune signature confers poor prognosis in HNSCC. Oncoimmunology 2021;10:1947569. [PMID: 34377590 DOI: 10.1080/2162402X.2021.1947569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
400 Kanaya N. The 2020 Incentive Award of the Okayama Medical Association in Cancer Research (2020 Hayashibara Prize and Yamada Prize). Okayama I Z 2021;133:90-92. [DOI: 10.4044/joma.133.90] [Reference Citation Analysis]
401 Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol 2021;18:473-87. [PMID: 33790428 DOI: 10.1038/s41571-021-00492-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 33.0] [Reference Citation Analysis]
402 Bordry N, Astaras C, Ongaro M, Goossens N, Frossard JL, Koessler T. Recent advances in gastrointestinal cancers. World J Gastroenterol 2021; 27(28): 4493-4503 [PMID: 34366620 DOI: 10.3748/wjg.v27.i28.4493] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
403 Mashima T, Wakatsuki T, Kawata N, Jang MK, Nagamori A, Yoshida H, Nakamura K, Migita T, Seimiya H, Yamaguchi K. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo. Sci Rep 2021;11:15125. [PMID: 34302038 DOI: 10.1038/s41598-021-94584-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
404 Zhang F, Zhu X, Zhang Q, Zhou P, Hao L. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy. Aging (Albany NY) 2021;13:18827-38. [PMID: 34297698 DOI: 10.18632/aging.203326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
405 Sasaki A, Kawazoe A, Eto T, Okunaka M, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Akimoto T, Shitara K. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open 2020;4:e000775. [PMID: 32719002 DOI: 10.1136/esmoopen-2020-000775] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
406 Kang BW, Chau I. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. ESMO Open 2020;5:e000791. [PMID: 32817133 DOI: 10.1136/esmoopen-2020-000791] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
407 Zhou B, He N, Hong J, Yang T, Ng DM, Gao X, Yan K, Fan X, Zheng Z, Chen P, Zheng J, Zheng Q. HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study. BMC Surg 2021;21:308. [PMID: 34253213 DOI: 10.1186/s12893-021-01307-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
408 Tian Y, Li R, Liu Y, Li M, Song Y, Zheng Y, Gao A, Wen Q, Su G, Sun Y. The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:667650. [PMID: 34322382 DOI: 10.3389/fonc.2021.667650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
409 Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. Oncoimmunology 2021;10:1950411. [PMID: 34290909 DOI: 10.1080/2162402X.2021.1950411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
410 Kim N, Yu JI, Lim DH, Lee J, Kim ST, Hong JY, Kang WK, Jeong WK, Kim KM. Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. Front Immunol 2021;12:701668. [PMID: 34305941 DOI: 10.3389/fimmu.2021.701668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
411 Baxter MA, Middleton F, Cagney HP, Petty RD. Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers. Br J Cancer 2021. [PMID: 34230609 DOI: 10.1038/s41416-021-01425-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
412 Nishi M, Shimada M, Tokunaga T, Higashijima J, Yoshikawa K, Kashihara H, Takasu C, Ishikawa D, Wada Y, Eto S, Yoshimoto T. Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer. World J Surg Oncol 2021;19:201. [PMID: 34229704 DOI: 10.1186/s12957-021-02319-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
413 Dang W, Xiao J, Ma Q, Miao J, Cao M, Chen L, Shi Y, Yao X, Yu S, Liu X, Cui Y, Zhang X, Bian X. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia. Brain Tumor Pathol 2021;38:189-200. [PMID: 34231121 DOI: 10.1007/s10014-021-00404-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
414 Que Y, Wang J, Zhu J, Li N, Huang J, Lu S, Sun F, Zhang L, Zhen Z, Zhang L, Cai R, Guo H, Sun X, Zhang Y. Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer. Front Immunol 2021;12:647733. [PMID: 34295326 DOI: 10.3389/fimmu.2021.647733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
415 De Falco V, Poliero L, Vitello PP, Ciardiello D, Vitale P, Zanaletti N, Giunta EF, Terminiello M, Caputo V, Carlino F, Di Liello R, Ventriglia A, Famiglietti V, Martinelli E, Morgillo F, Orditura M, De Vita F, Fasano M, Napolitano S, Martini G, Della Corte CM, Franco R, Altucci L, Ciardiello F, Troiani T. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'. ESMO Open 2020;5:e000675. [PMID: 32234730 DOI: 10.1136/esmoopen-2020-000675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
416 Li X, Gu X, Xu J, Chen L, Li H, Meng D, Bai H, Yang J, Qian J. Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report. Onco Targets Ther 2021;14:3983-9. [PMID: 34234467 DOI: 10.2147/OTT.S310421] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
417 Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-95. [PMID: 34197702 DOI: 10.1002/cac2.12193] [Cited by in Crossref: 111] [Cited by in F6Publishing: 115] [Article Influence: 55.5] [Reference Citation Analysis]
418 Komo T, Suzuki T, Tazawa H, Sada H, Morimoto H, Shimada N, Hadano N, Onoe T, Sudo T, Shimizu Y, Tashiro H. Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report. Int J Surg Case Rep 2021;84:106161. [PMID: 34237686 DOI: 10.1016/j.ijscr.2021.106161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
419 Horinouchi T, Yoshida N, Matsumoto C, Hara Y, Toihata T, Iwatsuki M, Baba Y, Miyamoto Y, Baba H. Human Epidermal Growth Factor Receptor 2-positive Primary Adenocarcinoma in the Cervical Oesophagus: A Case Report. In Vivo 2021;35:2297-303. [PMID: 34182509 DOI: 10.21873/invivo.12503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
420 Kumamoto T, Tomita T, Hojo Y, Nakamura T, Kurahashi Y, Ishida Y, Miwa H, Hirota S, Shinohara H. Pathological Complete Response and Successful Conversion Surgery After Nivolumab Therapy for Stage IV Oesophagogastric Junction Cancer. In Vivo 2021;35:2247-51. [PMID: 34182503 DOI: 10.21873/invivo.12497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
421 Nakayama I, Takahari D, Wakatsuki T, Osumi H, Chin K, Ogura M, Sato T, Suzuki T, Kamiimabeppu D, Ooki A, Suenaga M, Shinozaki E, Yamaguchi K. Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting. ESMO Open 2020;5:e000595. [PMID: 32273288 DOI: 10.1136/esmoopen-2019-000595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
422 Chen Y, Sun Z, Chen W, Liu C, Chai R, Ding J, Liu W, Feng X, Zhou J, Shen X, Huang S, Xu Z. The Immune Subtypes and Landscape of Gastric Cancer and to Predict Based on the Whole-Slide Images Using Deep Learning. Front Immunol 2021;12:685992. [PMID: 34262565 DOI: 10.3389/fimmu.2021.685992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
423 Yamaguchi K, Tsuchihashi K, Tsuji K, Kito Y, Tanoue K, Ohmura H, Ito M, Isobe T, Ariyama H, Kusaba H, Akashi K, Baba E. Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report. Medicine (Baltimore) 2021;100:e25773. [PMID: 34106609 DOI: 10.1097/MD.0000000000025773] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
424 Kubota Y, Yoshimura K, Hamada K, Hirasawa Y, Shida M, Taniguchi M, Matsui H, Ariizumi H, Ishiguro T, Suzuki N, Ohkuma R, Sambe T, Ishida H, Horiike A, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Kobayashi S, Tsunoda T. Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer. In Vivo 2021;35:1865-75. [PMID: 33910874 DOI: 10.21873/invivo.12449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
425 Watanabe H, Yamada T, Komori K, Hara K, Kano K, Takahashi K, Kumazu Y, Fujikawa H, Numata M, Aoyama T, Tamagawa H, Inokuchi Y, Machida N, Shiozawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Ogata T, Oshima T. Effect of Prognostic Nutrition Index in Gastric or Gastro-oesophageal Junction Cancer Patients Undergoing Nivolumab Monotherapy. In Vivo 2021;35:563-9. [PMID: 33402510 DOI: 10.21873/invivo.12292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
426 Ando T, Ueda A, Ogawa K, Motoo I, Kajiura S, Nakajima T, Hirano K, Okumura T, Tsukada K, Hara T, Suzuki N, Nakada N, Horikawa N, Fujii T, Yasuda I. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis. In Vivo 2021;35:475-82. [PMID: 33402499 DOI: 10.21873/invivo.12281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
427 Namikawa T, Maeda M, Yokota K, Tanioka N, Fukudome I, Iwabu J, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Assessment of Systemic Inflammatory Response and Nutritional Markers in Patients With Trastuzumab-treated Unresectable Advanced Gastric Cancer. In Vivo 2020;34:2851-7. [PMID: 32871824 DOI: 10.21873/invivo.12112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
428 Challoner BR, von Loga K, Woolston A, Griffiths B, Sivamanoharan N, Semiannikova M, Newey A, Barber LJ, Mansfield D, Hewitt LC, Saito Y, Davarzani N, Starling N, Melcher A, Grabsch HI, Gerlinger M. Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. J Natl Cancer Inst 2021;113:88-98. [PMID: 32324860 DOI: 10.1093/jnci/djaa051] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
429 Liu R, Yang F, Yin JY, Liu YZ, Zhang W, Zhou HH. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study. Front Immunol 2021;12:685370. [PMID: 34220837 DOI: 10.3389/fimmu.2021.685370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
430 Wei XL, Liu QW, Liu FR, Yuan SS, Li XF, Li JN, Yang AL, Ling YH. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer. Oncoimmunology 2021;10:1938381. [PMID: 34235004 DOI: 10.1080/2162402X.2021.1938381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
431 Gou M, Zhang Y, Liu T, Qu T, Si H, Wang Z, Yan H, Qian N, Dai G. The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy. Front Oncol 2021;11:655716. [PMID: 34211839 DOI: 10.3389/fonc.2021.655716] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
432 Fong CY, Chau I. Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. Pharmacogenomics 2021;22:703-26. [PMID: 34120461 DOI: 10.2217/pgs-2020-0090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
433 Takushima Y, Igarashi A, Yoshihara H, Shitara K, Doi T. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan. Jpn J Clin Oncol 2021:hyab086. [PMID: 34128042 DOI: 10.1093/jjco/hyab086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
434 Li S, Gao J, Xu Q, Zhang X, Huang M, Dai X, Huang K, Liu L. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors. Front Immunol 2021;12:693314. [PMID: 34177954 DOI: 10.3389/fimmu.2021.693314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
435 Tian X, Zhu Q, Zhang Z. Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review. Onco Targets Ther 2021;14:3701-8. [PMID: 34135598 DOI: 10.2147/OTT.S305039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
436 Lin S, Liu T, Chen J, Li G, Dang J. Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis. PLoS One 2021;16:e0252751. [PMID: 34086780 DOI: 10.1371/journal.pone.0252751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
437 Lai LT, Gu WG, Hu MB, Wang WJ, Wang SS, Huai YJ, Mei JH, Wang CL. Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. Aging (Albany NY) 2021;13:15413-32. [PMID: 34086601 DOI: 10.18632/aging.203100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
438 Popper U, Rumpold H. Update ESMO: gastric and esophageal cancer. memo 2021;14:180-183. [DOI: 10.1007/s12254-021-00694-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
439 Chen Y, Zhang C, Peng Z, Qi C, Gong J, Zhang X, Li J, Shen L. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. Front Oncol 2021;11:589022. [PMID: 34141607 DOI: 10.3389/fonc.2021.589022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
440 Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, D'Hondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study. Cancer Med 2021;10:4366-74. [PMID: 34057299 DOI: 10.1002/cam4.3976] [Reference Citation Analysis]
441 Shoji H, Takahari D, Hara H, Nagashima K, Adachi J, Boku N. A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811). Future Sci OA 2021;7:FSO721. [PMID: 34258028 DOI: 10.2144/fsoa-2021-0023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
442 da Silva LL, Aguiar PN Jr, Park R, Edelman Saul E, Haaland B, de Lima Lopes G. Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials. Cancers (Basel) 2021;13:2614. [PMID: 34073475 DOI: 10.3390/cancers13112614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
443 Tian Y, Huang A, Yang Y, Dang Q, Wen Q, Wang L, Sun Y. Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:662392. [PMID: 34109117 DOI: 10.3389/fonc.2021.662392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
444 Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai Y, Liu T, Zhou Q, Zhao J, Shu Y, Huang X, Wang S, Wang J, Zhou A, Ye D, Sun T, Gao Y, Yang S, Wang Z, Li J, Wu YL. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J Immunother Cancer 2020;8:e000437. [PMID: 32561638 DOI: 10.1136/jitc-2019-000437] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 21.5] [Reference Citation Analysis]
445 Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci 2021;22:5421. [PMID: 34063828 DOI: 10.3390/ijms22115421] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
446 Kovaleva OV, Podlesnaya PA, Gratchev AN, Chang VL, Ognerubov NA, Kushlinskii NE. Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint. J Mod Onco 2021;23:122-127. [DOI: 10.26442/18151434.2021.1.200749] [Reference Citation Analysis]
447 Tan B, Khattak A, Felip E, Kelly K, Rich P, Wang D, Helwig C, Dussault I, Ojalvo LS, Isambert N. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. Target Oncol 2021;16:435-46. [PMID: 34009501 DOI: 10.1007/s11523-021-00809-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
448 Matsuoka T, Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World J Gastrointest Oncol 2021; 13(5): 366-390 [PMID: 34040699 DOI: 10.4251/wjgo.v13.i5.366] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
449 Azuma T, Takeuchi T, Matayoshi Y, Namiki S, Obara T, Imamura K, Takamori M. Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. Sci Rep 2021;11:10264. [PMID: 33986326 DOI: 10.1038/s41598-021-88744-0] [Reference Citation Analysis]
450 Inamori K, Togashi Y, Fukuoka S, Akagi K, Ogasawara K, Irie T, Motooka D, Kobayashi Y, Sugiyama D, Kojima M, Shiiya N, Nakamura S, Maruyama S, Suzuki Y, Ito M, Nishikawa H. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. JCI Insight 2021;6:137365. [PMID: 33755600 DOI: 10.1172/jci.insight.137365] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
451 Mizukami K, Sakata Y, Seo K, Kitamoto S, Mura T, Kikkawa A, Hiraki K. Multicenter Joint Retrospective Study on the Onset of Immune-related Adverse Events by TPS in Patients Indicated for Non-small Cell Lung Cancer Pembrolizumab Monotherapy. Jpn J Pharm Health Care Sci 2021;47:239-249. [DOI: 10.5649/jjphcs.47.239] [Reference Citation Analysis]
452 Kim JW. Gastrointestinal cancer treatment with immune checkpoint inhibitors. J Korean Med Assoc 2021;64:342-8. [DOI: 10.5124/jkma.2021.64.5.342] [Reference Citation Analysis]
453 Jiao X, Wei X, Li S, Liu C, Chen H, Gong J, Li J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Wang Y, Wang Y, Zhuo N, Zhang H, Lu Z, Shen L. A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. NPJ Precis Oncol 2021;5:36. [PMID: 33947957 DOI: 10.1038/s41698-021-00172-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
454 Jácome AA, Morris VK, Eng C. Immunotherapy for GI Cancers. Advances in Oncology 2021;1:283-295. [DOI: 10.1016/j.yao.2021.02.024] [Reference Citation Analysis]
455 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
456 Yoon K, Chen YJ, Chao J. A narrative review of combining radiation and immunotherapy in gastroesophageal cancers. Transl Cancer Res 2021;10:2586-95. [PMID: 35116572 DOI: 10.21037/tcr-20-2210] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
457 Park JS, Choe EA, Park S, Nam CM, Hyung WJ, Noh SH, Lee S, Kim HS, Jung M, Chung HC, Rha SY. Detection of asymptomatic recurrence improves survival of gastric cancer patients. Cancer Med 2021;10:3249-60. [PMID: 33932104 DOI: 10.1002/cam4.3899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
458 Fu J, Li WZ, McGrath NA, Lai CW, Brar G, Xiang YQ, Xie C. Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:650292. [PMID: 33968750 DOI: 10.3389/fonc.2021.650292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
459 Petrillo A, Giunta EF, Pappalardo A, Bosso D, Attademo L, Cardalesi C, Diana A, Fabbrocini A, Fabozzi T, Giordano P, Ottaviano M, Rosanova M, Silvestri A, Federico P, Daniele B. Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them. J Clin Med 2021;10:1777. [PMID: 33921760 DOI: 10.3390/jcm10081777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
460 Spagnolo F, Boutros A, Cecchi F, Croce E, Tanda ET, Queirolo P. Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. BMC Cancer 2021;21:425. [PMID: 33865350 DOI: 10.1186/s12885-021-08165-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
461 Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Cui P, Huang D, Huang Z, Wu Z, Hu Y. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:562315. [PMID: 33937012 DOI: 10.3389/fonc.2021.562315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
462 Yang Y, Wang C, Dai C, Liu X, Li W, Huang M, Zhao X, Ji D, Li J, Guo W. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1. Acta Biochim Biophys Sin (Shanghai) 2021;53:547-57. [PMID: 33693450 DOI: 10.1093/abbs/gmab026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
463 Matsumoto C, Iwatsuki M, Morinaga T, Yamashita K, Nakamura K, Kurashige J, Eto K, Iwagami S, Baba Y, Yoshida N, Miyamoto Y, Baba H. Long-term survival after multidisciplinary treatments for advanced esophagogastric junction cancer. Int Cancer Conf J 2021;10:207-11. [PMID: 34221833 DOI: 10.1007/s13691-021-00480-4] [Reference Citation Analysis]
464 Park R, Da Silva LL, Saeed A. Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. Cancers (Basel) 2021;13:1715. [PMID: 33916348 DOI: 10.3390/cancers13071715] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
465 Meng Q, Lu YX, Ruan DY, Yu K, Chen YX, Xiao M, Wang Y, Liu ZX, Xu RH, Ju HQ, Qiu MZ. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer. Mol Ther Nucleic Acids 2021;24:695-710. [PMID: 33996253 DOI: 10.1016/j.omtn.2021.03.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
466 Taira K, Kimura A, Nakata A, Nadatani Y, Fukunaga S, Otani K, Hosomi S, Tanaka F, Kamata N, Nagami Y, Watanabe T, Fujiwara Y. A case of nivolumab-induced cervical lymphadenopathy in a patient with gastric cancer. J Gastrointest Oncol 2021;12:880-4. [PMID: 34012675 DOI: 10.21037/jgo-20-315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
467 Evrard C, Louvet C, Hajbi FE, Fiore FD, Malicot KL, Aparicio T, Bouché O, Laurent-Puig P, Bibeau F, Lecomte T, Lièvre A, Guimbaud R, Kim S, Zaanan A, Sokol H, Chibaudel B, Desrame J, Pierre S, Gonzalez D, Lepage C, Tougeron D. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. Dig Liver Dis 2021;53:420-6. [PMID: 33358124 DOI: 10.1016/j.dld.2020.11.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
468 Ghidini M, Petrillo A, Botticelli A, Trapani D, Parisi A, La Salvia A, Sajjadi E, Piciotti R, Fusco N, Khakoo S. How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. J Clin Med 2021;10:1412. [PMID: 33915839 DOI: 10.3390/jcm10071412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
469 Chen C, Gu YM, Zhang F, Zhang ZC, Zhang YT, He YD, Wang L, Zhou N, Tang FT, Liu HJ, Li YM. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology 2021;10:1901434. [PMID: 33854821 DOI: 10.1080/2162402X.2021.1901434] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
470 Itoh S, Yoshizumi T, Kitamura Y, Yugawa K, Iseda N, Shimagaki T, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M. Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation. Hepatol Commun 2021;5:1278-89. [PMID: 34278175 DOI: 10.1002/hep4.1715] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
471 Hu Q, Nonaka K, Wakiyama H, Miyashita Y, Fujimoto Y, Jogo T, Hokonohara K, Nakanishi R, Hisamatsu Y, Ando K, Kimura Y, Masuda T, Oki E, Mimori K, Oda Y, Mori M. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. Cancer Med 2021;10:3129-38. [PMID: 33769705 DOI: 10.1002/cam4.3828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
472 Li G, Wang G, Chi F, Jia Y, Wang X, Mu Q, Qin K, Zhu X, Pang J, Xu B, Feng G, Niu Y, Gong T, Zhang H, Dong X, Liu T, Ma J, Gao Z, Tao K, Li F, Xu J, Yu B. Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer. J Immunother Cancer 2021;9:e002218. [PMID: 33753568 DOI: 10.1136/jitc-2020-002218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
473 Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Nishiyama T, Chen LT, Kang YK. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer 2021;24:946-58. [PMID: 33743112 DOI: 10.1007/s10120-021-01173-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
474 Kumamoto K, Tasaki T, Ohnishi K, Shibata M, Shimajiri S, Harada M, Komohara Y, Nakayama T. CD169 Expression on Lymph Node Macrophages Predicts in Patients With Gastric Cancer. Front Oncol 2021;11:636751. [PMID: 33816277 DOI: 10.3389/fonc.2021.636751] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
475 Shimozaki K, Hirata K, Horie S, Chida A, Tsugaru K, Hayashi Y, Kawasaki K, Miyanaga R, Hayashi H, Mizuno R, Funakoshi T, Hosoe N, Hamamoto Y, Kanai T. The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. Diagnostics (Basel) 2021;11:543. [PMID: 33803735 DOI: 10.3390/diagnostics11030543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
476 Zhao Q, Chen Y, Du S, Yang X, Chen Y, Ji Y, Zeng Z. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther 2021;22:175-83. [PMID: 33722163 DOI: 10.1080/15384047.2020.1834792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Fan X, Wang D, Zhang W, Liu J, Liu C, Li Q, Ma Z, Li H, Guan X, Bai Y, Yang J, Lou C, Li X, Wang G, Li Z. Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti-PD-1 Therapy. Front Cell Dev Biol 2021;9:638312. [PMID: 33791296 DOI: 10.3389/fcell.2021.638312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
478 Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers (Basel) 2021;13:1304. [PMID: 33804024 DOI: 10.3390/cancers13061304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
479 Mansoor W, Arkenau HT, Alsina M, Shitara K, Thuss-Patience P, Cuffe S, Dvorkin M, Park D, Ando T, Van Den Eynde M, Beretta GD, Zaniboni A, Doi T, Tabernero J, Ilson DH, Makris L, Benhadji KA, Van Cutsem E. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. Gastric Cancer 2021;24:970-7. [PMID: 33713215 DOI: 10.1007/s10120-021-01156-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
480 Zeng Z, Yang B, Liao Z. Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Front Oncol 2021;11:650481. [PMID: 33777812 DOI: 10.3389/fonc.2021.650481] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
481 Matsumoto H, Shimokawa N, Sato H, Yoshida Y, Takami T. Intramedullary spinal cord metastasis of gastric cancer. J Craniovertebr Junction Spine 2021;12:77-80. [PMID: 33850386 DOI: 10.4103/jcvjs.JCVJS_163_20] [Reference Citation Analysis]
482 Suzuki M, Hosaka H, Fukai Y, Mochida Y, Ozawa D, Kogure N, Yamada K, Ojima H. Conversion surgery for metastatic gastric cancer at 2 years after initial diagnosis of cancer of unknown primary with metastasis of cervical lymph nodes and ovary: a case report. Surg Case Rep 2021;7:62. [PMID: 33665675 DOI: 10.1186/s40792-021-01145-3] [Reference Citation Analysis]
483 Aoki M, Iwasa S, Boku N. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer 2021;24:567-76. [PMID: 33646464 DOI: 10.1007/s10120-021-01164-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
484 Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 2021;9:513. [PMID: 33850910 DOI: 10.21037/atm-21-434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
485 Masetti M, Lorenzen S. Therapie von Tumoren des Magens und des Ösophagus - aktueller Stand. InFo Hämatol Onkol 2021;24:39-49. [DOI: 10.1007/s15004-021-8575-0] [Reference Citation Analysis]
486 Wang Z, Kang W, Li O, Qi F, Wang J, You Y, He P, Suo Z, Zheng Y, Liu HM. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharm Sin B 2021;11:694-707. [PMID: 33777676 DOI: 10.1016/j.apsb.2020.11.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
487 Kim YY, Lee J, Jeong WK, Kim ST, Kim JH, Hong JY, Kang WK, Kim KM, Sohn I, Choi D. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer 2021;24:457-66. [PMID: 32970267 DOI: 10.1007/s10120-020-01124-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
488 Tokuyama N, Takegawa N, Nishikawa M, Sakai A, Mimura T, Kushida S, Tsumura H, Yamamoto Y, Miki I, Tsuda M. Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer. PLoS One 2021;16:e0247645. [PMID: 33635904 DOI: 10.1371/journal.pone.0247645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
489 Harada H, Soeno T, Nishizawa N, Washio M, Sakuraya M, Ushiku H, Niihara M, Hosoda K, Kumamoto Y, Naitoh T, Sangai T, Hiki N, Yamashita K. Prospective study to validate the clinical utility of DNA diagnosis of peritoneal fluid cytology test in gastric cancer. Cancer Sci 2021;112:1644-54. [PMID: 33576114 DOI: 10.1111/cas.14850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
490 Yu J, Zhang Q, Wang M, Liang S, Huang H, Xie L, Cui C, Yu J. Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer. Biosci Rep 2021;41:BSR20203336. [PMID: 33492335 DOI: 10.1042/BSR20203336] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
491 Yamakoshi Y, Tanaka H, Sakimura C, Mori T, Deguchi S, Yoshii M, Tamura T, Toyokawa T, Lee S, Muguruma K, Hirakawa K, Ohira M. Association between the preoperative neutrophil-to-lymphocyte ratio and tertiary lymphoid structures surrounding tumor in gastric cancer. Mol Clin Oncol 2021;14:76. [PMID: 33680464 DOI: 10.3892/mco.2021.2238] [Reference Citation Analysis]
492 Li S, Yang H, Li S, Zhao Z, Wang D, Fu W. High expression of regulator of G-protein signalling 1 is associated with the poor differentiation and prognosis of gastric cancer. Oncol Lett 2021;21:322. [PMID: 33692854 DOI: 10.3892/ol.2021.12584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
493 Catanese S, Lordick F. Targeted and immunotherapy in the era of personalised gastric cancer treatment. Best Pract Res Clin Gastroenterol 2021;50-51:101738. [PMID: 33975679 DOI: 10.1016/j.bpg.2021.101738] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
494 Mimura K, Kua LF, Xiao JF, Asuncion BR, Nakayama Y, Syn N, Fazreen Z, Soong R, Kono K, Yong WP. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models. Gastric Cancer 2021;24:611-23. [PMID: 33611641 DOI: 10.1007/s10120-020-01151-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
495 Kataoka H, Nishie H, Tanaka M, Sasaki M, Nomoto A, Osaki T, Okamoto Y, Yano S. Potential of Photodynamic Therapy Based on Sugar-Conjugated Photosensitizers. J Clin Med 2021;10:841. [PMID: 33670714 DOI: 10.3390/jcm10040841] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
496 Matsumura S, Nakamori M, Tsuji T, Kato T, Nakamura M, Ojima T, Fukuhara H, Ino Y, Todo T, Yamaue H. Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer. Oncotarget 2021;12:344-54. [PMID: 33659045 DOI: 10.18632/oncotarget.27873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
497 Zaidi AH, Kelly RJ, Gorbunova A, Omstead AN, Salvitti MS, Zheng P, Kosovec JE, Lee S, Ayazi S, Babar L, Finley GG, Goel A, Jobe BA. Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model. Oncotarget 2021;12:292-303. [PMID: 33659041 DOI: 10.18632/oncotarget.27886] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
498 Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N, Kadowaki S, Makiyama A, Machida N, Hirano H, Hirata K, Hara H, Yabusaki H, Komatsu Y, Muro K. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers (Basel) 2021;13:805. [PMID: 33671871 DOI: 10.3390/cancers13040805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
499 Businello G, Galuppini F, Fassan M. The impact of recent next generation sequencing and the need for a new classification in gastric cancer. Best Pract Res Clin Gastroenterol 2021;50-51:101730. [PMID: 33975684 DOI: 10.1016/j.bpg.2021.101730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
500 Ando K, Hu Q, Kasagi Y, Oki E, Mori M. Recent developments in cancer research: Expectations for a new remedy. Ann Gastroenterol Surg 2021;5:419-26. [PMID: 34337290 DOI: 10.1002/ags3.12440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
501 Yoneda A, Kuroki T, Eguchi S. Immunotherapeutic advances in gastric cancer. Surg Today 2021. [PMID: 33590326 DOI: 10.1007/s00595-021-02236-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
502 Ji S, Li J, Chang L, Zhao C, Jia R, Tan Z, Liu R, Zhang Y, Li Y, Yin G, Guan Y, Xia X, Yi X, Xu J. Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor. Clin Transl Oncol 2021;23:1646-56. [PMID: 33583004 DOI: 10.1007/s12094-021-02562-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
503 Shin HM, Kim G, Kim S, Sim JH, Choi J, Kim M, Kwon M, Ye SK, Lee DS, Cho SW, Kim ST, Lee J, Kim HR. Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. Nat Commun 2021;12:975. [PMID: 33579944 DOI: 10.1038/s41467-021-21299-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
504 Högner A, Thuss-Patience P. Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma. Pharmaceuticals (Basel) 2021;14:151. [PMID: 33673374 DOI: 10.3390/ph14020151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
505 Zhang S, Zhou Z, Wang L, Li M, Zhang F, Zeng X. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis 2021;12:2040622320976996. [PMID: 33633822 DOI: 10.1177/2040622320976996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
506 Cetin B, Gumusay O. Understanding relevant immune mechanisms in gastrointestinal oncology. J Oncol Pharm Pract 2021;27:1222-34. [PMID: 33557689 DOI: 10.1177/1078155221992862] [Reference Citation Analysis]
507 Jiang L, Gong X, Liao W, Lv N, Yan R. Molecular targeted treatment and drug delivery system for gastric cancer. J Cancer Res Clin Oncol 2021;147:973-86. [PMID: 33550445 DOI: 10.1007/s00432-021-03520-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
508 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
509 Irino T, Matsuda S, Wada N, Kawakubo H, Kitagawa Y. Essential updates 2019/2020: Perioperative and surgical management of gastric cancer. Ann Gastroenterol Surg 2021;5:162-72. [PMID: 33860136 DOI: 10.1002/ags3.12438] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
510 Noh MG, Yoon Y, Kim G, Kim H, Lee E, Kim Y, Park C, Lee KH, Park H. Practical prediction model of the clinical response to programmed death-ligand 1 inhibitors in advanced gastric cancer. Exp Mol Med 2021;53:223-34. [PMID: 33547412 DOI: 10.1038/s12276-021-00559-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
511 Li JY, Chen YP, Li YQ, Liu N, Ma J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer 2021;20:27. [PMID: 33541368 DOI: 10.1186/s12943-021-01317-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
512 Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol 2020;6:1571-80. [PMID: 32880601 DOI: 10.1001/jamaoncol.2020.3370] [Cited by in Crossref: 280] [Cited by in F6Publishing: 314] [Article Influence: 140.0] [Reference Citation Analysis]
513 Xing M, Ooi WF, Tan J, Qamra A, Lee PH, Li Z, Xu C, Padmanabhan N, Lim JQ, Guo YA, Yao X, Amit M, Ng LM, Sheng T, Wang J, Huang KK, Anene-Nzelu CG, Ho SWT, Ray M, Ma L, Fazzi G, Lim KJ, Wijaya GC, Zhang S, Nandi T, Yan T, Chang MM, Das K, Isa ZFA, Wu J, Poon PSY, Lam YN, Lin JS, Tay ST, Lee MH, Tan ALK, Ong X, White K, Rozen SG, Beer M, Foo RSY, Grabsch HI, Skanderup AJ, Li S, Teh BT, Tan P. Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. J Clin Invest 2020;130:3005-20. [PMID: 32364535 DOI: 10.1172/JCI126726] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
514 Yamashita K, Hosoda K, Niihara M, Hiki N. History and emerging trends in chemotherapy for gastric cancer. Ann Gastroenterol Surg 2021;5:446-56. [PMID: 34337293 DOI: 10.1002/ags3.12439] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
515 Collienne M, Arnold D. GOBLET-Studie (AIO-KRK-0320). Forum 2021;36:74-75. [DOI: 10.1007/s12312-020-00892-y] [Reference Citation Analysis]
516 Kim W, Chu TH, Nienhüser H, Jiang Z, Del Portillo A, Remotti HE, White RA, Hayakawa Y, Tomita H, Fox JG, Drake CG, Wang TC. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology 2021;160:781-96. [PMID: 33129844 DOI: 10.1053/j.gastro.2020.10.036] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 17.0] [Reference Citation Analysis]
517 Wei XL, Xu JY, Wang DS, Chen DL, Ren C, Li JN, Wang F, Wang FH, Xu RH. Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. Ther Adv Med Oncol 2021;13:1758835921988996. [PMID: 33613701 DOI: 10.1177/1758835921988996] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
518 Voutsadakis IA. A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. Euroasian J Hepatogastroenterol 2020;10:56-63. [PMID: 33511066 DOI: 10.5005/jp-journals-10018-1321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
519 Hsu CC, Liao WY, Chang KY, Chan TS, Huang PJ, Chiang CT, Shan YS, Cheng LH, Liao TY, Tsai KK. A multi-mode Wnt- and stemness-regulatory module dictated by FOXM1 and ASPM isoform I in gastric cancer. Gastric Cancer 2021;24:624-39. [PMID: 33515163 DOI: 10.1007/s10120-020-01154-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
520 Ng MCH, Choo SP. Combination of immunotherapy with chemotherapy in first line treatment of metastatic gastric cancer? Too much, too little or just right? Ann Transl Med 2020;8:1692. [PMID: 33490204 DOI: 10.21037/atm-20-4699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
521 Huemer F, Leisch M, Geisberger R, Zaborsky N, Greil R. miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. Pharmaceuticals (Basel) 2021;14:89. [PMID: 33530393 DOI: 10.3390/ph14020089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
522 Kinoshita J, Yamaguchi T, Moriyama H, Fushida S. Current status of conversion surgery for stage IV gastric cancer. Surg Today 2021. [PMID: 33486610 DOI: 10.1007/s00595-020-02222-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
523 Donlon NE, Power R, Hayes C, Davern M, Reynolds JV, Lysaght J. Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play. Int J Mol Sci 2021;22:1071. [PMID: 33499003 DOI: 10.3390/ijms22031071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
524 Kono Y, Choda Y, Nakagawa M, Miyahara K, Ishida M, Kubota T, Seo K, Hirata T, Obayashi Y, Gotoda T, Moritou Y, Okikawa Y, Iwamoto Y, Okada H. Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab. Target Oncol 2021;16:237-48. [PMID: 33475927 DOI: 10.1007/s11523-021-00790-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
525 Nakano H, Saito M, Nakajima S, Saito K, Nakayama Y, Kase K, Yamada L, Kanke Y, Hanayama H, Onozawa H, Okayama H, Fujita S, Sakamoto W, Saze Z, Momma T, Mimura K, Ohki S, Goto A, Kono K. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms. Sci Rep 2021;11:1982. [PMID: 33479394 DOI: 10.1038/s41598-021-81667-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
526 Dahiya DS, Kichloo A, Singh J, Albosta M, Lekkala M. Current immunotherapy in gastrointestinal malignancies A Review. J Investig Med 2021;69:689-96. [PMID: 33443046 DOI: 10.1136/jim-2020-001654] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
527 Zhao DY, Sun XZ, Yao SK. Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer. World J Gastrointest Oncol 2021; 13(1): 37-57 [PMID: 33510848 DOI: 10.4251/wjgo.v13.i1.37] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
528 Saeed A, Park R, Sun W. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. J Hematol Oncol 2021;14:13. [PMID: 33436042 DOI: 10.1186/s13045-021-01034-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
529 Lagisetty KH, McEwen DP, Nancarrow DJ, Schiebel JG, Ferrer-Torres D, Ray D, Frankel TL, Lin J, Chang AC, Kresty LA, Beer DG. Immune determinants of Barrett's progression to esophageal adenocarcinoma. JCI Insight 2021;6:143888. [PMID: 33290281 DOI: 10.1172/jci.insight.143888] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
530 Kotani D, Shitara K. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol 2021;13:1758835920986518. [PMID: 33473250 DOI: 10.1177/1758835920986518] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
531 Liu R, Liao YZ, Zhang W, Zhou HH. Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes. Front Oncol 2020;10:575264. [PMID: 33489882 DOI: 10.3389/fonc.2020.575264] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
532 Jiang Q, Feng M, Li Y, Lang J, Wei H, Yu T. Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS. Front Pharmacol 2020;11:574511. [PMID: 33390946 DOI: 10.3389/fphar.2020.574511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
533 Cui L, Wang X, Zhang D. TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer. Front Cell Dev Biol 2020;8:611444. [PMID: 33469538 DOI: 10.3389/fcell.2020.611444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
534 Torres JA, de Jesus VHF. Circulating Tumor Cells in Gastric Cancer. Atlas of Liquid Biopsy 2021. [DOI: 10.1007/978-3-030-69879-9_7] [Reference Citation Analysis]
535 Lum C, Frentzas S. Case studies highlighting the multiple facets of gastric cancer: one diagnosis, multiple approaches. Research and Clinical Applications of Targeting Gastric Neoplasms 2021. [DOI: 10.1016/b978-0-323-85563-1.00010-1] [Reference Citation Analysis]
536 Huang Q, Zheng Y, Gao Z, Yuan L, Sun Y, Chen H. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. J Cancer 2021;12:1133-43. [PMID: 33442411 DOI: 10.7150/jca.49325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
537 Okada M, Yamamoto S, Kato K, Department of Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, Department of Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, Department of Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma. Oncology & Hematology Review (US) 2021;16:90. [DOI: 10.17925/ohr.2021.16.2.90] [Reference Citation Analysis]
538 Arrazubi V, Alsina M. Immunotherapy of Gastric Cancer: Focus on Perioperative Strategies. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_3] [Reference Citation Analysis]
539 Nishibeppu K, Komatsu S, Kiuchi J, Kishimoto T, Takashima Y, Shoda K, Arita T, Kosuga T, Konishi H, Shiozaki A, Kubota T, Okamoto K, Fujiwara H, Tsuda H, Otsuji E. TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer. J Cancer 2021;12:316-25. [PMID: 33391428 DOI: 10.7150/jca.47577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
540 Balasubramanian A, John A, Segelov E. Current state of chemotherapy and immunotherapy regimens in gastric cancer. Research and Clinical Applications of Targeting Gastric Neoplasms 2021. [DOI: 10.1016/b978-0-323-85563-1.00008-3] [Reference Citation Analysis]
541 Derks S, van Laarhoven HWM. Perspective on the Immunotherapy of Esophageal Cancer. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_2] [Reference Citation Analysis]
542 Moy RH, Janjigian YY. Stomach: The Standard of Care ± HER2. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_4] [Reference Citation Analysis]
543 De Vita F, Tirino G, Pompella L, Petrillo A. Gastric Cancer: Advanced/Metastatic Disease. Practical Medical Oncology Textbook 2021. [DOI: 10.1007/978-3-030-56051-5_36] [Reference Citation Analysis]
544 Bartels P, Thuss-patience P. Inductive Preoperative Chemotherapy for Peritoneal Metastases of Tumors of the Upper GI Tract. Peritoneal Tumors and Metastases 2021. [DOI: 10.1007/978-3-030-62640-2_7] [Reference Citation Analysis]
545 Kubota Y, Kawazoe A, Shitara K. Perspective on the Immunotherapy of Gastric Cancer. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_5] [Reference Citation Analysis]
546 Bajpai M, (David) Zhou Z. Biomarkers of Esophageal Cancers and Precancerous Lesions. Physiology in Health and Disease 2021. [DOI: 10.1007/978-3-030-67951-4_5] [Reference Citation Analysis]
547 Palle J, Taïeb J, Zaanan A. Biomarkers for Immunotherapy in Gastrointestinal Cancers. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_10] [Reference Citation Analysis]
548 Xu J, Xu N, Bai Y, Liu R, Mao C, Sui H, Wang X, Jiang Q, Dou Y. Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. Oncoimmunology 2020;10:1864908. [PMID: 33457083 DOI: 10.1080/2162402X.2020.1864908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
549 Gupta VG, Rangaraju RR, Abbas W, Bajpai P, Khetrapal R. Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy. South Asian J Cancer 2019;8:65-8. [PMID: 30766859 DOI: 10.4103/sajc.sajc_167_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
550 Meng J, Zhou Y, Lu X, Bian Z, Chen Y, Zhou J, Zhang L, Hao Z, Zhang M, Liang C. Immune response drives outcomes in prostate cancer: implications for immunotherapy. Mol Oncol 2021;15:1358-75. [PMID: 33338321 DOI: 10.1002/1878-0261.12887] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
551 Noto JM, Peek RM Jr. RNF43: A Biomarker With Potential Ramifications for Therapeutic Intervention in Gastric Cancer. Cell Mol Gastroenterol Hepatol 2021;11:1202-3. [PMID: 33347817 DOI: 10.1016/j.jcmgh.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
552 Yoshikawa-Kimura A, Taira K, Katanosaka Y, Nakata A, Nadatani Y, Fukunaga S, Otani K, Hosomi S, Tanaka F, Kamata N, Nagami Y, Watanabe T, Fujiwara Y. A Rare Case of Clival Metastasis in a Patient with Gastric Cancer. Intern Med 2020;59:3161-4. [PMID: 33328414 DOI: 10.2169/internalmedicine.5457-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
553 Xiang A, Lin X, Xu L, Chen H, Guo J, Zhou F. PCOLCE Is Potent Prognostic Biomarker and Associates With Immune Infiltration in Gastric Cancer. Front Mol Biosci 2020;7:544895. [PMID: 33392251 DOI: 10.3389/fmolb.2020.544895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
554 Wei Y, Li Y, Du Q, Peng X, Jin J, Guo H, Li Y, Li Q. Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. J Immunol Res 2020;2020:5269787. [PMID: 33381603 DOI: 10.1155/2020/5269787] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
555 Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2020;6:375-84. [PMID: 31876895 DOI: 10.1001/jamaoncol.2019.5367] [Cited by in Crossref: 120] [Cited by in F6Publishing: 135] [Article Influence: 40.0] [Reference Citation Analysis]
556 Chen XJ, Yuan SQ, Duan JL, Chen YM, Chen S, Wang Y, Li YF. The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. Dis Markers 2020;2020:6717912. [PMID: 33488843 DOI: 10.1155/2020/6717912] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
557 Zhang Y, Lin A, Li Y, Ding W, Meng H, Luo P, Zhang J. Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer. Front Cell Dev Biol 2020;8:608969. [PMID: 33363171 DOI: 10.3389/fcell.2020.608969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
558 Palle J, Rochand A, Pernot S, Gallois C, Taïeb J, Zaanan A. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. Drugs 2020;80:401-15. [PMID: 32077003 DOI: 10.1007/s40265-020-01272-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
559 Cascinu S, Bodoky G, Muro K, Van Cutsem E, Oh SC, Folprecht G, Ananda S, Girotto G, Wainberg ZA, Miron MLL, Ajani J, Wei R, Liepa AM, Carlesi R, Emig M, Ohtsu A. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist 2021;26:e414-24. [PMID: 33274542 DOI: 10.1002/onco.13623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
560 Kim DW, Schell MJ, Kim RD. Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer-Reply. JAMA Oncol 2020;6:1981-2. [PMID: 33090188 DOI: 10.1001/jamaoncol.2020.4821] [Reference Citation Analysis]
561 Toyota S, Orita H, Fukuyama Y, Motoyoshi S, Kawanami S, Maeda S, Kuramitsu E, Ichimanda M, Nagamatsu S, Nagata S, Kai S, Korenaga D, Mori M. Successful Conversion Surgery Following Chylous Ascites After Nivolumab for Advanced Gastric Cancer. In Vivo 2020;34:583-5. [PMID: 32111756 DOI: 10.21873/invivo.11810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
562 Puhr HC, Ilhan-mutlu A. Molecular profiling in gastroesophageal cancer—clinical routine and future perspective. memo 2020;13:440-444. [DOI: 10.1007/s12254-019-00534-7] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
563 Nozawa K, Narita Y, Hosoda W, Muro K. Dramatic Response in a Patient with Metastatic Gastric Cancer Using Trifluridine/Tipiracil after Rapid Disease Progression while on Nivolumab. Case Rep Oncol 2020;13:1381-6. [PMID: 33442359 DOI: 10.1159/000510405] [Reference Citation Analysis]
564 Qian L, Liu F, Chu Y, Zhai Q, Wei X, Shao J, Li R, Xu Q, Yu L, Liu B, Liu Q. MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT. Cancer Manag Res 2020;12:12215-23. [PMID: 33273858 DOI: 10.2147/CMAR.S279978] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
565 Bai J, Yang B, Shi R, Shao X, Yang Y, Wang F, Xiao J, Qu X, Liu Y, Zhang Y, Li Z. Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker. Aging (Albany NY) 2020;12:25101-19. [PMID: 33221769 DOI: 10.18632/aging.104084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
566 Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Cochrane Database Syst Rev 2020;11:CD012078. [PMID: 33210731 DOI: 10.1002/14651858.CD012078.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
567 Ogata T, Narita Y, Misawa K, Hosoda W, Muro K. Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake. Clin Case Rep 2021;9:50-6. [PMID: 33489132 DOI: 10.1002/ccr3.3399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
568 Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coşkun HS, Cubillo Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang YJ. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol 2021;39:966-77. [PMID: 33197226 DOI: 10.1200/JCO.20.00892] [Cited by in Crossref: 47] [Cited by in F6Publishing: 59] [Article Influence: 15.7] [Reference Citation Analysis]
569 Yang L, Dong XZ, Xing XX, Cui XH, Li L, Zhang L. Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis. World J Gastrointest Oncol 2020; 12(11): 1346-1363 [PMID: 33250966 DOI: 10.4251/wjgo.v12.i11.1346] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
570 Halpern N, Grinshpun A, Boursi B, Golan T, Margalit O, Aderka D, Friedman E, Laitman Y, Hubert A, Kadouri L, Hamburger T, Barnes-Kedar I, Levi Z, Ben-Aharon I, Brenner B, Goldberg Y, Peretz T, Shacham-Shmueli E. Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review. Onco Targets Ther. 2020;13:11637-11644. [PMID: 33235458 DOI: 10.2147/ott.s276814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
571 Liu X, Cao Y, Lv K, Gu Y, Jin K, He X, Fang H, Fei Y, Shi M, Lin C, Liu H, Li H, He H, Xu J, Li R, Zhang H. Tumor-infiltrating podoplanin+ cells in gastric cancer: clinical outcomes and association with immune contexture. Oncoimmunology 2020;9:1845038. [PMID: 33235820 DOI: 10.1080/2162402X.2020.1845038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
572 Yatsuda Y, Hirose S, Ito Y, Onoda T, Sugiyama Y, Nagafuchi M, Suzuki H, Niisato Y, Tange Y, Ikeda T, Yamada T, Yamamoto Y, Ohyama Osawa M, Sakamoto N, Moriwaki T, Mizokami Y. A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient. Intern Med 2021;60:1011-7. [PMID: 33162479 DOI: 10.2169/internalmedicine.5893-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
573 Li W, Li Q, Yu Y, Wang Y, Chen E, Chen L, Wang Z, Cui Y, Liu T. Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma. Cancer Manag Res 2020;12:11113-9. [PMID: 33173344 DOI: 10.2147/CMAR.S276969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
574 Shimoji K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Takeno S, Hide M, Teishima J, Ohdan H, Hattori N. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers. JAMA Netw Open 2020;3:e2022906. [PMID: 33180128 DOI: 10.1001/jamanetworkopen.2020.22906] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
575 Ballhausen A, Bartels P, Högner A, Thuss-patience P. Systemtherapie des Ösophaguskarzinoms. TumorDiagnostik & Therapie 2020;41:588-594. [DOI: 10.1055/a-1229-7648] [Reference Citation Analysis]
576 Liu H, Xu D, Wang W, Sun F, Zhang S, Yang X, Tian Y. Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:570080. [PMID: 33194659 DOI: 10.3389/fonc.2020.570080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
577 Imamura Y, Watanabe M, Oki E, Morita M, Baba H. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg 2021;5:46-59. [PMID: 33532680 DOI: 10.1002/ags3.12406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
578 Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, Morinaga T, Nakao Y, Harada K, Eto K, Kurashige J, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Ajani JA, Baba H. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. Br J Cancer 2021;124:595-603. [PMID: 33100329 DOI: 10.1038/s41416-020-01138-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
579 Khalafi S, Lockhart AC, Livingstone AS, El-Rifai W. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet? Cancers (Basel) 2020;12:E3077. [PMID: 33105560 DOI: 10.3390/cancers12113077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
580 Wang Y, Kong D, Wang C, Chen J, Li J, Liu Z, Li X, Wang Z, Yao G, Wang X. A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials. Technol Cancer Res Treat 2020;19:1533033820967454. [PMID: 33084525 DOI: 10.1177/1533033820967454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
581 Fujimori D, Kinoshita J, Yamaguchi T, Nakamura Y, Gunjigake K, Ohama T, Sato K, Yamamoto M, Tsukamoto T, Nomura S, Ohta T, Fushida S. Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer. BMC Cancer 2020;20:1014. [PMID: 33081727 DOI: 10.1186/s12885-020-07477-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
582 Arigami T, Matsushita D, Okubo K, Tanaka T, Sasaki K, Noda M, Kita Y, Mori S, Tsuruda Y, Kurahara H, Ohtsuka T. Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report. Surg Case Rep 2020;6:271. [PMID: 33074364 DOI: 10.1186/s40792-020-01050-1] [Reference Citation Analysis]
583 Sato Y, Wada I, Odaira K, Hosoi A, Kobayashi Y, Nagaoka K, Karasaki T, Matsushita H, Yagi K, Yamashita H, Fujita M, Watanabe S, Kamatani T, Miya F, Mineno J, Nakagawa H, Tsunoda T, Takahashi S, Seto Y, Kakimi K. Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells. Clin Transl Immunology 2020;9:e1194. [PMID: 33101677 DOI: 10.1002/cti2.1194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
584 Song Y, Li N, Li Q, Liang X, Zhang S, Fan Q, Yin X, Zhuang Z, Liu Y, Zhang J, Kou X, Zhong H, Wang X, Dou Y, Huang J. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. J Immunother Cancer 2020;8:e001279. [PMID: 33060149 DOI: 10.1136/jitc-2020-001279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
585 Miki Y, Yashiro M, Moyano-Galceran L, Sugimoto A, Ohira M, Lehti K. Crosstalk Between Cancer Associated Fibroblasts and Cancer Cells in Scirrhous Type Gastric Cancer. Front Oncol 2020;10:568557. [PMID: 33178597 DOI: 10.3389/fonc.2020.568557] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
586 Tanaka Y, Wada H, Goto R, Osada T, Yamamura K, Fukaya S, Shimizu A, Okubo M, Minamiguchi K, Ikizawa K, Sasaki E, Utsugi T. TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice. Sci Rep 2020;10:17284. [PMID: 33057061 DOI: 10.1038/s41598-020-74187-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
587 Harada K, Rogers JE, Iwatsuki M, Yamashita K, Baba H, Ajani JA. Recent advances in treating oesophageal cancer. F1000Res 2020;9:F1000 Faculty Rev-1189. [PMID: 33042518 DOI: 10.12688/f1000research.22926.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
588 Sun Y, Li S, Yu W, Zhao Z, Gao J, Chen C, Wei M, Liu T, Li L, Liu L. N6-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer. Cell Death Dis 2020;11:836. [PMID: 33037176 DOI: 10.1038/s41419-020-03049-w] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
589 El Gharib K, Kourie HR. Is ramucirumab still the only second-line treatment in metastatic gastric cancer? Pharmacogenomics 2020;21:1203-6. [PMID: 33030093 DOI: 10.2217/pgs-2020-0118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
590 Park W, Bang JH, Nam AR, Jin MH, Seo H, Kim JM, Oh KS, Kim TY, Oh DY. Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients. Cancer Res Treat 2021;53:199-206. [PMID: 33070562 DOI: 10.4143/crt.2020.497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
591 Koo DH, Ryu MH, Lee MY, Chae H, Kim EJ, Moon MS, Kang YK. Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting. Cancer Res Treat 2021;53:436-44. [PMID: 33070558 DOI: 10.4143/crt.2020.725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
592 Epistola RJ, Chao J. Systemic therapy for advanced gastroesophageal cancers: progress and pitfalls. Transl Gastroenterol Hepatol 2020;5:53. [PMID: 33073048 DOI: 10.21037/tgh.2020.01.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
593 Ku GY. Next generation sequencing in gastric or gastroesophageal adenocarcinoma. Transl Gastroenterol Hepatol 2020;5:56. [PMID: 33073051 DOI: 10.21037/tgh.2020.01.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
594 Iyer P, Moslim M, Farma JM, Denlinger CS. Diffuse gastric cancer: histologic, molecular, and genetic basis of disease. Transl Gastroenterol Hepatol 2020;5:52. [PMID: 33073047 DOI: 10.21037/tgh.2020.01.02] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
595 Chandra R, Balachandar N, Wang S, Reznik S, Zeh H, Porembka M. The changing face of gastric cancer: epidemiologic trends and advances in novel therapies. Cancer Gene Ther 2021;28:390-9. [PMID: 33009508 DOI: 10.1038/s41417-020-00234-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
596 Fang D, Lu G. Expression and role of nuclear receptor-interacting protein 1 (NRIP1) in stomach adenocarcinoma. Ann Transl Med 2020;8:1293. [PMID: 33209873 DOI: 10.21037/atm-20-6197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
597 Nakano S, Yuki S, Kawamoto Y, Nakatsumi H, Ando T, Kajiura S, Yoshikawa A, Harada K, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Dazai M, Sasaki T, Sakamoto N, Komatsu Y. Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study. Int J Clin Oncol 2020;25:1800-1806. [DOI: 10.1007/s10147-020-01720-y] [Reference Citation Analysis]
598 Nakamura N, Kinami S, Fujita J, Kaida D, Tomita Y, Miyata T, Fujita H, Takamura H, Ueda N, Kosaka T. Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases. Asian Pac J Cancer Prev 2020;21:2955-60. [PMID: 33112554 DOI: 10.31557/APJCP.2020.21.10.2955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
599 Bomze D, Asher N, Hasan Ali O, Flatz L, Azoulay D, Markel G, Meirson T. Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. JAMA Netw Open 2020;3:e2017675. [PMID: 33095247 DOI: 10.1001/jamanetworkopen.2020.17675] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
600 Chen C, An L, Cheng Y, Luo X, Li Z, Liu X. Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis. Front Oncol 2020;10:1404. [PMID: 32983970 DOI: 10.3389/fonc.2020.01404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
601 Petrillo A, Smyth EC. Biomarkers for Precision Treatment in Gastric Cancer. Visc Med 2020;36:364-72. [PMID: 33178733 DOI: 10.1159/000510489] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
602 Gambardella V, Fleitas T, Tarazona N, Papaccio F, Huerta M, Roselló S, Gimeno-Valiente F, Roda D, Cervantes A. Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. J Clin Med 2020;9:E3049. [PMID: 32971757 DOI: 10.3390/jcm9093049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
603 Yu S, Hu C, Cai L, Du X, Lin F, Yu Q, Liu L, Zhang C, Liu X, Li W, Zhan Y. Seven-Gene Signature Based on Glycolysis Is Closely Related to the Prognosis and Tumor Immune Infiltration of Patients With Gastric Cancer. Front Oncol 2020;10:1778. [PMID: 33072557 DOI: 10.3389/fonc.2020.01778] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
604 Kim SW, Roh J, Lee HS, Ryu MH, Park YS, Park CS. Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer. Gastric Cancer 2021;24:327-40. [PMID: 32924090 DOI: 10.1007/s10120-020-01120-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
605 Parisi A, Porzio G, Ficorella C. Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. Cancers (Basel) 2020;12:E2598. [PMID: 32932914 DOI: 10.3390/cancers12092598] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
606 Doi H, Ninomiya M, Toyota K, Hirahara S, Kuhara Y, Shirakawa K, Yano R, Kobayashi H, Hashimoto Y, Yokoyama Y, Sakashita Y, Miyamoto K. A case of multiple metastatic gastric cancer with primary lesion vanished after administrating nivolumab, and the effect remains even after discontinuance of therapy. Int Cancer Conf J 2020;9:187-92. [PMID: 32904060 DOI: 10.1007/s13691-020-00432-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
607 Kawazoe H, Nakamura T. Outcomes of Clinical Pharmacy Research Aimed at Avoiding or Reducing Cancer Chemotherapy-induced Adverse Reaction. Jpn J Pharm Health Care Sci 2020;46:467-480. [DOI: 10.5649/jjphcs.46.467] [Reference Citation Analysis]
608 Nakazawa Y, Gannichida A, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 2020;46:481-8. [DOI: 10.5649/jjphcs.46.481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
609 Nasr R, Shamseddine A, Mukherji D, Nassar F, Temraz S. The Crosstalk between Microbiome and Immune Response in Gastric Cancer. Int J Mol Sci 2020;21:E6586. [PMID: 32916853 DOI: 10.3390/ijms21186586] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
610 Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 2020;39:1179-203. [PMID: 32894370 DOI: 10.1007/s10555-020-09925-3] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 31.7] [Reference Citation Analysis]
611 Marshall S, Kizuki A, Kitaoji T, Imada H, Kato H, Hosoda M, Ishikawa M, Sakura H. Type 1 Diabetes, ACTH Deficiency, and Hypothyroidism Simultaneously Induced by Nivolumab Therapy in a Patient with Gastric Cancer: A Case Report. Case Rep Oncol 2020;13:1185-90. [PMID: 33173483 DOI: 10.1159/000510044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
612 Kundel Y, Sternschuss M, Moore A, Perl G, Brenner B, Goldvaser H. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis. Cancer Med 2020;9:7613-25. [PMID: 32869544 DOI: 10.1002/cam4.3417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
613 Hsu A, Zayac AS, Eturi A, Almhanna K. Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020. Ann Transl Med 2020;8:1109. [PMID: 33145328 DOI: 10.21037/atm-20-1159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
614 Wei Q, Yuan X, Li J, Xu Q, Ying J. PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study. Transl Cancer Res 2020;9:5315-22. [PMID: 35117897 DOI: 10.21037/tcr-20-1333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
615 Shi XJ, Wei Y, Ji B. Systems Biology of Gastric Cancer: Perspectives on the Omics-Based Diagnosis and Treatment.Front Mol Biosci. 2020;7:203. [PMID: 33005629 DOI: 10.3389/fmolb.2020.00203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
616 Yamaguchi Y, Katata Y, Sano F, Tanioka H, Okawaki M, Yamamura M, Nagasaka T. Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study. Mol Clin Oncol 2020;13:55. [PMID: 32905239 DOI: 10.3892/mco.2020.2125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
617 Eso Y, Seno H. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Therap Adv Gastroenterol. 2020;13:1756284820948773. [PMID: 32913444 DOI: 10.1177/1756284820948773] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 8.7] [Reference Citation Analysis]
618 Li X, Chen L, Gu C, Sun Q, Li J. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. PeerJ 2020;8:e9536. [PMID: 32874775 DOI: 10.7717/peerj.9536] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
619 Lordick F, Hacker U, Gockel I, Bläker H. Magenkarzinom: Neue molekulare Konzepte. Deutsches Ärzteblatt Online 2020. [DOI: 10.3238/personko.2020.08.17.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
620 Tanaka H, Kanda M, Miwa T, Umeda S, Sawaki K, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y. G protein subunit gamma 4 expression has potential of detection, prediction, and therapeutic target for liver metastasis of gastric cancer.. [DOI: 10.1101/2020.08.14.20175034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
621 Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Peng B, Shen L, Xu N. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer 2020;20:760. [PMID: 32795349 DOI: 10.1186/s12885-020-07251-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
622 Asai A, Yasuoka H, Matsui M, Tsuchimoto Y, Fukunishi S, Higuchi K. Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression. Cancers (Basel) 2020;12:E2286. [PMID: 32824016 DOI: 10.3390/cancers12082286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
623 Hong SA, Hwang HW, Kim MK, Lee TJ, Yim K, Won HS, Sun S, Kim EY, Ko YH. High Endothelial Venule with Concomitant High CD8+ Tumor-Infiltrating Lymphocytes Is Associated with a Favorable Prognosis in Resected Gastric Cancer. J Clin Med 2020;9:E2628. [PMID: 32823631 DOI: 10.3390/jcm9082628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
624 Güthle M, Ettrich T, Seufferlein T. Immunotherapy in Gastrointestinal Cancers. Visc Med 2020;36:231-7. [PMID: 32775355 DOI: 10.1159/000507798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
625 Lu Z, Peng Z, Liu C, Wang Z, Wang Y, Jiao X, Li J, Shen L. Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. Innovation (N Y) 2020;1:100041. [PMID: 34557714 DOI: 10.1016/j.xinn.2020.100041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
626 Turkes F, Mencel J, Starling N. Targeting the immune milieu in gastrointestinal cancers. J Gastroenterol 2020;55:909-26. [PMID: 32748171 DOI: 10.1007/s00535-020-01710-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
627 Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV, Li R, Wei J, Wang L, Liu B, Nowakowski GS, Wang ML, Wang Y. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e2012534. [PMID: 32766800 DOI: 10.1001/jamanetworkopen.2020.12534] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 13.7] [Reference Citation Analysis]
628 Cotes Sanchís A, Gallego J, Hernandez R, Arrazubi V, Custodio A, Cano JM, Aguado G, Macias I, Lopez C, López F, Visa L, Garrido M, Martínez Lago N, Fernández Montes A, Limón ML, Azkárate A, Pimentel P, Reguera P, Ramchandani A, Cacho JD, Martín Carnicero A, Granja M, Martín Richard M, Hernández Pérez C, Hurtado A, Serra O, Buxo E, Vidal Tocino R, Jimenez-Fonseca P, Carmona-Bayonas A. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. PLoS One 2020;15:e0235848. [PMID: 32735623 DOI: 10.1371/journal.pone.0235848] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
629 Yamamoto K, Omori T, Hara H, Shinno N, Sugimura K, Miyata H, Takahashi H, Fujiwara Y, Ohue M, Yano M. Minimally invasive surgery is feasible after preoperative chemotherapy for stage IV gastric cancer. Ann Gastroenterol Surg 2020;4:396-404. [PMID: 32724883 DOI: 10.1002/ags3.12343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
630 Accordino G, Lettieri S, Bortolotto C, Benvenuti S, Gallotti A, Gattoni E, Agustoni F, Pozzi E, Rinaldi P, Primiceri C, Morbini P, Lancia A, Stella GM. From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers-A Multidisciplinary Perspective. Cancers (Basel) 2020;12:E2105. [PMID: 32751137 DOI: 10.3390/cancers12082105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
631 Song X, Qi W, Guo J, Sun L, Ding A, Zhao G, Li H, Qiu W, Lv J. Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress. Oncol Lett 2020;20:46. [PMID: 32802168 DOI: 10.3892/ol.2020.11905] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
632 Nie S, Yuan Y. The Role of Gastric Mucosal Immunity in Gastric Diseases. J Immunol Res 2020;2020:7927054. [PMID: 32775468 DOI: 10.1155/2020/7927054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
633 Kuhara Y, Ninomiya M, Hirahara S, Doi H, Kenji S, Toyota K, Yano R, Kobayashi H, Hashimoto Y, Yokoyama Y, Sakashita Y, Miyamoto K. A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect. Int Cancer Conf J 2020;9:193-8. [PMID: 32904110 DOI: 10.1007/s13691-020-00433-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
634 Matsumoto T, Yamamoto Y, Kuriona Y, Okazaki U, Kimura S, Miura K, Tsuduki T, Watanabe T, Mastumoto Y, Takatani M. Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses. BMC Cancer 2020;20:684. [PMID: 32698781 DOI: 10.1186/s12885-020-07176-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
635 Matsumoto R, Arigami T, Matsushita D, Okubo K, Tanaka T, Yanagita S, Sasaki K, Noda M, Kita Y, Mori S, Kurahara H, Ohtsuka T. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report. World J Surg Oncol 2020;18:179. [PMID: 32693806 DOI: 10.1186/s12957-020-01954-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
636 Bai R, Chen N, Liang T, Li L, Lv Z, Lv X, Cui J. Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction? Front Oncol 2020;10:912. [PMID: 32793461 DOI: 10.3389/fonc.2020.00912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
637 Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, Kawakami H, Tanaka K, Hayashi H, Takeda M, Maeda N, Kagari T, Hirotani K, Tsurutani J, Nishio K, Doi K, Miyazawa M, Nakagawa K. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest 2020;130:374-88. [PMID: 31661465 DOI: 10.1172/JCI126598] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
638 Ye J, Ji X, Dennis PA, Abdullah H, Mukhopadhyay P. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis. Clin Pharmacol Ther 2020;108:1274-88. [PMID: 32564368 DOI: 10.1002/cpt.1956] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
639 Ishii T, Kawazoe A, Sasaki A, Mishima S, Kentaro S, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Kuwata T, Ishii G, Shitara K. Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. Ther Adv Med Oncol 2020;12:1758835920942377. [PMID: 32733607 DOI: 10.1177/1758835920942377] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
640 Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol 2020;12:1758835920937612. [PMID: 32728392 DOI: 10.1177/1758835920937612] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
641 Sakakida T, Ishikawa T, Uchino J, Tabuchi Y, Komori S, Asai J, Arai A, Tsunezuka H, Kosuga T, Konishi H, Hongo F, Inoue M, Hirano S, Ukimura O, Taguchi T, Takayama K, Itoh Y. Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. Oncol Lett 2020;20:14. [PMID: 32774487 DOI: 10.3892/ol.2020.11875] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
642 Li J, Zhang Y, Hu D, Gong T, Xu R, Gao J. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer. Aging (Albany NY) 2020;12:14271-84. [PMID: 32668412 DOI: 10.18632/aging.103457] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
643 Liu T, Jin B, Chen J, Wang H, Lin S, Dang J, Li G. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. Ther Adv Med Oncol 2020;12:1758835920940927. [PMID: 32774474 DOI: 10.1177/1758835920940927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
644 Matsuoka H, Hayashi T, Takigami K, Imaizumi K, Shiroki R, Ohmiya N, Sugiura K, Kawada K, Sawaki A, Maeda K, Ando Y, Uyama I. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer 2020;20:656. [PMID: 32664888 DOI: 10.1186/s12885-020-07142-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
645 Song P, Zhang D, Cui X, Zhang L. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer 2020;11:2406-30. [PMID: 32643323 DOI: 10.1111/1759-7714.13541] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
646 Qiu MZ, He CY, Yang DJ, Zhou DL, Zhao BW, Wang XJ, Yang LQ, Lu SX, Wang FH, Xu RH. Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients. Ther Adv Med Oncol 2020;12:1758835920937434. [PMID: 32670421 DOI: 10.1177/1758835920937434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
647 Kurosaki T, Kawakami H, Mitani S, Kawabata R, Takahama T, Nonagase Y, Fumita S, Ozaki T, Chiba Y, Tamura T, Nakagawa K. Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer. In Vivo 2020;34:1921-9. [PMID: 32606164 DOI: 10.21873/invivo.11989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
648 Wei XL, Ren C, Wang FH, Zhang Y, Zhao HY, Zou BY, Wang ZQ, Qiu MZ, Zhang DS, Luo HY, Wang F, Yao S, Xu RH. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. Cancer Commun (Lond) 2020;40:345-54. [PMID: 32589350 DOI: 10.1002/cac2.12068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
649 Ishikawa W, Kikuchi S, Ogawa T, Tabuchi M, Tazawa H, Kuroda S, Noma K, Nishizaki M, Kagawa S, Urata Y, Fujiwara T. Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer. Mol Ther Oncolytics 2020;18:262-71. [PMID: 32728614 DOI: 10.1016/j.omto.2020.06.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
650 Yasuoka H, Asai A, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis. Sci Rep 2020;10:10377. [PMID: 32587357 DOI: 10.1038/s41598-020-67497-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
651 Imai Y, Chiba T, Kondo T, Kanzaki H, Kanayama K, Ao J, Kojima R, Kusakabe Y, Nakamura M, Saito T, Nakagawa R, Suzuki E, Nakamoto S, Muroyama R, Tawada A, Matsumura T, Nakagawa T, Kato J, Kotani A, Matsubara H, Kato N. Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer. Oncol Lett 2020;20:2161-8. [PMID: 32782533 DOI: 10.3892/ol.2020.11757] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
652 Zhou C, Fan N, Liu F, Fang N, Plum PS, Thieme R, Gockel I, Gromnitza S, Hillmer AM, Chon SH, Schlösser HA, Bruns CJ, Zhao Y. Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer. Cells 2020;9:E1481. [PMID: 32560537 DOI: 10.3390/cells9061481] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
653 Shimozaki K, Sukawa Y, Beppu N, Kurihara I, Suzuki S, Mizuno R, Funakoshi T, Ikemura S, Tsugaru K, Togasaki K, Kawasaki K, Hirata K, Hayashi H, Hamamoto Y, Takaishi H, Kanai T. Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. Cancer Manag Res 2020;12:4585-93. [PMID: 32606951 DOI: 10.2147/CMAR.S247554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
654 Yamashita K, Iwatsuki M, Ajani JA, Baba H. Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. Ann Gastroenterol Surg 2020;4:369-78. [PMID: 32724880 DOI: 10.1002/ags3.12348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
655 Zhang X, Pan Z. Influence of microbiota on immunity and immunotherapy for gastric and esophageal cancers. Gastroenterol Rep (Oxf) 2020;8:206-14. [PMID: 32665852 DOI: 10.1093/gastro/goaa014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
656 Power R, Lowery MA, Reynolds JV, Dunne MR. The Cancer-Immune Set Point in Oesophageal Cancer. Front Oncol. 2020;10:891. [PMID: 32582553 DOI: 10.3389/fonc.2020.00891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
657 Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30:1479-1486. [PMID: 31236579 DOI: 10.1093/annonc/mdz197] [Cited by in Crossref: 208] [Cited by in F6Publishing: 216] [Article Influence: 69.3] [Reference Citation Analysis]
658 Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol 2019;30:1487-95. [PMID: 31240302 DOI: 10.1093/annonc/mdz199] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 19.3] [Reference Citation Analysis]
659 Mitani S, Kadowaki S, Komori A, Kondoh C, Oze I, Kato K, Masuishi T, Honda K, Narita Y, Taniguchi H, Ando M, Tanaka T, Tajika M, Muro K. A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies. Adv Ther 2020;37:2853-64. [PMID: 32378071 DOI: 10.1007/s12325-020-01358-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
660 Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild JR, Kretzschmar A, Ettrich T, Lindig U, Jacobasch L, Pink D, Al-Batran SE, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer 2020;20:503. [PMID: 32487035 DOI: 10.1186/s12885-020-06958-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
661 Meng J, Zhou Y, Lu X, Bian Z, Chen Y, Fan S, Zhou J, Zhang L, Hao Z, Zhang M, Liang C. Immune Response Drives Outcomes in Prostate Cancer: Implications for Immunotherapy.. [DOI: 10.1101/2020.05.26.117218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
662 Liu Q, Zhang D, Qian H, Chu Y, Yang Y, Shao J, Xu Q, Liu B. Superior Antitumor Efficacy of IFN-α2b-Incorporated Photo-Cross-Linked Hydrogels Combined with T Cell Transfer and Low-Dose Irradiation Against Gastric Cancer. Int J Nanomedicine 2020;15:3669-80. [PMID: 32547021 DOI: 10.2147/IJN.S249174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
663 Ye M, Huang D, Zhang Q, Weng W, Tan C, Qin G, Jiang W, Sheng W, Wang L. Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. Cancer Cell Int 2020;20:186. [PMID: 32489322 DOI: 10.1186/s12935-020-01273-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
664 Hu Q, Hasuda H, Ueki K, Tsuchimoto A, Zaitsu Y, Tsuda Y, Hisamatsu Y, Nakashima Y, Ando K, Kimura Y, Oki E, Mori M. Reintroduction of nivolumab in a patient with gastric cancer after improvement of nivolumab-induced acute interstitial nephritis: a case report. Int Cancer Conf J 2020;9:127-32. [PMID: 32582516 DOI: 10.1007/s13691-020-00418-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
665 Shulgin B, Kosinsky Y, Omelchenko A, Chu L, Mugundu G, Aksenov S, Pimentel R, DeYulia G, Kim G, Peskov K, Helmlinger G. Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. Oncoimmunology 2020;9:1748982. [PMID: 32934874 DOI: 10.1080/2162402X.2020.1748982] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
666 Sundar R, Smyth EC, Peng S, Yeong JPS, Tan P. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Front Oncol 2020;10:763. [PMID: 32500029 DOI: 10.3389/fonc.2020.00763] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
667 Nie S, Yang G, Lu H. Current Molecular Targeted Agents for Advanced Gastric Cancer. Onco Targets Ther. 2020;13:4075-4088. [PMID: 32494161 DOI: 10.2147/ott.s246412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
668 Rodriquenz MG, Roviello G, D'Angelo A, Lavacchi D, Roviello F, Polom K. MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy. J Clin Med 2020;9:E1427. [PMID: 32403403 DOI: 10.3390/jcm9051427] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
669 Huynh JC, Schwab E, Ji J, Kim E, Joseph A, Hendifar A, Cho M, Gong J. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. Cancers (Basel). 2020;12. [PMID: 32384640 DOI: 10.3390/cancers12051168] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
670 Beer A, Taghizadeh H, Schiefer AI, Puhr HC, Karner AK, Jomrich G, Schoppmann SF, Kain R, Preusser M, Ilhan-Mutlu A. PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. Pathol Oncol Res 2020;26:2225-35. [PMID: 32372174 DOI: 10.1007/s12253-020-00814-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
671 Nakayama Y, Mimura K, Kua L, Okayama H, Min AKT, Saito K, Hanayama H, Watanabe Y, Saito M, Momma T, Saze Z, Ohki S, Suzuki Y, Ichikawa D, Yong W, Kono K. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. Gastric Cancer 2020;23:961-73. [DOI: 10.1007/s10120-020-01079-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
672 Nakamura N, Kinami S, Fujita J, Kaida D, Tomita Y, Miyata T, Fujita H, Ueda N, Takamura H, Kosaka T. A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab. Case Rep Oncol 2020;13:702-7. [PMID: 32774260 DOI: 10.1159/000507955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
673 Miyatani K, Miyauchi W, Kono Y, Shishido Y, Watanabe J, Hanaki T, Kihara K, Matsunaga T, Yamamoto M, Fukumoto Y, Tokuyasu N, Takano S, Sakamoto T, Honjo S, Hasegawa T, Fujiwara Y. Successful treatment of peritoneal recurrence after gastric cancer surgery with intravenous and intraperitoneal paclitaxel combined with S-1 chemotherapy: a case report. Surg Case Rep 2020;6:88. [PMID: 32358679 DOI: 10.1186/s40792-020-00849-2] [Reference Citation Analysis]
674 Iwasa S, Kudo T, Takahari D, Hara H, Kato K, Satoh T. Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. Int J Clin Oncol 2020;25:1223-32. [PMID: 32347434 DOI: 10.1007/s10147-020-01684-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
675 Däster S, Eppenberger-Castori S, Mele V, Schäfer HM, Schmid L, Weixler B, Soysal SD, Droeser RA, Spagnoli GC, Kettelhack C, Oertli D, Terracciano L, Tornillo L, von Holzen U. Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. Front Med (Lausanne) 2020;7:144. [PMID: 32411711 DOI: 10.3389/fmed.2020.00144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
676 Arai H, Nakajima TE. Recent Developments of Systemic Chemotherapy for Gastric Cancer. Cancers (Basel) 2020;12:E1100. [PMID: 32354119 DOI: 10.3390/cancers12051100] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
677 Chen MH, Fang WL, Hung YP, Chao Y. Mucinous gastric adenocarcinoma: A good candidate for immune therapy? J Chin Med Assoc 2020;83:624-5. [PMID: 32332521 DOI: 10.1097/JCMA.0000000000000329] [Reference Citation Analysis]
678 Pan WT, Zhou SN, Pan MX, Luo QY, Zhang L, Yang DJ, Qiu M. Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis. Front Oncol 2020;10:513. [PMID: 32391262 DOI: 10.3389/fonc.2020.00513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
679 Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2021;80:36-48. [PMID: 32327425 DOI: 10.1136/annrheumdis-2020-217139] [Cited by in Crossref: 80] [Cited by in F6Publishing: 89] [Article Influence: 26.7] [Reference Citation Analysis]
680 D'Ugo D, Agnes A, Grieco M, Biondi A, Persiani R. Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects. Updates Surg 2020;72:355-78. [PMID: 32306277 DOI: 10.1007/s13304-020-00771-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
681 Qiu H. Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer. Cancer Commun (Lond) 2020;40:194-6. [PMID: 32277740 DOI: 10.1002/cac2.12019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
682 Li S, Sun S, Xiang H, Yang J, Peng M, Gao Q. Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials. Oncoimmunology 2020;9:1746113. [PMID: 32313724 DOI: 10.1080/2162402X.2020.1746113] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
683 Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y, Todo T. Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer. Mol Ther Oncolytics 2020;17:205-15. [PMID: 32346610 DOI: 10.1016/j.omto.2020.03.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
684 Hirose S, Moriwaki T, Yamaura M, Suganuma D, Tajima H, Sato M, Enami C, Yamada T, Yamamoto Y, Sakamoto N, Hyodo I. A case of advanced gastric cancer showing HER2 positivity after chemotherapy. Int Cancer Conf J 2020;9:112-5. [PMID: 32582513 DOI: 10.1007/s13691-020-00412-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
685 Ji A, Jin R, Zhang R, Li H. Primary small cell carcinoma of the esophagus: progression in the last decade. Ann Transl Med 2020;8:502. [PMID: 32395546 DOI: 10.21037/atm.2020.03.214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
686 Kim J, Byeon S, Kim H, Yeo JH, Hong JY, Lee J, Lim HY, Kang WK, Kim ST. Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. Targ Oncol 2020;15:203-209. [DOI: 10.1007/s11523-020-00713-1] [Reference Citation Analysis]
687 Mendis S, Gill S. Cautious optimism-the current role of immunotherapy in gastrointestinal cancers. Curr Oncol 2020;27:S59-68. [PMID: 32368175 DOI: 10.3747/co.27.5095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
688 Hamamoto Y, Piao Y, Makiyama A. Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and/or those with ascites. Gastric Cancer 2020;23:363-72. [PMID: 32236760 DOI: 10.1007/s10120-020-01067-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
689 Kim HS, Jeong H, Shim MK. Evaluation of Efficacy and Safety of Nivolumab and Pembrolizumab in Elderly Cancer Patients. Korean J Clin Pharm 2020;30:11-18. [DOI: 10.24304/kjcp.2020.30.1.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
690 Kim J, Chang JW, Park JY. Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure. J Liver Cancer 2020;20:72-77. [DOI: 10.17998/jlc.20.1.72] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
691 Huemer F, Weiss L, Regitnig P, Winder T, Hartmann B, Thaler J, Piringer G, Schmitt CA, Eisterer W, Gänzer H, Wüstner A, Andel J, Jagdt B, Ulmer H, Greil R, Wöll E. Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry. J Clin Med 2020;9:E935. [PMID: 32235305 DOI: 10.3390/jcm9040935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
692 Xu C, Sui S, Shang Y, Yu Z, Han J, Zhang G, Ntim M, Hu M, Gong P, Chen H, Zhang X. The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. J Adv Res 2020;24:139-48. [PMID: 32322419 DOI: 10.1016/j.jare.2020.03.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
693 Ohmura H, Yamaguchi K, Hanamura F, Ito M, Makiyama A, Uchino K, Shimokawa H, Tamura S, Esaki T, Mitsugi K, Shibata Y, Oda H, Tsuchihashi K, Ariyama H, Kusaba H, Oda Y, Akashi K, Baba E. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. Br J Cancer 2020;122:1507-17. [PMID: 32203221 DOI: 10.1038/s41416-020-0810-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
694 Li R, Zhang H, Cao Y, Liu X, Chen Y, Qi Y, Wang J, Yu K, Lin C, Liu H, He H, Li H, Chen L, Shen Z, Qin J, Zhang W, Sun Y, Xu J. Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer. Cancer Immunol Immunother 2020;69:1327-36. [PMID: 32200421 DOI: 10.1007/s00262-020-02550-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
695 Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv L, Liu J, Xu Y, Shen Y, Yang M. Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020;19:62. [PMID: 32192494 DOI: 10.1186/s12943-020-01185-7] [Cited by in Crossref: 140] [Cited by in F6Publishing: 159] [Article Influence: 46.7] [Reference Citation Analysis]
696 Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, Bendell J, Enzinger P, Marina N, Xiang H, Deng W, Powers J, Wainberg ZA. Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. J Clin Oncol 2020;38:2418-26. [PMID: 32167861 DOI: 10.1200/JCO.19.01834] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
697 Kim J, Kim B, Kang SY, Heo YJ, Park SH, Kim ST, Kang WK, Lee J, Kim KM. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. Front Oncol. 2020;10:314. [PMID: 32232003 DOI: 10.3389/fonc.2020.00314] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
698 Waki K, Kawano K, Tsuda N, Komatsu N, Yamada A. CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients. Cancer Sci 2020;111:1124-31. [PMID: 32058620 DOI: 10.1111/cas.14349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
699 Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30:250-258. [PMID: 30566590 DOI: 10.1093/annonc/mdy540] [Cited by in Crossref: 136] [Cited by in F6Publishing: 157] [Article Influence: 45.3] [Reference Citation Analysis]
700 Kono Y, Saito H, Miyauchi W, Shimizu S, Murakami Y, Shishido Y, Miyatani K, Matsunaga T, Fukumoto Y, Nakayama Y, Sakurai C, Hatsuzawa K, Fujiwara Y. Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients. BMC Cancer 2020;20:175. [PMID: 32131763 DOI: 10.1186/s12885-020-6629-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
701 Tabernero J, Alsina M, Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Ando T, Yalçın Ş, Van Cutsem E, Sabater J, Skanji D, Leger C, Amellal N, Ilson DH. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. Gastric Cancer 2020;23:689-98. [PMID: 32128634 DOI: 10.1007/s10120-020-01053-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
702 Ninomiya K, Oze I, Kato Y, Kubo T, Ichihara E, Rai K, Ohashi K, Kozuki T, Tabata M, Maeda Y, Kiura K, Hotta K. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. Acta Oncol 2020;59:249-56. [PMID: 31782328 DOI: 10.1080/0284186X.2019.1695062] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
703 Tian Y, Zhang Z, Yang X, Li D, Zhang L, Li Z, Zhang S, Mao Y, Jin C, Zhao Y. The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:261. [PMID: 32181158 DOI: 10.3389/fonc.2020.00261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
704 Jin H, Li P, Mao C, Zhu K, Chen H, Gao Y, Yu J. Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability. Onco Targets Ther 2020;13:1751-6. [PMID: 32161470 DOI: 10.2147/OTT.S243298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
705 Karstens KF, Kempski J, Giannou AD, Pelczar P, Steglich B, Steurer S, Freiwald E, Woestemeier A, Konczalla L, Tachezy M, Reeh M, Bockhorn M, Perez D, Mann O, Lohse AW, Roesch T, Izbicki JR, Gagliani N, Huber S. Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival. Cancer Immunol Immunother 2020;69:1043-56. [PMID: 32100077 DOI: 10.1007/s00262-020-02517-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
706 Zhou YJ, Zhu GQ, Lu XF, Zheng KI, Wang QW, Chen JN, Zhang QW, Yan FR, Li XB. Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. Cancer Immunol Immunother 2020;69:1057-69. [PMID: 32100076 DOI: 10.1007/s00262-020-02525-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
707 Furuta Y, Miyamoto H, Naoe H, Shimoda M, Hinokuma Y, Miyamura T, Miyashita A, Fukushima S, Tanaka M, Sasaki Y. Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis. Case Rep Gastroenterol 2020;14:103-9. [PMID: 32231510 DOI: 10.1159/000506186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
708 Zhang K, Chen L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases. Ther Adv Med Oncol. 2020;12:1758835920904803. [PMID: 32127925 DOI: 10.1177/1758835920904803] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
709 Sun Y, Li S, Yu W, Chen C, Liu T, Li L, Zhang D, Zhao Z, Gao J, Wang X, Shi D, Liu L. CD148 Serves as a Prognostic Marker of Gastric Cancer and Hinders Tumor Progression by Dephosphorylating EGFR. J Cancer 2020;11:2667-78. [PMID: 32201537 DOI: 10.7150/jca.40955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
710 Kim TS, da Silva E, Coit DG, Tang LH. Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype. Am J Surg Pathol 2019;43:851-60. [PMID: 30969179 DOI: 10.1097/PAS.0000000000001253] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
711 Tirino G, Petrillo A, Pompella L, Pappalardo A, Laterza MM, Panarese I, Sabetta R, Franco R, Galizia G, Ciardiello F, De Vita F. Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report. Front Oncol 2020;10:130. [PMID: 32128313 DOI: 10.3389/fonc.2020.00130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
712 Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol 2019;5:1008-19. [PMID: 31021376 DOI: 10.1001/jamaoncol.2019.0393] [Cited by in Crossref: 321] [Cited by in F6Publishing: 351] [Article Influence: 107.0] [Reference Citation Analysis]
713 Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis. JAMA Oncol 2019;5:529-36. [PMID: 30605213 DOI: 10.1001/jamaoncol.2018.5904] [Cited by in Crossref: 118] [Cited by in F6Publishing: 130] [Article Influence: 39.3] [Reference Citation Analysis]
714 Sun L, Zhang L, Yu J, Zhang Y, Pang X, Ma C, Shen M, Ruan S, Wasan HS, Qiu S. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep 2020;10:2083. [PMID: 32034198 DOI: 10.1038/s41598-020-58674-4] [Cited by in Crossref: 73] [Cited by in F6Publishing: 79] [Article Influence: 24.3] [Reference Citation Analysis]
715 Zhao B, Zhao H, Zhao J. Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. Ther Adv Med Oncol 2020;12:1758835919895753. [PMID: 32082425 DOI: 10.1177/1758835919895753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
716 Sherry AD, Newman NB, Anderson JL, Osmundson EC. Systemic inflammatory dynamics during chemoradiotherapy predict response, relapse, metastasis, and survival in esophageal carcinoma. J Surg Oncol 2020;121:303-12. [PMID: 31799692 DOI: 10.1002/jso.25793] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
717 Bello MN, Biarge FS, Arnal MD, Sejas AG, González MG. Actualización en cáncer gástrico. Medicine - Programa de Formación Médica Continuada Acreditado 2020;13:117-125. [DOI: 10.1016/j.med.2020.01.020] [Reference Citation Analysis]
718 Smyth E, Knödler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, Wagner AD, Moehler M, Lordick F. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. Front Oncol 2019;9:1320. [PMID: 32083013 DOI: 10.3389/fonc.2019.01320] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
719 Sasako M. Progress in the treatment of gastric cancer in Japan over the last 50 years. Ann Gastroenterol Surg 2020;4:21-9. [PMID: 32021955 DOI: 10.1002/ags3.12306] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
720 Petrillo A, Tirino G, Zito Marino F, Pompella L, Sabetta R, Panarese I, Pappalardo A, Caterino M, Ventriglia A, Laterza MM, Morgillo F, Orditura M, Ciardiello F, Franco R, De Vita F. Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population. Onco Targets Ther 2020;13:867-76. [PMID: 32099391 DOI: 10.2147/OTT.S229813] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
721 Puhr HC, Preusser M, Prager G, Ilhan-Mutlu A. New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice? Cancers (Basel) 2020;12:E301. [PMID: 32012895 DOI: 10.3390/cancers12020301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
722 Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365 [PMID: 31988594 DOI: 10.3748/wjg.v26.i3.353] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis]
723 Moore A, Hikri E, Goshen-Lago T, Barkan T, Morgenstern S, Brook E, Maderer A, Roth W, Gordon N, Kashtan H, Brenner B, Moehler M, Aharon IB. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis? BMC Cancer 2020;20:34. [PMID: 31937281 DOI: 10.1186/s12885-020-6517-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
724 Roviello G, Corona SP, D'Angelo A, Rosellini P, Nobili S, Mini E. Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis. Int J Mol Sci 2020;21:E448. [PMID: 31936762 DOI: 10.3390/ijms21020448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
725 Kanaya N, Kuroda S, Kakiuchi Y, Kumon K, Tsumura T, Hashimoto M, Morihiro T, Kubota T, Aoyama K, Kikuchi S, Nishizaki M, Kagawa S, Tazawa H, Mizuguchi H, Urata Y, Fujiwara T. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Mol Ther 2020;28:794-804. [PMID: 31991110 DOI: 10.1016/j.ymthe.2020.01.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
726 Tanaka T, Arigami T, Uenosono Y, Yanagita S, Matsushita D, Okubo K, Kijima T, Uchikado Y, Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, Maemura K, Ishigami S, Natsugoe S. A long-term survivor of recurrent esophagogastric junction adenocarcinoma treated with multidisciplinary therapy: a case report. Surg Case Rep 2020;6:13. [PMID: 31919764 DOI: 10.1186/s40792-020-0776-5] [Reference Citation Analysis]
727 Mehta R, Kommalapati A, Kim RD. The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer. Cancer Manag Res 2020;12:51-7. [PMID: 32021422 DOI: 10.2147/CMAR.S199827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
728 Hirotsu Y, Hada M, Amemiya K, Oyama T, Mochizuki H, Omata M. Multi-regional sequencing reveals clonal and polyclonal seeding from primary tumor to metastases in advanced gastric cancer. J Gastroenterol 2020;55:553-64. [PMID: 31912238 DOI: 10.1007/s00535-019-01659-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
729 Zayac A, Almhanna K. Esophageal, gastric cancer and immunotherapy: small steps in the right direction? Transl Gastroenterol Hepatol 2020;5:9. [PMID: 32190777 DOI: 10.21037/tgh.2019.09.05] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
730 Li W, Qie J, Zhang Y, Chang J. Spatiotemporal Changes in Checkpoint Molecule Expression. Adv Exp Med Biol 2020;1248:167-200. [PMID: 32185711 DOI: 10.1007/978-981-15-3266-5_8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
731 Jang MJ, Chao J. Esophageal and Gastric Cancer. Oncology in the Precision Medicine Era 2020. [DOI: 10.1007/978-3-030-31471-2_3] [Reference Citation Analysis]
732 Chen C, Gu Y, Zhang Z, Zhang Y, He Y, Tang F, Liu H, Li Y. Construction of PD1/CD28 Fusion Receptor Enhances Anti-Tumor Ability of c-Met CAR-T in Gastric Cancer. SSRN Journal. [DOI: 10.2139/ssrn.3738093] [Reference Citation Analysis]
733 Venkata Prasuja N. Immunotherapeutics of Gastrointestinal Malignancies. Immunotherapy for Gastrointestinal Malignancies 2020. [DOI: 10.1007/978-981-15-6487-1_4] [Reference Citation Analysis]
734 Sarin R, Peela S. Immunotherapy in Gastrointestinal Malignancies. Novel therapeutic approaches for gastrointestinal malignancies 2020. [DOI: 10.1007/978-981-15-5471-1_2] [Reference Citation Analysis]
735 Hara T, Ninomiya M, Doi H, Kuhara Y, Kidate K, Toyota K, Kobayashi H, Hashimoto Y, Sakashita Y, Miyamoto K, Shimamoto F. Gastric Cancer Showing Partial Response 10 Months after Administration of Nivolumab. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2020;53:1-7. [DOI: 10.5833/jjgs.2019.0043] [Reference Citation Analysis]
736 Greally M, Ku GY. Immunotherapy in Esophageal Cancer. Esophageal Cancer 2020. [DOI: 10.1007/978-3-030-29832-6_15] [Reference Citation Analysis]
737 Zhang Z, Xie T, Zhang X, Qi C, Shen L, Peng Z. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. Chin J Cancer Res 2020;32:287-302. [PMID: 32694895 DOI: 10.21147/j.issn.1000-9604.2020.03.02] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
738 Rahman AU, Sarvepalli D, Rashid MU, Ali S, Naeem A, Imran A, Zahid E, Ahmad S. Emerging Roles of Phytochemicals in the Pathobiology and Management of Esophageal Cancer. Phytochemicals Targeting Tumor Microenvironment in Gastrointestinal Cancers 2020. [DOI: 10.1007/978-3-030-48405-7_8] [Reference Citation Analysis]
739 Ahn DH, Bekaii-saab T. Systemic Treatment for Metastatic or Recurrent Disease. Esophageal Cancer 2020. [DOI: 10.1007/978-3-030-29832-6_14] [Reference Citation Analysis]
740 Sabeerabi B, Arva Tatireddygari VR, Vadde R. Therapeutic Vaccines for Gastrointestinal Malignancies. Immunotherapy for Gastrointestinal Malignancies 2020. [DOI: 10.1007/978-981-15-6487-1_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
741 Sanjari-moghaddam A, Sadeghi F, Soleyman-jahi S. Immunotherapy of Gastric and Esophageal Cancers. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-57949-4_8] [Reference Citation Analysis]
742 Huang LT, Ma JT, Zhang SL, Li XH, Sun L, Jing W, Zhao JZ, Wang YR, Han CB. Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report. Front Oncol 2019;9:1453. [PMID: 31956604 DOI: 10.3389/fonc.2019.01453] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
743 Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23:510-519. [PMID: 31863227 DOI: 10.1007/s10120-019-01034-7] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 18.8] [Reference Citation Analysis]
744 Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: Towards targeted therapies. Cell Oncol (Dordr) 2020;43:195-209. [PMID: 31848929 DOI: 10.1007/s13402-019-00488-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 62] [Article Influence: 13.5] [Reference Citation Analysis]
745 Kashima S, Tanabe H, Tanino M, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, Kunogi T, Takahashi K, Ando K, Ueno N, Moriichi K, Fukudo M, Tasaki Y, Hosokawa M, Mizukami Y, Fujiya M, Okumura T. Lymph Node Metastasis From Gastroesophageal Cancer Successfully Treated by Nivolumab: A Case Report of a Young Patient. Front Oncol 2019;9:1375. [PMID: 31921639 DOI: 10.3389/fonc.2019.01375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
746 Shi L, Feng M, Du S, Wei X, Song H, Yixin X, Song J, Wenxian G. Adenosine Generated by Regulatory T Cells Induces CD8+ T Cell Exhaustion in Gastric Cancer through A2aR Pathway. Biomed Res Int 2019;2019:4093214. [PMID: 31930120 DOI: 10.1155/2019/4093214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
747 Ando Y, Hayashi T, Sugimoto R, Nishibe S, Ito K, Kawada K, Ikeda Y, Yamada S, Imaizumi K. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. Invest New Drugs 2020;38:1200-6. [PMID: 31823160 DOI: 10.1007/s10637-019-00881-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
748 Iqbal S, McDonough S, Lenz HJ, Ilson D, Burtness B, Nangia CS, Barzi A, Schneider CJ, Liu JJ, Dotan E, Guthrie KA, Hochster HS. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. J Clin Oncol 2020;38:472-9. [PMID: 31815582 DOI: 10.1200/JCO.19.00925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
749 Lu J, Yang J, Liang Y, Meng H, Zhao J, Zhang X. Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. Front Pharmacol 2019;10:1453. [PMID: 31920646 DOI: 10.3389/fphar.2019.01453] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
750 Luo Z, Rong Z, Huang C. Surgery Strategies for Gastric Cancer With Liver Metastasis. Front Oncol 2019;9:1353. [PMID: 31921626 DOI: 10.3389/fonc.2019.01353] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
751 Klempner SJ, Schrock AB, Ali SM, Kubicky CD, Taylor MH. Acquired CTNNB1 Mutation Drives Immune Checkpoint Inhibitor–Acquired Resistance in a Microsatellite Instability–High Gastroesophageal Adenocarcinoma With Brain Metastases. JCO Precision Oncology 2019. [DOI: 10.1200/po.18.00208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
752 Besaw RJ, Smith MP, Zerillo JA, Bullock AJ. Chronic intestinal pseudo-obstruction in a patient with metastatic gastro-oesophageal junction cancer receiving treatment with pembrolizumab. BMJ Case Rep 2019;12:e232388. [DOI: 10.1136/bcr-2019-232388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
753 Shuto T, Nishikawa J, Shimokuri K, Yanagi A, Takagi T, Takagi F, Miura O, Iida M, Nagano H, Takemoto Y, Harada E, Suehiro Y, Yamasaki T, Okamoto T, Sakaida I. Establishment of a Screening Method for Epstein-Barr Virus-Associated Gastric Carcinoma by Droplet Digital PCR. Microorganisms 2019;7:E628. [PMID: 31795435 DOI: 10.3390/microorganisms7120628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
754 Hong Y, Ding ZY. PD-1 Inhibitors in the Advanced Esophageal Cancer. Front Pharmacol 2019;10:1418. [PMID: 31920637 DOI: 10.3389/fphar.2019.01418] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
755 Pan PC, Haggiagi A. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. Curr Oncol Rep 2019;21:108. [PMID: 31776691 DOI: 10.1007/s11912-019-0859-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
756 Bonilla CE, Esguerra J, Mendoza Díaz S, Álvarez A, Morales R L. Abscopal Effect After Palliative Radiotherapy in a Patient with a Gastric Adenocarcinoma Disseminated to Retroperitoneal Space: Case Report from a Latin American Reference Center and Review of the Literature. Cureus 2019;11:e6235. [PMID: 31890434 DOI: 10.7759/cureus.6235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
757 Xu D, Li J, Li RY, Lan T, Xiao C, Gong P. PD-L1 Expression Is Regulated By NF-κB During EMT Signaling In Gastric Carcinoma. Onco Targets Ther 2019;12:10099-105. [PMID: 31819504 DOI: 10.2147/OTT.S224053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
758 Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase III, randomised trial of avelumab vs physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29:2052-2060. [PMID: 30052729 DOI: 10.1093/annonc/mdy264] [Cited by in Crossref: 259] [Cited by in F6Publishing: 285] [Article Influence: 64.8] [Reference Citation Analysis]
759 Batista S, Gregório AC, Hanada Otake A, Couto N, Costa-Silva B. The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective. J Oncol 2019;2019:6240505. [PMID: 31885581 DOI: 10.1155/2019/6240505] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
760 Folprecht G. Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer. Cancer Commun (Lond) 2019;39:74. [PMID: 31727167 DOI: 10.1186/s40880-019-0417-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
761 Nagaraja AK, Kikuchi O, Bass AJ. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discov 2019;9:1656-72. [PMID: 31727671 DOI: 10.1158/2159-8290.CD-19-0487] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
762 Ye DM, Xu G, Ma W, Li Y, Luo W, Xiao Y, Liu Y, Zhang Z. Significant function and research progress of biomarkers in gastric cancer. Oncol Lett 2020;19:17-29. [PMID: 31897111 DOI: 10.3892/ol.2019.11078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
763 Huang PW, Chang JW. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J 2019;42:299-306. [PMID: 31783990 DOI: 10.1016/j.bj.2019.09.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
764 Lu D, Ni Z, Liu X, Feng S, Dong X, Shi X, Zhai J, Mai S, Jiang J, Wang Z, Wu H, Cai K. Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. J Immunol Res 2019;2019:1919082. [PMID: 31781673 DOI: 10.1155/2019/1919082] [Cited by in Crossref: 56] [Cited by in F6Publishing: 66] [Article Influence: 14.0] [Reference Citation Analysis]
765 Lu J, Li L, Lan Y, Liang Y, Meng H. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. Cancer Med. 2019;8:7503-7515. [PMID: 31679184 DOI: 10.1002/cam4.2661] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
766 Kwak Y, Seo AN, Lee HE, Lee HS. Tumor immune response and immunotherapy in gastric cancer. J Pathol Transl Med 2020;54:20-33. [PMID: 31674166 DOI: 10.4132/jptm.2019.10.08] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
767 Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2020;26:846-854. [PMID: 31676670 DOI: 10.1158/1078-0432.ccr-19-2443] [Cited by in Crossref: 24] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
768 Yu B, Yang H, Sabin A. A note on the determination of non-inferiority margins with application in oncology clinical trials. Contemp Clin Trials Commun 2019;16:100454. [PMID: 31650074 DOI: 10.1016/j.conctc.2019.100454] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
769 Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, Sundararajan S. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies (Basel) 2019;8:E51. [PMID: 31640266 DOI: 10.3390/antib8040051] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
770 Park HS, Kwon WS, Park S, Jo E, Lim SJ, Lee CK, Lee JB, Jung M, Kim HS, Beom SH, Park JY, Kim TS, Chung HC, Rha SY. Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. J Immunother Cancer 2019;7:268. [PMID: 31639056 DOI: 10.1186/s40425-019-0708-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
771 Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019;19:974. [PMID: 31638948 DOI: 10.1186/s12885-019-6150-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 78] [Article Influence: 17.5] [Reference Citation Analysis]
772 Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM. Precision medicine in gastric cancer. World J Gastrointest Oncol 2019; 11(10): 804-829 [PMID: 31662821 DOI: 10.4251/wjgo.v11.i10.804] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
773 Kanazawa Y, Kakinuma D, Matsuno K, Fujita I, Hagiwara N, Matsutani T, Nomura T, Yoshiyuki T, Kato S, Yoshida H. Historical Changes in Chemotherapy for Gastric Cancer in Japan. Nihon Ika Daigaku Igakkai Zasshi 2019;15:155-163. [DOI: 10.1272/manms.15.155] [Reference Citation Analysis]
774 Pellino A, Riello E, Nappo F, Brignola S, Murgioni S, Djaballah SA, Lonardi S, Zagonel V, Rugge M, Loupakis F, Fassan M. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World J Gastroenterol 2019; 25(38): 5773-5788 [PMID: 31636471 DOI: 10.3748/wjg.v25.i38.5773] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 58] [Article Influence: 13.3] [Reference Citation Analysis]
775 Tokunaga M, Sato Y, Nakagawa M, Aburatani T, Matsuyama T, Nakajima Y, Kinugasa Y. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today. 2020;50:30-37. [PMID: 31612329 DOI: 10.1007/s00595-019-01896-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
776 Selim JH, Shaheen S, Sheu WC, Hsueh CT. Targeted and novel therapy in advanced gastric cancer. Exp Hematol Oncol 2019;8:25. [PMID: 31632839 DOI: 10.1186/s40164-019-0149-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
777 Pereira MA, Ramos MFKP, Dias AR, Faraj SF, Ribeiro RRE, de Castria TB, Zilberstein B, Alves VAF, Ribeiro U Jr, de Mello ES. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. Mol Diagn Ther 2019;23:761-71. [PMID: 31595457 DOI: 10.1007/s40291-019-00424-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
778 Kikuchi T, Mimura K, Okayama H, Nakayama Y, Saito K, Yamada L, Endo E, Sakamoto W, Fujita S, Endo H, Saito M, Momma T, Saze Z, Ohki S, Kono K. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ. Oncol Lett 2019;18:5977-85. [PMID: 31788072 DOI: 10.3892/ol.2019.10953] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
779 Huang YF, Xie WJ, Fan HY, Du J. Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. Front Oncol 2019;9:972. [PMID: 31632907 DOI: 10.3389/fonc.2019.00972] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
780 Ueno M, Doi A, Sunami T, Takayama H, Mouri H, Mizuno M. Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics: an analysis in real-world setting. J Gastrointest Oncol. 2019;10:957-964. [PMID: 31602334 DOI: 10.21037/jgo.2019.05.07] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
781 Pericay C, Macías-declara I, Arrazubi V, Vilà L, Marín M. Treatment in Esophagogastric Junction Cancer: Past, Present and Future. Cirugía Española (English Edition) 2019;97:459-464. [DOI: 10.1016/j.cireng.2019.03.020] [Reference Citation Analysis]
782 Moy RH, Dos Santos Fernandes G, Jonsson P, Chou JF, Basunia A, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Gabler A, Berger MF, Tang LH, Hechtman JF, Kelsen DP, Schattner M, Ilson DH, Solit DB, Taylor BS, Schultz N, Capanu M, Janjigian YY. Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. Oncologist 2020;25:e68-74. [PMID: 31570517 DOI: 10.1634/theoncologist.2019-0492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
783 Yang L, Wang Y, Wang H. Use of immunotherapy in the treatment of gastric cancer. Oncol Lett 2019;18:5681-90. [PMID: 31788040 DOI: 10.3892/ol.2019.10935] [Cited by in Crossref: 11]&nb